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INTRODUCTION 
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1. MELANOPSIN RETINAL GANGLION CELLS: ROLE 
IN CIRCADIAN PHOTOENTRAINMENT  
1.1. Discovery, anatomy and physiology 
Melanopsin-containing retinal ganglion cells (mRGCs) represent a new class of 
photoreceptors, mainly involved in the non-image forming functions of the eye, with 
a crucial role in photoentrainment of circadian rhythms (Hannibal et al., 2002a; 
Berson et al., 2002; Hattar et al., 2002). The discovery of mRGCs came from the 
observation that in mice models of retinal degeneration (rd/rd and rd/rd cl) light was 
still producing photoentrainment of their circadian rhythms (Foster et al., 1991; 
Freedman et al., 1999; Lucas et al., 1999). Thus, the existence of a circadian 
photoreceptor was postulated and in 2002, after the identification of the melanopsin 
photopigment (Provencio et al., 1998; Provencio et al., 2000), converging evidences 
proved that a small subset of retinal ganglion cells (RGCs), intrinsically 
photosensitive because expressing melanopsin, projected to the hypothalamic 
suprachiasmatic nucleus (SCN) through the retino-hypothalamic tract (RHT) 
(Gooley et al., 2001; Hannibal et al., 2002a,b; Hattar et al., 2002; Berson et al., 
2002). The RHT was a well-known anatomical pathway connecting the eye to the 
SCN (Moore and Lenn 1972; Sadun et al., 1984; Moore et al., 1995), the master 
biological clock, but with the discovery of mRGCs its origin from a subset of RGCs 
was finally proven. Circadian rhythms are biological rhythms characterized by an 
intrinsic period of about 24 hours and the SCN represent the master circadian clock 
deputed to the generation of an endogenous circadian rhythm and synchronization of 
all the peripheral oscillators. The process by which circadian rhythms are 
synchronized to the light-dark cycle is named photoentrainment (Peirson et al., 
2005). Many biological functions present circadian oscillations during the 24-hours, 
mainly hormons but also sleep-wake cycle and cognition.   
Melanopsin-expressing RGCs represent about 1% of the RGCs in humans (Hannibal 
et al., 2004a). They are preferentially located in the parafoveal and far nasal regions 
of the retina (Hannibal et al., 2004a; Dacey et al., 2005). These cells are 
characterized by a large soma (15-20µm), with a central nucleus, and, in humans, are 
located in about equal proportions in the retinal ganglion cell (Figure 1A) and inner 
nuclear layers (Figure 1B).  
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Figure 1. Postmortem human retina, immunoperoxidase staining for melanopsin with 
diaminobenzadine, light microscopy; Retina from a control demonstrating a melanopsin-positive 
retinal ganglion cell (mRGC) in the RGC layer (RGL) (A) and in the inner nuclear layer (INL) (B). In 
A and B dendrites extend to the “off” layer of the inner plexiform layer (formalin-fixed, paraffin 
embedded 5 !m section, counterstained with Mayer’s hematoxylin, magnification 1000x). In both 
cells a centrally located nucleus and peripherally-stained soma are visible (La Morgia et al., 2012a).  
 
The mRGCs are currently classified in subtypes, based on the levels of melanopsin 
expression, dendritic field harborization, physiology and central projections (Baver et 
al., 2008; Ecker et al., 2010, Schmidt et al., 2011a,b). The three most characterized 
subtypes are the M1 mRGCs, which stratify in the outermost sublamina of the inner 
plexiform layer (IPL), the M2 stratifying in the innermost sublamina of the IPL and 
the bistratified M3 with dendrites in both inner and outer sublaminae.  The M4 cells 
have the largest soma and dendritic fields, whereas the M5 type have small and 
highly branched arbors and cannot be stained with melanopsin antibody, but retain a 
weak intrinsic response to light (Figure 2).  
 
 
 
Figure 2. Schematic representation of different subtypes of mRGCs and their projections to the CNS 
(modified from Schmidt et al., 2011b) 
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The pigment is expressed primarily in the membrane of the soma and dendrites and 
even in the axons running within the retinal nerve fiber layer (Figure 1). The large 
and embricated dendritic fields constitute a photoreceptive net in the retina 
(Provencio et al., 2002) (Figure 3).  
The mRGCs are characterized by unique photoreceptive properties. In fact, they are 
intrinsically photosensitive, i.e. depolarize in response to light stimuli even if they 
are completely isolated from the surrounding retinal structures, and use a 
rhabdomeric photoreceptive system, similar to invertebrates (Isoldi et al., 2005; Do 
and Yau, 2010). They are maximally sensitive to short wavelength blue light (peak 
response at 480 nm) having a sustained response to light, which persists also when 
the light is switched off (Foster, 2005; Do and Yau, 2010). Although they are 
independently functioning photoreceptors, they also receive inputs from rods and 
cones, through amacrine and bipolar cells (Viney et al., 2007). This organization 
allows the input from several types of retinal cells leading signals from the classical 
photoreceptors, rods and cones, constituting an “irradiance-detector” system in the 
eye (Viney et al., 2007; Jusuf et al., 2007; Schmidt and Kofuji, 2009, 2010; Lall et 
al., 2010). 
The phylogenic and ontogenic importance of this cellular system is demonstrated by 
the fact that the melanopsin photopigment was discovered in many invertebrate 
organisms and that in rodents these cells start to respond to light at post-natal day 0, 
before the classic photoreceptors, i.e. rods and cones, start to function (Hannibal and 
Fahrenkrug, 2004b; Sekaran et al., 2005; Tu et al., 2005; Koyanagi and Terakita, 
2008; Davies et al., 2010; González-Menéndez et al., 2010). The importance of this 
cellular system is also supported by the observation that in the subterranean blind 
mole rat the circadian photoentrainment persists, thanks to the residual presence of 
mRGCs projecting to brain structures deputed to control circadian rhythms, 
notwithstanding the involution of the conventional visual pathway (Cooper et al., 
1993).  
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Figure 3. Photoreceptive net in human retina (La Morgia et al., 2012a) 
1.2. Projections and biological functions: relevance for circadian 
photoentrainment 
The central projections of mRGCs are extensive, suggesting their influence on many 
non-image forming functions of the eye (Hattar et al., 2006; Vandewalle et al., 
2009a; Benarroch, 2011). The primary projection of mRGCs is the SCN, through the 
RHT, instrumental in mediating the photoentrainment of circadian rhythms. The 
RHT uses glutamate as well as aspartate, PACAP and substance P as 
neurotransmitters (Golombek and Rosenstein, 2010; Figure 4). The SCN is the main 
target of mRGCs and may be subdivided in two main areas: 1) the core or 
ventrolateral area, which contains neurons releasing vasoactive intestinal polypeptide 
(VIP) and gastrin-releasing peptide (GRP) and receives most afferents from the 
retina 2) the shell or dorsomedial area, which contains neurons releasing arginine 
vasopressin (AVP) and calretinin and receives projections from the ventrolateral and 
limbic areas (Golombek and Rosenstein, 2010; Hannibal et al., 2006a; Figure 5). 
The neurons in the core region express clock genes such as Per1 and Per2 whose 
expression is regulated and activated by light. The communication between the core 
and shell of the SCN allows an oscillation with a coherent period of the SCN.   
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Figure 4. Representation of the RHT originating from the retina and innervating the SCN using 
Glutamate and PACAP as neurotransmitters (modified from Golombek and Rosenstein, 2010)  
 
Figure 5. Anatomical and biochemical organization of the SCN (modified from Golombek and 
Rosenstein, 2010)  
 
Moreover, a multisynaptic pathway originating from the retina innervates the clock 
from the ventral lateral geniculate nucleus and the thalamic intergeniculate leaflet 
using Neuropeptide Y and GABA as neurotransmitters (Golombek and Rosenstein, 
2010). A further important projection of the mRGCs is to the olivary pretectal 
nucleus, by which they constitute the afferent arm of the pupillary light reflex, 
contributing mainly its sustained component (Kawasaki and Kardon, 2007). The 
widespread projections of mRGCs include many other key structures involved in 
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sleep regulation, and in particular the hypothalamic ventrolateral preoptic nucleus 
(VLPO), which contains sleep-active neurons, the lateral hypothalamic area, and 
subcortical areas related to arousal (brainstem and thalami) (Vandewalle et al., 2007; 
Vandewalle et al., 2009a). In fact, recent functional Magnetic Resonance Imaging 
(fMRI) studies suggested an important role of light in modulating cognitive functions 
and emotions (Vandewalle et al., 2009a). In particular, blue light increases activity, 
within the first few seconds of exposure, in left hippocampus, thalamus and 
amygdala during a working memory task (Vandewalle et al., 2007). Moreover, these 
cells regulate, through a polysynaptic pathway, the melatonin synthesis by the pineal 
gland and its suppression induced by light exposure (Brainard et al., 1983; Thapan et 
al., 2001; Brainard et al., 2001) (Figure 6). Moreover, PET studies demonstrated that 
light influences cortical regions involved in attention such as the occipito-parietal 
attention network (Perrin et al., 2004). 
 
 
Figure 6. Main projection of mRGCs and biological functions of mRGCs are shown with particular 
reference to non-image forming visual functions (modified from Benarroch, 2011) 
 
The mRGCs also target the lateral habenula along the limbic circuitry, and the 
intergeniculate leaflet of the thalamus involved in non-photic regulation of circadian 
rhythms (Hannibal et al., 2006a, 2006b; Hattar et al., 2006). Overall, these cells 
contribute to many non-image forming functions of the eye and have an important 
role in modulating circadian rhythms, alertness, sleep, cognition and emotion 
(Vandewalle et al., 2007, 2009a, 2010; Schmidt et al., 2009).  
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Even if most mRGC projections are to brain nuclei involved in non-image forming 
visual functions recent studies breake this paradigm and show that mRGCs may also 
project to structures involved in visual perception (Dacey et al., 2005; Ecker et al., 
2010; Brown et al., 2010). By using a Cre-recombinase based melanopsin reporter in 
a mouse model, it was shown that mRGCs innervate the superior colliculus and 
dorsal lateral geniculate nucleus, both nuclei being retinotopically organized for 
object localization and discrimination (Ecker et al., 2010; Brown et al., 2010). In a 
further experiment, by using mice lacking classic rod/cone photoreception, it has 
been also shown that these animals maintain measurable visual acuity (Ecker et al., 
2010; Brown et al., 2010). Moreover, mRGCs, through the projections to dura-
sensitive neurons in the posterior thalamus, play an important role in the 
exacerbation of migraine headache by light (Noseda et al., 2010, Noseda and 
Burstein, 2011).  
Interestingly, recent data demonstrated that distinct subtypes of mRGCs have 
different target in the SCN. In fact, the M1 subclass, with the highest melanopsin 
level expression and the highest light sensitivity is predominantly responsible for 
circadian photoentrainment and PLR regulation. In particular the Brn3b-positive type 
1 mRGCs project to all M1 targets except the SCN, thus mainly contributing to the 
PLR through their projections to the OPN. At difference, the Brn3b-negative type 1 
mRGCs are the main contributors for circadian photoentrainment. The non-M1 
subclasses, characterized by lower melanopsin expression and less light sensitivity, 
may be more relevant for the image-forming and other functions like emotion 
modulation through projections to amygdala, limbic circuitry and periacqueductal 
gray (Schmidt et al., 2011a,b).  
The widespread projections of mRGCs to multiple structures of the brain underlie the 
important role they play in physiology. The extensive influence of this parallel visual 
system on many biological functions provides a unique opportunity to study the 
impact of light and the role of the eye in human pathology.  
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2. MELANOPSIN RETINAL GANGLION CELLS AND 
SLEEP  
2.1. Circadian and homeostatic regulation of sleep 
Sleep is regulated by the interaction of homeostatic and circadian processes. The 
homeostatic process (S) can be defined as the increase of propensity to sleep as a 
function of the duration of prior waking and its dissipation during sleep (Borbély, 
1982; Borbély and Tobler, 2011). The principal neurophysiological marker of 
process S is the Slow Wave Activity (SWA) during NREM sleep. The circadian 
process (C) controls the distribution of wake and sleep throughout the 24 hours 
(Daan et al., 1984; Acherman and Borbely, 2003) and depends on the activity of the 
suprachiasmatic nucleus (SCN), the master circadian pacemaker. In fact, it has been 
documented that damage of the SCN deranges the circadian regulation of sleep 
(Saper, 2005a,b). The intrinsic period of the SCN is not exactly 24 hours and requires 
daily adjustment to the light-dark cycle, a process known as photoentrainment. The 
light represents the main “time giver” (zeitgeber) for the synchronization of circadian 
rhythms and light information reaches the SCN from the mRGCs through the RHT 
(Berson, 2003).  
The homeostatic and circadian processes operate in parallel, but interact and 
influence each other (Cajochen, 2010). In fact, many cerebral structures with a 
crucial role in homeostatic sleep regulation, such as the VLPO, are modulated by 
circadian influences and by direct projections from the mRGCs (Dijk and Archer, 
2009). Moreover, the SCN interacts with the ventral and the dorsal 
subparaventricular zones, and with the VLPO through the dorsomedial nucleus of the 
hypothalamus (DMH) (Saper, 2005a,b). This nucleus is important for integrating 
circadian rhythms and sleep, motor activity, feeding and corticosteroid secretion 
(Saper, 2005a, 2005b). The interaction between the circadian and homeostatic 
processes is also reinforced by the observation of a different homeostatic regulation 
in morningness/eveningness types, which are characterized by a different timing of 
sleep, i.e. the chronotype (Mongrain et al., 2006, 2007). Moreover, emerging data 
support a non-circadian role of the so-called clock genes, the molecular machinery of 
the SCN, whose cyclic expression controls the circadian rhythm of many biological 
functions (Rosenwasser, 2010). In fact, homeostatic deregulation may be secondary 
to circadian clock disruption, either involving clock genes, or SCN or melanopsin 
itself (Franken and Dijk 2009; Dijk and Archer, 2009, 2010). Abnormal homeostatic 
phenotypes have been documented in mice lacking the core clock genes, Cry1 and 
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Cry2 and in mice homozygous for the Bmal1 deletion and Clock mutation (Franken 
and Dijk, 2009). Similarly, the variable number of tandem repeats polymorphism in 
the Per3 gene, linked to extreme diurnal preference (eveningness) and delayed sleep 
phase syndrome (Archer et al., 2003), influences EEG markers of the homeostatic 
process, such as SWA (Viola et al., 2007; Vandewalle et al., 2009b). Furthermore, 
lesions of the SCN may produce abnormalities in homeostatic aspects of sleep 
regulation (Mistlberger, 2005). Conversely, the homeostatic status may influence the 
circadian variation of different cognitive functions and sleep variables in humans, as 
well as the expression of clock genes may present sleep-wake cycle dependent 
changes (Franken and Djik 2009). Overall, the impact of clock genes on metabolism, 
mood, cognition and sleep is extremely wide and may explain the important 
contribution of the circadian process in regulating different aspects of sleep. Finally, 
the sleep features of the subterranean mole rat, Spalax ehrenbergi, are very similar to 
other non-subterranean mammals, suggesting that the maintenance of the RHT 
system may be sufficient to drive a normal photoentrainment of the sleep-wake 
cycle, even in the absence of eyes as organ for vision (Tobler and Deboer, 2001).  
2.2. Role of mRGCs in sleep 
Recently, much emphasis has been given to the role that mRGCs may have in the 
specific modulation of sleep. In fact, Lupi and coauthors demonstrated that the 
genetic ablation of the melanopsin gene (Opn4) in mice abolishes the light-mediated 
induction of sleep. This sleep induction is related to the activation of sleep-promoting 
neurons in the VLPO and superior colliculus, as demonstrated by the strong increase 
in Fos espression induced by light exposure, suggesting that melanopsin-based 
photoreception is necessary and sufficient for sleep regulation (Lupi et al., 2008). 
Sleep in these mice is induced after 7-10 minutes of exposure to light at high 
irradiance (more than 50 µW/cm2) and this response seems independent to 
rods/cones contribution (Lupi et al., 2008). Similarly, Altimus and coauthors 
demonstrated that mRGCs play a direct role in light-induced modification of EEG 
activity in mice (Altimus et al., 2008). These authors, at difference with Lupi and 
colleagues, showed that both rod-cone and melanopsin-based photoreception are 
necessary for exerting the full effect of light on sleep regulation (Altimus et al., 
2008). Further studies support a relevant role of mRGCs in the regulation of sleep 
homeostasis (Tsai et al., 2009). Indeed, the SWA, a marker of homeostatic drive, was 
significantly reduced after sleep deprivation in the Opn4 -/- mice (Tsai et al., 2009).  
In this study the authors also showed that time of day modulated the acute effects of 
light and dark only in the Opn4-/- mice, suggesting that melanopsin compensates for 
circadian changes in rod-cone sensitivity. Moreover, melanopsin influences EEG 
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activity modifications induced by dark pulses, having an alerting effect (Tsai et al., 
2009). The brain areas implicated in the acute effects of light on sleep-promoting 
neurons are the SCN and VLPO, as demonstrated by the 50% reduction in the 
activation of SCN neuronal activity after light pulse in the Opn4-/- mice and the light-
induced c-fos activation in the VLPO area (Tsai et al., 2009). The preminent role of 
mRGCs in regulating alertness/sleep is also supported by recent brain functional 
magnetic resonance studies showing that brief light exposure to blue light induces a 
significant activation of brainstem structures related to arousal regulation and this 
effect may depend also on circadian phenotype (Vandewalle et al., 2007, 2011a). 
Overall, these findings point to an important role of melanopsin in modulating, 
independently, not only the circadian aspect of sleep but also its homeostatic 
component. This hypothesis is well supported by the observation that different 
circadian phenotypes are characterized by distinguishable homeostatic regulation 
(Mongrain et al., 2006, 2007). Given that melanopsin exerts a fundamental role in 
photoentrainment of circadian rhythms and that chronotypes 
(‘morningness’/’eveningness’) reflect the ability to be entrained to the light-dark 
cycle, it is reasonable that genetic polymorphic variants in the melanopsin gene may 
play a relevant role in modulating the circadian phenotype. At this regard, the 
recently described association of a missense variant (P10L) of the OPN4 gene with 
the seasonal affective disorder (Roecklein et al., 2009) may well support this 
hypothesis. Seasonal affective disorder (SAD) is characterized by recurrent 
depression during the short days and long nights of fall and winter. An abnormal 
responsiveness to light has been suggested to be part of the mechanism leading to the 
seasonality of the disorder, which results in a possible circadian misalignment, and 
explains the efficacy of light therapy, in particular the blue light in this disorder 
(Glickman et al., 2006; Lewy, 2009a; Lewy et al., 2009b).  
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3. MELANOPSIN RETINAL GANGLION CELLS IN 
HUMAN DISEASES 
3.1. Melanopsin RGCs in human diseases 
There are only a limited number of studies on the melanopsin system in human 
diseases.  
As pointed out previously, the discovery of mRGCs came from the observation that 
in mice with extensive loss of rods and cones light was still able to photoentrain 
circadian rhythms (Foster et al., 1991; Freedman et al., 1999; Lucas et al., 1999).  
In humans, this was reflected by the observation that patients suffering blinding 
disorders with either extensive damage of rods and cones or different types of optic 
neuropathy maintained the melatonin suppression response induced by light and the 
light sensitivity (Czeisler et al., 1995; Pèrez-Rico et al., 2009; Zaidi et al., 2007).  
Differently, in other ocular disorders, such as glaucomatous optic neuropathy, 
mRGCs may be lost leading to the occurrence of circadian rhythms dysfunction and 
melatonin suppression response abnormalities (Drouyer et al., 2008; Pèrez-Rico et al. 
2010).  
Moreover, a possibile relevant role of mRGCs in mood disorders, and in particular in 
SAD, is suggested by the efficacy of blue light therapy and by the previously 
mentioned observation that a genetic variant in the Opn4 gene was associated with 
SAD (Lewy et al., 2006, 2009a,b; Roecklein et al., 2009). 
A further role of mRGCs in human disorders has been recently suggested in the 
exacerbation of migraine induced by light (Noseda et al., 2010, 2011). In this study, 
in fact, photosensitivity during migraine was present in blind migraineous patients 
with light perception, but absent in blind migraineous patients without light 
perception. Indeed, the authors of this study demonstrated that the activity of the 
dura-sensitive thalamocortical neurons, which are part of the nociceptive pathway 
underlying migraine pain, is modulated by light through the projections received 
from mRGCs (Noseda et al., 2010). 
3.2. Melanopsin RGCs in hereditary optic neuropathies 
At difference with retinal diseases characterized by extensive and selective loss of 
rods and cones, a class of inherited optic neuropathies, such as Leber’s hereditary 
optic neuropathy (LHON) and dominant optic atrophy (DOA), is characterized by 
selective loss of RGCs, thus representing an ideal model for studying a pathology 
potentially affecting mRGCs.  
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Previous to this PhD project we studied the mRGCs system in LHON and DOA by 
melatonin suppression test by light in affected LHON and DOA patients compared to 
controls, and by immunohistochemistry in post-mortem retinal and optic nerve 
specimens from LHON patients and controls. Overall, this study revealed that 
mRGCs were relatively spared and still able to sufficiently support circadian 
photoentrainment (La Morgia et al., 2010) (see annex 1). In fact, these patients had a 
melatonin suppression response induced by light comparable to controls and the 
analysis of retinal and optic nerve specimens revealed that mRGCs were 
preferentially spared compared to regular RGCs (La Morgia et al., 2010; Figure 7-8). 
The observation that mRGCs are spared in mitochondrial optic neuropathies explains 
the maintenace of the PLR reflex in these patients, an odd clinical feature known for 
a long time but never fully explained (La Morgia et al. 2010, 2011) (see annex 1, 2).  
 
 
Figure 7. Melatonin suppression test results in controls and optic neuropathy patients (La Morgia et 
al., 2010) 
                         
 
Figure 8. Left panel: immunohistochemical analysis on post-mortem retinas revealed that mRGCs are 
preferentially spared in comparison to the massive loss of regular RGCs in LHON patients. Right 
panel: distribution of mRGCs showed that they are more concentrated around the fovea (La Morgia et 
al., 2010)  
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Other authors subsequently confirmed these findings (Kawasaki et al., 2010; Moura 
et al., 2011; Storoni et al., 2011). Furthermore, a mice model with rotenone-induced 
optic neuropathy mimicking LHON was also shown to maintain the PLR (Zhang et 
al., 2006). Complexively, these observations suggest that mRGCs have specific 
metabolic properties that make them more resistant to neurodegeneration in 
mitochondrial optic neuropathies. This is also supported by studies showing 
increased resistance of mRGCs to different kind of injuries, such as for example 
optic nerve transection (von Bussman et al., 1993; Robinson and Madison, 2004; Li 
et al., 2008). Von Bussman and colleagues reported that a small subset (about 1%) of 
RGCs survived to optic nerve transection and these cells had large bodies, 
intensively stained with cytochrome oxidase (COX), pointing to mRGCs (Von 
Busman et al., 1993). Subsequently, Li and colleagues substantiated that mRGCs are 
indeed spared after optic nerve transection (Li et al., 2008). Other evidences of 
mRGCs robustness are provided by studies on cell toxicity to monosodium glutamate 
(Chambille and Serviere, 1993; Hannibal et al., 2001).  
The “special” robustness of mRGCs to different stressful insults remains an open 
question, which needs specifically designed studies. In this PhD project the analysis 
of the mRGCs system in hereditary optic neuropathies has been further expanded.  
Overall, optic neuropathies are a general paradigm to investigate a possible 
pathology affecting mRGCs, following the assumption that the specific involvement 
of RGCs in human diseases has the potential to affect also the melanopsin-expressing 
RGCs.  
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4. OPTIC NERVE INVOLVEMENT IN AGING AND 
NEURODEGENERATIVE DISORDERS.  
4.1. Aging 
An age-related loss of axons in the optic nerve has been documented in different 
histopathological studies (Dolman et al., 1980; Johnson et al., 1987; Balazsi et al., 
1984). In particular, Johnson and coauthors found a similar loss of axons in the 
central and peripheral portions of the optic nerve without any specific regional 
pattern (Johnson et al., 1987). Similarly, more recent optical coherence tomography 
(OCT) studies demonstrated an age-related reduction of retinal nerve fiber layer 
(RNFL) thickness (Budenz et al., 2007; Feuer et al., 2011). The decline of the 
average RNFL thickness documented by these two studies was 2.0 and 2.4 µm 
respectively for every decade of age. This decline, according to Feuer and 
colleagues, is not a homogeneous phenomenon, showing a preferential loss of RNFL 
in the superior quadrant (Feuer et al., 2011). The temporal and inferior quadrant 
showed significantly less evident decline of retinal nerve fibers compared to the 
superior (Feuer et al., 2011). Overall, these studies document an age-related loss of 
axons in the optic nerve that becomes relevant in depleting the optic nerves from the 
age 60.  
4.2. Alzheimer Disease and Mild Cognitive Impairment 
Complex visual complaints, including difficulties in reading or finding objects, depth 
perception, perceiving structure from motion, color recognition and contrast 
sensitivity abnormalities are frequent in Alzheimer Disease (AD), and can affect up 
to 40% of AD patients (Mendez et al., 1990; Guo et al., 2010; Sadun et al., 1987; 
Katz and Rimmer, 1989a; Jackson and Owsley, 2003).  
The presence of these abnormalities may be related to a primary retinal degeneration, 
as well as to a damage of the primary visual and visual associative areas. Since 1986 
it was shown by Hinton and colleagues that in post-mortem retinas and optic nerves 
of AD patients there was loss of RGCs and related axons, involving preferentially the 
M-cell system, in the apparent absence of neurofibrillary or amyloid angiopathy 
(Hinton et al., 1986; Sadun and Bassi, 1990) (Figure 9). 
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Figure 9. Optic nerves stained by p-Phenylenediamine method are shown. A. Normal control. B and 
C. Alzheimer optic nerves showing moderate (B) and severe (C) degenerated profile with looser 
axonal packing in the severe case (Hinton et al., 1986) 
 
After this report, other authors showed the presence of optic nerve degeneration, 
being more evident in the superior and inferior quadrants and in the foveal region in 
post-mortem tissues of AD patients (Blanks et al., 1989; 1996a; 1996b). Age-related 
amyloid deposition in RGCs and RNFL has been documented in the human retina 
from normal individuals (Löffler et al., 1995), as well as evidence of retinal A" 
deposition has been reported in transgenic mouse models of AD (Ning et al., 2008; 
Perez et al., 2009; Dutescu et al., 2009; Liu et al., 2009). Further, the presence of 
amyloid plaques has been detected in whole-mounted post-mortem retinas of AD 
patients stained with curcumin and anti-A"42 antibodies (Koronyo-Hamaoui et al., 
2011) (Figure 10). 
 
Figure 10. a-f Whole-mounted retinas from normal individuals and possible AD patients stained with 
curcumin anti-A"42 antibodies. A" plaques cannot be detected in cognitively normal individuals (a); 
in patients with severe-stage AD abundant A" plaques are visible (f) (modified from Koronyo-
Hamaoui et al., 2011)  
 
More recently, the use of OCT allowed objective measurements of RNFL and 
macular thickness for in-vivo quantitative evaluation of RGCs loss in AD. Parisi and 
coauthors in 2001 found significant and generalized RNFL thinning and pattern 
electroretinogram (pERG) abnormalities in 17 AD patients (Parisi et al., 2001, 2003). 
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Similarly, in 2006, Iseri and coauthors demonstrated a significant thinning of average 
RNFL, as well as thinning of the superior, inferior and nasal quadrants, and reduction 
of macular volume in 14 AD patients compared to controls, in the absence of visual 
evoked potentials (VEPs) abnormalities. The reduction of macular volume was 
correlated to the degree of cognitive impairment (Iseri et al., 2006). Significant 
thinning of the RNFL in the superior quadrant and decreased blood vein flow in the 
retina were also reported in early AD cases (Berisha et al., 2007). Moreover, also 
patients with amnestic mild cognitive impairment may present a diffuse reduction of 
the RNFL, as assessed by OCT, suggesting that optic nerve involvement may be a 
pre-clinical sign of neurodegeneration in AD (Paquet et al., 2007; Kesler et al., 
2011). More recently Lu and coauthors demonstrated RNFL thinning of the superior 
and inferior quadrants in 22 AD patients (Lu et al., 2010). The preferential 
involvement of the superior and inferior quadrants is compatible with the seminal 
observations of a preferential involvement of the magnocellular system in AD 
(Hinton et al., 1986; Sadun and Bassi, 1990), as well as with the electrophysiological 
findings. This pattern resembles the optic neuropathy occurring in glaucoma (Brusini 
and Johnson, 2007), which interestingly has a higher incidence in AD patients (Bayer 
et al., 2002a,b). However, the link between AD and glaucoma remains elusive and 
pathogenic mechanisms linking the two conditions are controversial (Wostyn et al., 
2009, 2010).  
Further, Kesler and coauthors demonstrated a significant decrease of RNFL thickness 
in both MCI (n=24) and AD (n=30) patients compared to controls, more evident in 
the superior quadrant for AD, and in the inferior for both MCI and AD patients 
(Kesler et al., 2011).  A summary of OCT findings in AD is reported in Table 1.  
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Table 1. OCT findings in AD and MCI patients. 
 
The presence of retinal degeneration in AD is also supported by electrophysiological 
investigations with VEPs and pERGs recordings, which demonstrated an abnormal 
RGCs function, even at early stages of the disease (Visser et al., 1976, 1985; Coben 
et al., 1983; Pollock et al., 1989; Katz et al., 1989b; Parisi et al., 2001; Trick et al., 
1989; Sartucci et al., 2010; Krasodomska et al., 2010). Interestingly, Krasodomska 
and coauthors studied 30 early AD patients, with Mini-Mental score more than 21 
and duration of the disease less than 2 years, reporting an increased implicit time of 
the P50-wave and amplitude reduction of the P50 and N-95 in pERG examination, an 
increased latency of P-100 wave as well as a significant prolonged retino-cortical 
time (RCT) in pattern VEPs (Krasodomska et al., 2010). Sartucci and coauthors, 
using both chromatic and luminance visual stimuli in 15 early AD cases, described 
abnormal pERG and VEPs responses with normal retinocortical conduction time, 
compatible with a primary dysfunction of the magnocellular pathway in AD 
(Sartucci et al., 2010). These findings are in accordance with the observation of a 
prevalent deposition of amyloid plaques and neurofibrillary tangles in the primary 
visual cortex prevalent in the M-pathway described in AD (Hof et al., 1997) and 
propose that the involvement of the retina may be secondary to a retrograde axonal 
degeneration (Sartucci et al., 2010).  
Overall, these findings suggest an early involvement of the visual system in the 
neurodegenerative process in AD, prompting the screening of retinal abnormalities in 
mild cognitive impairment patients. It is still controversial whether the visual 
OCT N.patients MMSE Results 
Parisi V et al. 2001 
Clinical 
Neurophysiol 
Stratus 17 AD 
14 controls 
11-19 !avg RNFL 
! RNFL thickness in all 4 
quadrants 
no correlation with MMSE 
Iseri PK et al. 2006 
J Neurophthalmol 
Stratus 14 AD  
15 controls 
18.5 ± 6.3 !avg RNFL thickness 
!sup/inf/nasal RNFL  
!macular volume 
Paquet C et al. 2007 
Neuroscience letters 
Stratus 23 MCI,  
14 mild AD 
12 sev AD 
mild AD 
(20-25); severe 
AD (11-19) 
!avg RNF thickness in MCI, 
mild and severe AD 
Berisha F et al. 2007 
IOVS 
Stratus 9 AD 
8 controls 
24 (17-30) !sup RNFL thickness 
abnormal blood flow rate 
Lu Y et al. 2010 
Neuroscience letters 
Stratus 22 AD 
22 ctrls 
not specified !avg RNFL 
!sup/inf RNFL thickness 
Kesler A et al. 2011 
Clin Neurol 
Neurosurg 
Stratus 24 MCI 
30 AD 
24 ctrls 
28.1 ± 2.1 (MCI) 
23.6 ± 4.3 (AD) 
!avg RNFL in MCI and AD 
!inf RNFL in MCI and AD 
!sup RNFL in AD 
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problems are a consequence of a primary retinal or cortical involvement in AD, or 
both. In support of a primary retinal contribution to the occurrence of visual 
dysfunction in AD is the evidence that melatonin suppression response induced by 
light in AD patients is impaired, suggesting the presence of an abnormal mRGCs-
RHT-SCN axis (Ohashi et al., 1999).  
The presence of a specific involvement of the mRGCs system may also explain the 
occurrence of impaired pupillary light reflex described in AD, even if this has been 
also related to the presence of a cholinergic defect (Fotiou et al., 2007, 2009). 
4.3. Parkinson disease 
In the last few years emerging evidences support the involvement of the retina and 
the optic nerve in the neurodegenerative process in PD, explaining the occurrence of 
visual dysfunction in PD (Bodis-Wollner 2009; Archibald et al., 2009, 2011a). 
Visual problems, including abnormalities in colour vision, may occur early and are 
by some authors proposed as markers, among the nonmotor signs, with the best 
discriminatory power in distinguishing early PD from controls (Diederich et al., 
2010). Visual dysfunction, and in particular colour vision abnormalities seem to 
occur more likely in PD patients with Rem Behavior Disorder (RBD) than without 
RBD, and they are also described in idiopathic RBD (Postuma et al., 2008, 2009), 
suggesting that different subgroups of PD patients may have different clinical 
expression of non-motor symptoms. In particular, impaired visual acuity (Jones et al., 
1992; Matsui et al., 2006), abnormal contrast sensitivity (Regan and Neima, 1984; 
Bodis-Wollner et al., 1987; Diederich et al., 2002), colour vision abnormalities (Price 
et al., 1992; Silva et al., 2005) and optic nerve degeneration have been described in 
PD (Hunt et al., 1995; Archibald et al., 2009). Furthermore, impaired visual 
processing has been related to visual hallucinations in PD (Meppelink et al., 2009). 
The defects in contrast sensitivity described in PD have been related to the dopamine 
deficiency in the retina, as demonstrated by the fact that many of these alterations 
improve after the administration of L-Dopa (Bulens et al., 1987; Hutton et al., 1993). 
In fact, retinal depletion of dopamine in PD patients has been described since 1988 
(Nguyen-Legros, 1988, Harnois and Di Paolo, 1990; Bodis-Wollner, 1990) and 
shown to play a relevant role in the contrast sensitivity, VEPs and pERG 
abnormalities described in these patients (Bodis-Wollner and Yahr, 1978; Tagliati et 
al., 1996). Retinal dopamine regulates, via D1 receptors, the light adaptation process 
influencing the surrounding organization of the RGCs (Bodis-Wollner, 2009). 
Further, visual evoked potentials and pattern ERG abnormalities described in PD 
may be reversed by the administration of L-DOPA (Peppe et al., 1995, 1998). 
Moreover, the observation of reduced dopamine content in the retina of PD patients 
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may turn out relevant in the occurrence of circadian rhythms dysfunction in PD. In 
fact dopaminergic amacrine cells interact bidirectionally and influence the activity of 
mRGCs (Zhang et al., 2008; Vugler et al., 2007) and dopamine itself may influence 
the melanopsin gene expression (Sakamoto et al., 2005; Hannibal et al., 2006c). An 
abnormal retinal dopaminergic function may impair the integrity of the mRGCs 
system, possibly contributing to the occurrence of circadian and sleep problems in 
PD patients.  
Optical coherence tomography (OCT) and Heidelberg Retina Tomograph (HRT) 
measurements in PD patients documented a reduction of the retinal nerve fiber layer 
(RNFL) thickness in both early and more advanced stages of the disease. Inzelberg 
and coauthors in 2004 described a significant thinning of the RNFL thickness by 
OCT in the inferotemporal quadrants in 10 PD patients (Inzelberg et al., 2004). 
Yavas and coauthors found a significant RNFL thickness reduction by HRT in the 
nasal, superonasal, inferonasal and inferotemporal sectors in 44 PD patients and, 
interestingly, the RNFL thickness was higher for patients treated with l-DOPA than 
with dopamine agonists, suggesting a possible neuroprotective role of levodopa 
therapy (Yavas et al., 2007). Similarly, Altintas and coauthors described a 
generalized reduction of the RNFL by OCT, which reached the significance for the 
superior and nasal quadrants, and of the macular thickness and macular volume in 17 
PD patients compared to controls (Altintas et al., 2008). In this series foveal 
thickness is correlated with UPDRS score (Altintas et al., 2008). More recently Hajee 
and coauthors, using a Fourier-domain OCT, found a significant thinning of the 
superior and inferior thickness of macular inner retinal layer in 24 early PD patients 
(48% of the sample were drug naïve patients) (Hajee et al., 2009). These 
measurements did not correlate with the disease severity (Hajee et al., 2009). 
Moschos and colleagues, combining the OCT and multifocal ERG techniques 
demonstrated a significant thinning of the RNFL thickness in the inferotemporal 
quadrant and reduced foveal electrical activity in 16 PD patients without visual 
impairment (Moschos et al., 2011). Cubo and coauthors found a reduced foveal 
thickness in 9 PD and 9 essential tremor patients compared to controls (Cubo et al., 
2010). Differently, Archibald and colleagues did not find any differences in terms of 
retinal thickness between 34 PD patients and 17 controls (Archibald et al., 2011b). 
Similarly, Aaker and coauthors did not find significant differences between PD and 
controls in terms of RNFL thickness, but only for macular thickness measurements 
(Aaker et al., 2010).  
A summary of OCT findings in PD is reported in Table 2. 
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Table 2. OCT findings in PD patients. 
 
The observation that optic nerve dysfunction may occur early in the disease course is 
extremely important, representing a possible reliable early biomarker for the 
diagnosis of PD.  
Interestingly, a mouse model with a spontaneous deletion in the ubiquitin C-terminal 
hydrolase L1 (UCH-L1; Park5), whose variants are associated with sporadic AD and 
PD, is characterized by a disturbed sleep/wake rhythm in association with a 
significant reduction of mRGCs in the retina (Pfeffer et al., 2012). This is direct 
evidence connecting the retinal pathology to the abnormalities of circadian rhythms 
and sleep in a model of neurodegeneration.  
Overall, the involvement of the retina, and in particular of the RGCs in the 
neurodegenerative process in PD may allow to hypothesize a contribution of the 
mRGCs system in the occurrence of sleep and circadian rhythms dysfunction in PD 
human patients.  
 
OCT N.patients Results 
Inzelberg et al. 2004 
Vis Res 
Stratus 10 PD 
10 ctrls 
!inf RNFL thickness 
!temp RNFL thickness 
No correlation with disease duration 
Yavas et al. 2007  
Eur J of Opthalmol 
Heidelberg 
Retinal 
Tomograph 
44 PD  
21 controls 
!avg, nasal, supero and infero-nasal and 
infero-temporal RNF thickness  
(patients on L-dopa have thicker RNFL) 
Altintas et al. 2008 
Doc Ophthalmol 
Stratus 17 PD 
11 controls 
!avg, sup and nasal RNFL thickness and 
!macular thickness and volume (correlation 
foveal thickness/UPDRS) 
Hajee et al. 2009 
Arch Ophthalmol 
Spectral-
domain OCT 
(macula) 
24 PD (48% de-
novo) 
17 controls 
!  sup and inf thickness of macular IRL 
No correlation with severity of disease 
Moschos et al. 2010 
Eur J Opthalmol 
Stratus 16 PD 
20 controls 
!inf and temp RNFL thickness 
 
Cubo et al. 2010 
Mov Dis  
Stratus 9 PD; 8 ET 
9 controls 
!foveal thickness in PD and ET vs controls 
(thinner in the eye controlateral ete of the 
most affected side) 
Archibald et al. 2011 
Park and relat dis  
Stratus 34 PD 
17 controls 
no differences in RNFL thickness, macular 
thickness and volume 
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5. SLEEP AND CIRCADIAN DYSFUNCTION IN AGING 
AND NEURODEGENERATIVE DISORDERS 
5.1. Aging 
Sleep-related complaints are common in aging and affect up to 70% of the elderly 
population (Van Someren, 2000). They include difficulties in initiating and 
maintaining sleep with early awakenings, and changes in the quality and timing of 
sleep (Dijk et al., 2000; Huang et al., 2002; Bliwise et al., 2005; Wu and Swaab, 
2007a; Auger and Boeve, 2011). Sleep efficiency declines progressively with age, 
from approximatively 86% at age 37-54 to 79% over age 70 (Bliwise et al., 2005). 
Changes in the sleep architecture are represented by a reduction of the total sleep 
time and in particular of the time spent in slow wave sleep (SWS), but also reduced 
density of REM sleep and loss of increase of REM sleep through the night (Neikrug 
and Anconi-Israel, 2010). Changes in the timing of sleep include early awakenings 
and early bedtime. These modifications result from both an abnormal homeostatic 
regulation of sleep and/or dysfunctional regulation of circadian rhythms (Huang et 
al., 2002; Cajochen et al., 2006). In particular, the homeostatic changes described 
with aging comprise a reduction of the slow-wave and spindle frequency activity 
during sleep, and increased awakenings during the night (Cajochen et al., 2006). The 
circadian rhythm-related changes reported with aging are represented by a reduction 
of the amplitude of core body temperature by 20-30%, melatonin and cortisol 
circadian rhythms, earlier bed and wake-time and phase-advance of circadian 
rhythms (Mirmiran et al., 1992; Dijk et al., 2000). The latter has been interpreted not 
to be secondary to a change of the endogenous circadian period per se but to a 
weakened circadian process (Cajochen et al., 2006). The occurrence of sleep and 
circadian abnormalities in the elderly may be determined by: a) degenerative changes 
affecting the retina and the optic nerve (Johnson et al., 1987; Chakravarty et al., 
2010) b) reduced transmission of light, particularly blue light, through a yellowing 
ocular lens c) increased incidence of macular degeneration and glaucoma (Turner 
and Mainster, 2008; Heiduschka et al., 2010). Moreover, both in animal models and 
humans there is evidence that mRGCs are lost with aging (magnitude of 40% 
reduction) (Semo et al., 2003; Lax et al., 2011; Lupi et al. 2012; Esquiva et al., 
2010). Interestingly, Lupi and coauthors demonstrated that aging rather than retinal 
degeneration was more important in reducing the SCN response to retinal inputs 
(Lupi et al., 2012). In fact, the amplitude of light-induced Fos expression in the SCN 
is significantly reduced in aged mice but it is similar in wild-type and retinal 
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degenerated mice (Lupi et al., 2012). Further, the presence of lipofuscin deposits has 
been demonstrated in aging human retinas (Vugler et al., 2007). All these conditions 
may affect the ability of the eye to synchronize circadian rhythms to the light-dark 
cycle. Moreover, loss of mRGCs with aging may also affect, due to the projections of 
these cells to the VLPO, the stability of the flip-flop switch mechanism of sleep, 
hence leading to increased propensity to be awake during sleep (Saper, 2005a,b). 
Thus, the sleep abnormalities described in the elderly may be interpreted as a 
consequence of a reduced circadian signal. Moreover, at the level of the SCN, 
neurodegenerative changes including loss of vasopressin-expressing neurons and 
reduced sensitivity of the clock gene machinery to light stimuli may contribute to a 
reduced efficiency of the photoentrainment process (Hofman and Swaab, 1994; 
Hofman, 2000). Furthermore, degenerative changes of the pineal gland, 
abnormalities of the melatonin circadian rhythm (Skene et al., 1990; Wu and Swaab, 
2005), an increase in the calcium content of the pineal gland (Humbert and Pevet, 
1991), abnormal sympathetic regulation of melatonin synthesis (Wu and Swaab, 
2005) and decreased expression of melatonin receptors at the SCN level (Wu et al., 
2007b; Sánchez-Hidalgo et al., 2009) have all been reported with aging. Finally, 
elderly are less exposed to light and other non-photic zeitgbers, such as food and 
social enviroment (Auger and Boeve, 2011). The prominent role played by the 
mRGCs-RHT-SCN system in the pathogenesis of circadian and sleep problems in 
aging is also supported by the amelioration of sleep dysfunction with light therapy 
(Wu and Swaab, 2007a; Dowling et al., 2008; Riemersa-van der Leck et al., 2008). 
Further, the fragmentation of the rest-activity rhythm with age is relevant for the 
occurrence of age-related cognitive deficits (Oosterman et al., 2009) and the day-to-
day stability of sleep-wake rhythm is a strong predictor of cognitive disturbances 
(Carvalho-Bos et al., 2007), as well as the loss of sleep is a major predictor of the 
occurrence of dementia (Kang et al., 2009). Moreover, sleep-dependent consolidation 
of memory is altered with aging (Harand et al., 2012; Pace-Schott & Spencer, 2011). 
The management of sleep and circadian dysfunction occurring with age may be 
extremely important to counteract the age-related cognitive decline.  
5.2. Alzheimer Disease and Mild Cognitive Impairment 
The occurrence of sleep and circadian abnormalities is frequent (25-40%) in AD 
patients and may present early in the course of disease (Reynolds et al., 1988; 
Vitiello et al., 1991; Carpenter et al., 1995; McCurry et al., 1999; Van Someren et al., 
1997a,b; Moran et al., 2005; Wu and Swaab, 2007a). The severity of sleep disruption 
often worsens while the disease progresses over the years contributing to the severity 
of cognitive impairment (Moe et al., 1995). Rest-activity rhythm circadian 
 24 
dysfunction in AD patients compared to age-matched controls has been studied by 
prolonged actigraphic monitoring and is represented by fragmented sleep-wake cycle 
with frequent awakenings during the night and daytime naps, higher intradaily 
variability and less interdaily stability of the rest-activity rhythm, lower rhythm 
amplitude and later acrophase (Witting et al., 1990; Satlin et al., 1995; Van Someren 
et al., 1996, 1997a,b; Ancoli-Israel et al., 1997; Mishima et al., 1997; Hatfield et al., 
2004; Harper et al., 2005, 2008; Hu et al., 2009). These changes in the rest-activity 
rhythms may appear early in the disease course (Hu et al., 2009). Furthermore, an 
irregular sleep-wake pattern and a phase advance of the sleep-wake rhythm have 
been reported in AD patients (Prinz et al., 1982). Polysomnographic studies also 
documented an abnormal macrostructure of sleep, and in particular reduced sleep 
efficiency and slow wave activity and longer REM sleep latency (Vitiello and Prinz, 
1989; Moe et al., 1995; Yesavage et al., 2004; Cooke et al., 2006). Moreover, AD 
patients frequently suffer sundowning, i.e. the occurrence of motor and behavioural 
agitation in the late evening/night. Sundowning may be considered as a 
chronobiological disorder related to an abnormal circadian rhythm of the body 
temperature, and in particular to a phase delay of this rhythm (Volicer et al., 2001). 
Furthermore, lower melatonin levels, especially in patients homozygous for the 
APOE #4 allele (Liu et al., 1999), reduced amplitude of melatonin circadian rhythm 
(Mishima et al., 1999), irregular melatonin rhythm (Uchida et al., 1996), lower 
cerebrospinal fluid levels of melatonin (Liu et al., 1999) as well as a significant 
reduction of the melatonin receptors type 1 expression characterizing the advanced 
stages of AD, have all been documented also in preclinical (Braak stages I-II) AD 
cases (Zhou et al., 2003, Wu et al., 2007b). Other examples of circadian dysfunction 
in AD include a phase-delay (Satlin et al., 1995; Volicer et al., 2001; Harper et al., 
2001), increased amplitude (Touitou et al., 1986) and disorganization of the body 
temperature circadian rhythm (Okawa et al., 1991). The presence of core body 
temperature disorganization may predict the occurrence of more severe sleep 
disturbances in these patients (Satlin et al., 1995). Abnormalities of heart rate 
(Reynolds et al., 1995), blood pressure (Otsuka et al., 1990) and cortisol rhythm 
(Hatfield et al., 2004) have also been documented in AD. Interpreting the circadian 
and sleep dysfunction in AD, it must be taken into account a possible abnormal phase 
relationship between circadian rhythms, as for elderly, explaining the discordance 
between the phase-delay of the temperature rhythm and the reported phase-advance 
of sleep rhythm (Auger and Boeve, 2011). 
Sleep and circadian abnormalities have also been described in mouse models of AD 
characterized by extracellular A" deposition (Wisor et al., 2005; Gimenez-Llort et 
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al., 2007; Sterniczuk et al., 2010). Wisor and coauthors, studying a mouse model 
with age-dependent deposition of amyloid in the brain, found that sleep 
abnormalities are related to the cholinergic deficiency, due to the accumulation of 
oligomeric A" species in the brainstem (Wisor et al., 2005). Interestingly, Sterniczuk 
and coauthors recently demonstrated in a triple transgenic AD mouse model that 
abnormalities of circadian rhythms are very early, preceding the AD pathology. In 
particular, the authors showed a reduced number of vasoactive intestinal polypeptide 
(VIP) and vasopressin (AVP) cells in the SCN of the AD mice compared to control 
animals (Sterniczuk et al., 2010).  
Many factors may contribute to the pathogenesis of circadian rhythms abnormalities 
in AD patients, which include genetic factors, as the APOE genotype (Yesavage et 
al., 2004), neurodegenerative changes of the retina and in particular of the mRGCs 
specific of AD, changes of the endogenous circadian period and neurodegenerative 
findings at the SCN level. The neurodegenerative changes affecting the SCN 
described in AD patients are more pronounced and occur earlier than in age-matched 
controls (Swaab et al., 1985, 1987). Moreover, the neuropathological findings 
characteristic of AD, such as tangles and pretangles, but not neuritic plaques, and 
reduced AVP gene expression have been found in the SCN of AD patients (Stopa et 
al., 1999; Wu and Swaab, 2007a). Another factor that may contribute to the 
pathogenesis of circadian dysfunction in AD, is the reduced light exposure during the 
day (Wu and Swaab, 2007a). Many of these changes are also relevant for the 
occurrence of circadian dysfunction in elderly, but in AD they are more dramatic, 
early and severe.   
The occurrence of circadian and sleep dysfunction has been documented also in 
about 14-59% of MCI patients, even if these data are mainly derived from subjective 
measures, such as sleep questionnaires (Beaulieu-Bonneau et al., 2009). In amnestic 
MCI patients a lower interdaily stability of the rest-activity rhythm and reduced sleep 
quality are associated to inadequate memory consolidation (Westerberg et al., 2010). 
Moreover, recent studies suggest that the presence of rest-activity rhythm 
abnormalities may represent a strong predictor for the development of dementia. In 
particular, the presence of decreased circadian activity rhythm amplitude and 
robustness, and delayed rhythm increases the risk of developing MCI and dementia 
in a 5 years follow-up study (Tranah et al., 2011). Moreover, chronic sleep restriction 
significantly increases the formation of amyloid plaques in an amyloid precursor 
protein transgenic mouse model, thus possibly playing a pathogenic role in the 
development of AD (Kang et al., 2009).  
A summary of studies on circadian rhythms in AD is provided in Table 3 and 4.  
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Table 3. Summary of studies on circadian rhythms findings in AD patients. 
Parameters N.patients Results 
Campbell et al. 
1988 
Actigraph 
 (Cosinor analysis) 
No differences between AD and 
controls 
Witting et al. 1990 
Biol Psychiatry 
Actigraph for 90-168 
hrs 
6 young ctrls 
13 old controls 
12 AD hospitalized (mod-sev) 
Lower IS and increased IV 
No significant differences between 
young and old controls 
Satlin et al. 1995 
Neurobiol of aging 
Actigraph for 72 hrs  
Core body T 
cosinor analysis and 
IS 
CR 
28 AD severe hospitalized 
10 controls 
Lower IS and increased nocturnal 
activity in AD 
Lower amplitude and later 
acrophase of locomotor activity 
and later acrophase of T’ rhythm 
Van Someren et al., 
1999 Chronobiol 
Int  
Actigraph for 2 weeks 
Non parametric 
methods compared to 
cosinor analysis 
17 AD hospitalized 
 
Reduced IS in AD 
IS improved by light therapy 
(parameter with high sensibility) 
Volicer et al. 2001 
Am J Psychiatr 
Actigraph (cosinor 
and non-parametric) 
Core-body T (72hrs) 
CR only for AD 
25 AD (severe) 
9 controls  
Reduced IS and later acrophase of 
rest-activity rhythm 
Higher temperature mesor, greater 
amplitude and later acrophase 
Later acrophase of T and locomot 
activity in sundowning pts 
Parameters N.patients Results 
Hatfield et al., 
2004 
Brain 
Actigraph for 28 days 
repeated after1 yr 
Non-parametric methods 
Cortisol rhythm 
Free-running 
19 ctrls 
27 AD not 
instituzionalized (mild, 
AD; n=13- and moderate 
AD; n=14) 
Reduced IS and RA; higher IV in 
moderate AD vs controls 
Positive correlation MMSE-IS 
Heterogeneous findings  
Normal cortisol rhythm 
Substantial stability after 1 yr 
Harper et al. 
2005 Am J Ger 
Psych 
Actigraph 
Temperature 
Non-parametric and 
cosinor analysis 
Costant routine 
Normal young (7)  
Old controls (7) and severe 
AD (7)  
Pre-constant routine for 72 hrs 
and constant routine for 36-
hrs 
Higher mesor, lower amplitude and 
delayed phase of T in AD 
Reduced IS and RA and higher IV 
Reduced mesor and absolute 
amplitude  
Harper et al.  
2008 Brain  
Actigraph for 72 hrs 
Temperature for 72 hrs 
SCN (Dorsomedial-
vasopressin and 
neurotensin neurons) 
neuropathology 
Non-parametric and 
cosinor analysis 
19 AD pts 
8 controls 
Significant loss of vasopressin 
neurons in AD 
Significant correlation between 
temperature rhythm and SCN 
degeneration 
Vasopressin loss ! increased IV 
Neurotensin loss ! reduced 
amplitude of temperature and RA 
of locomotor rhythm 
Hu K et al. 
PNAS 2009 
Scale-invariant activity 
fluctuations (driven by 
the SCN) 
Actigraph for 1 week 
13 young ctrls 
13 elderly ctrls 
12 very old controls 
13old- early stage AD 
14very-old  late stage AD 
Reduced scale invariance of activity 
fluctuation in AD 
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Table 4. Summary of studies on circadian rhythms findings in AD mouse models. 
5.3. Parkinson disease 
The presence of sleep disturbances in Parkinson disease (PD) is an early and frequent 
(up to 88% of PD patients) complaint, often preceding many years the onset of motor 
symptoms (Thorpy and Adler, 2005). In particular, Rem-sleep Behaviour Disorder 
(RBD), occurring in 15-50% of PD patients, may start up to half a century before the 
appearance of motor signs (Claassen et al., 2010, Menza et al., 2010). The early 
appearance of RBD in the clinical course of PD is in accordance with the temporal 
and topographical sequence of ascending pathology described by Braak and 
coauthors (Braak et al., 2002). Moreover, the majority of PD patients have 
disturbances in initiating and maintaining sleep, poor quality of sleep and frequent 
nighttime awakenings. The increased fragmentation of night sleep is related to many 
factors including rigidity, difficulty in changing body position and muscle cramps, as 
well as medication and concomitant sleep disorders. Polysomnographic recordings of 
PD patients documented an abnormal sleep macrostructure with reduced sleep 
efficiency, total sleep time, slow wave and REM sleep and increased wake-time 
during the night (Chokroverty, 1996; Diederich et al., 2005; Adler and Thorpy 2005; 
Simuni and Sethi, 2008). Actigraphic monitoring of PD patients demonstrated an 
elevated nocturnal activity level and an increased movement time during the night 
compared to controls (van Hilten et al., 1994; Stavitsky et al., 2010). Degenerative 
changes affecting the brainstem structures involved in the control of sleep and wake, 
such as the pedunculopontine nucleus (PPN), the locus coeruleus, the raphe nucleus, 
the ventrolateral tegmental area, and the suprachiasmatic nucleus, may all contribute 
to the occurrence of sleep disturbances in these patients (Simuni and Sethi, 2008).  
Parameters Animal models Results 
Wisor et al. 
Neuroscience 
2005 
Actigraphic monitoring 
in LD and DD cycles 
EEG 
Tg2576 mouse model
(amyloidogenic swedish 
mutation) 
(age-dependent amyloid 
deposition) 
Longer circadian period in constant 
darkness (secondary to cholinergic 
deficiency) 
Abnormal timing of sleep relative to 
the LD 12:12 cycle 
Lower delta power after sleep 
deprivation 
EEG power shifted to higher 
frequencies in NREM 
Sterniczuk et 
al., 2010 Brain 
Res 
Actigraphic monitoring 
in LD and DD cycles 
Free-running Period  
Photic phase shifting 
SCN Histology  
Triple transgenic AD mice 
(Abeta and tau pathology) 
Greater locomotor activity during 
the day and shorter free-running 
period before the appearance of AD 
pathology (enhanced aging findings) 
Loss of VIP and VP neurons in the 
SCN 
Normal photic phase shifting 
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Furthermore, in PD patients there is evidence of an increased incidence of Restless 
Legs Syndrome, Periodic Limb Movements and Obstructive Sleep Apnea Syndrome 
compared to the general population and these sleep disorders may contribute and 
aggravate the sleep fragmentation and excessive daytime sleepiness during the day 
(Poewe and Högl 2000; Simuni and Sethi, 2008). Excessive daytime sleepiness 
affects up to 50% of PD patients and may be explained by the contribution of many 
factors, including the motor disability, the frequent concomitant occurrence of 
primary sleep disorders, the use of dopaminergic drugs, and also degenerative 
changes involving the brainstem cholinergic, serotoninergic, and noradrenergic 
regions, such as the PPN, locus coeruleus-subcoeruleus complex, and the reticular 
activating system (Boeve et al., 2007), as well as the loss of orexinergic neurons in 
lateral hypothalamus (Langston and Forno, 1978; Fronczek et al., 2007). This latter 
finding may explain the presence of narcolepsy-like features in some PD patients 
(Arnulf, 2005; Haq et al., 2010). However, other studies did not support the 
involvement of the hypocretinergic neurons in the PD neurodegenerative process in 
PD (Compta et al., 2009). 
Circadian alterations in Parkinson disease include phase advance and reduced 
amplitude of melatonin circadian rhythm (Bordet et al., 2003), reduced body 
temperature rhythm amplitude (Cagnacci et al., 1990) and abnormalities of heart rate 
variability, blood pressure and rest-activity circadian rhythm (Senard et al., 1992; 
Pursiainen et al., 2002; Whitehead et al., 2008; Niwa et al., 2011). In particular, 
considering the rest-activity rhythm, PD patients present increased intradaily 
variability, lower peak and reduced amplitude of activity levels compared to controls 
(Whitehead et al., 2008). These differences are more pronounced in PD patients with 
hallucinations suggesting that the presence of circadian abnormalities may be limited 
to a subgroup of PD patients (Whitehead et al., 2008). Another study with 
actigraphic monitoring documented the presence of reduced rhythm amplitude in PD 
compared to controls (Niwa et al., 2011). However, in the evaluation of these 
findings many confounding factors must be taken into account, including the 
presence of motor artifacts and the influence of dopaminergic treatment. 
Interestingly, the presence of reduced amplitude and phase advance of circadian 
rhythm of temperature, heart rate and locomotor activity has been demonstrated also 
in a rat model of PD, produced by bilateral striatal 6-OHDA lesions (Ben and 
Bruguerolle, 2000). In this model the infusion of L-Dopa may restore, at least 
partially, the circadian rhythm abnormalities (Boulamery et al., 2010).  More 
recently, circadian abnormalities of rest-activity rhythm have been documented in a 
Park5 mouse model, which presented also loss of orexin neurons and mRGCs 
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(Pfeffer et al., 2012). Similarly, MPTP-treated monkeys presented early (before 
motor symptoms), persistant and relevant fragmentation and reduced amplitude of 
rest-activity rhythm (Vezoli et al., 2011) and transgenic ASO mice ($ synuclein 
overexpression) showed disrupted circadian rhythm aggravated by aging (Kudo et 
al., 2011). Moreover, there are both clinical (Bruguerolle & Simon, 2002; Cai et al., 
2010) and experimental evidences that dopamine depletion per se may affect 
circadian rhythms and expression of clock genes in different brain regions (Ben & 
Bruguerolle, 2000; Boulamery et al., 2010; Gravotta et al., 2011) and rats injected 
bilaterally with 6-hydroxydopamine showed a significant disruption of circadian 
rhythms in continuous darkness. These abnormalities are partially restored when the 
light-dark cycle was re-established (Gravotta et al., 2011). Overall, these findings 
point to a direct role of dopamine in regulating circadian rhythms.  
Furthermore, in PD there is also evidence of circadian fluctuation of motor 
symptoms during the day, which results from the combined influence of the 
dopaminergic pharmacologic effects, spontaneous circadian rhythm of motor activity 
and circadian changes of the dopaminergic function in the central nervous system 
(Bruguerolle and Simon, 2002). Recently, PD has been interpreted as a 
neuroendocrine disorder of circadian function (Willis, 2008a). This hypothesis is 
based on the consideration that the nigrostriatal and circadian system are integrated 
and proposes that the motor impairment in PD may result from the imbalance 
between dopamine and melatonin neurochemical functions. Within this frame, it is 
suggested that the nigrostriatal and the visual system play a major role in the 
pathogenesis of motor symptoms in PD (Willis, 2008a), as suggested by the 
increased severity of motor symptoms after ocular enucleation (Willis et al., 2008b). 
On the contrary, both light-therapy in humans (reducing melatonin levels) and 
intraocular injection of dopamine in animal models of PD may improve motor 
symptoms in PD patients (Paus et al., 2007; Willis, 2008c).  
A summary of studies on circadian rhythms in PD is provided in Table 5 and 6.  
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Table 5. Summary of studies on circadian rhythms findings in PD patients. 
 
 
Table 6. Summary of studies on circadian rhythms findings in PD mouse models. 
Parameters N.patients Results 
Pierangeli et al. 
2001 
Rectal T° 
SW cycle 
CR 
7 iPD 
14 MSA 
8 CTRLS 
Normal 24-hrs Rectal T° rhythm in PD 
 
Bordet et al. 2003 
Clin 
Neuropharmacol 
 
Melatonin 
Cortisol 
Rectal T° 
Rest-activity 
(Cosinor analysis) 
CR 
PD untreated (n=8) 
PD treated without 
LDMRC (n=10) 
PD treated with LDMRC 
(n=8) 
No control group 
Decreased amplitude of T° in treated pts 
Deacreased amplitude and phase advance 
of melatonin rhythm in treated pts 
Increased daytime secretion in group III 
No differences in rest-activity rhythms 
between groups 
Whitehaed et al. 
2008 
Mov Dis 
 
Rest-activity  
(Non-parametric 
analysis) 
IS-IV-RA 
50 PD (27 with 
allucinations and 23 
without)  
29 controls 
Increased IV in PD (p<0.001) 
Lower M10 (p<0.001) 
Lower amplitude (p<0.001) 
Allucinators PD lower IS, greater night-
time activity (L5) and reduced RA 
compared to non-allucinators (ANCOVA) 
Niwa et al. 2011 
Autonomic 
Neuroscience 
Rhythm pattern 
analysis (AW2 
program)* 
27 PD 
30 controls 
Higher sleep episodes out-of-bed and 
wake episode in-bed in PD 
Reduced rhythm amplitude in PD 
Parameters Animal models Results 
Ben V and 
Bruguerolle, 
Life Sciences 
2000; Boulamery 
et al., Chronobiol 
Int 2010 
Temperature 
Heart rate 
Locomotor activity 
(Fourier and cosinor 
analysis) 
6-OHDA striatal 
injection 
Rats 
Significant decrease of the mesor and 
phase advance of  HR, T° and locomotor 
activity rhythms  
Significant reduction of HR rhythm 
amplitude 
Partial restoration with L-Dopa  
Pfeffer et al.  
Neurobiology of 
aging 2010 
Rest-activity rhythm 
Orexin neurons 
Melanopsin cells 
PARK5 mouse 
model (UCH-L1) 
Abnormal sleep/wake rhythm 
Loss of orexin neurons  
Loss of melanopsin cells 
Gravotta et al., J 
Mol Neurosci 
2011 
Locomotor activity 
circadian rhythm 
Per2 expression 
6-OHDA 
intraventricular 
injection 
Rats 
Abnormal locomotor activity pattern in 
costant darkness with partial restoration 
in 12:12 LD 
Vezoli J et al.  
Plos One 2011 
Rest-activity rhythm
(Non-parametric 
analysis) 
IS-IV-RA 
CR 
MPTP monkeys 
(chronic low dose 
injection) 
Early (before motor symptoms 
appearance), persistant and relevant 
fragmentation of rest-activity rhythm 
(increased IV and reduced IS) with 
reduced amplitude 
Kudo et al.  
Experimental 
Neurology 2011 
12:12 LD 
skeleton period (1h 
light + 11h darkness) 
DD 
Light exposure 
Transgenic ASO 
mice (α-syn 
overxpression) 
Disrupted daily and circadian rhythms in 
ASO mice, increasing with age 
Normal photic response in ASO mice 
Delayed sleep onset  
Normal Per2 expression in the SCN 
Reduced firing rate in the SCN 
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6. OPN4 POLYMORPHISM AND CHRONOTYPE 
Chronotype or diurnal preference refers to the individual preference for timing of 
daily activities. Diurnal preferences represent an individual trait to be more active in 
the late evening (evening type or “owls”) or in the morning (morning type or 
“larks”).  
This trait is normally distributed and can be assessed using questionnaires such as the 
Horne-Östberg Questionnaire (Horne and Östberg, 1976) or the Munich Chronotype 
Questionnaire (Zavada et al., 2005). The latter questionnaire assesses the habitual 
times of activity/sleep taking also into account the different behavior of the subject in 
free and workdays (Zavada et al., 2005). Both the questionnaires show a strong 
correlation with other phase markers of the circadian clock such as temperature nadir 
and melatonin peak time (Duffy et al., 2001).  
Many studies have investigated the possible genetic basis of this individual trait 
mainly focusing on clock genes (Per1, Per2, Per3, CLOCK etc.) with frequently 
contrasting and non-reproducible results in different populations and cohort of 
individuals. The polymorphism in the clock genes most consistently associated with 
diurnal preference is the variable number of tandem repeats (rs57875989) in the 
coding region of the Per3 gene (Archer et al., 2003). Indeed, individuals 
homozygotes for the longer variant (PER35/5) have a stronger morning preference 
than individuals homozygotes for the shorter variant (PER34/4) (Ellis et al., 2009; 
Archer et al., 2003). This genetic variant revealed the strongest correlation with other 
markers of the circadian phase, such as the phase of melatonin rhythm. Moreover, 
this polymorphism has been shown to affect also sleep homeostasis. In fact, 
individuals homozygotes for the longer variant (PER35/5) are characterized by more 
SWA during sleep and are more vulnerable to sleep loss in terms of cognitive 
functions than the individuals homozygotes for the shorter variant (PER34/4) (Viola 
et al., 2007). In fact, individuals homozygotes for the longer variant (PER35/5) 
showed greater reduction in fMRI-assessed brain responses to an executive task, in 
response to total sleep deprivation (Dijk and Archer, 2010). These findings 
ultimately suggest that higher homeostatic sleep pressure in PER35/5, together with 
the influence on the circadian pacemaker, modulates the amplitude of diurnal 
variation in performance, underlying the strict connection between circadian 
rhythmicity and sleep homeostasis. These findings were further consolidated by 
Schimdt and coauthors demonstrating by functional MRI that chronotype influences 
processing-related cerebral activity. In fact evening types, at difference with morning 
types, maintained or even increased their hemodynamic responses from the 
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subjective morning to the subjective evening, suggesting that morning types 
experience higher vulnerability to prolonged wake period (Schmidt et al., 2012).  
Further, missense mutations in the CK1! and Per2 genes have been associated with 
advanced sleep phase syndrome (Wulff et al., 2009). A summary of main findings on 
genetic studies in relation to chronotype is provided in Table 7 (modified from 
Steinmeyer et al., 2009).  
To date, polymorphisms of the OPN4 gene have been studied only in relation to 
SAD, a mood disorder with a strong circadian basis, characterized by the occurrence 
of depression in fall and winter (Roecklein et al., 2009). The authors found that one 
OPN4 variant, the T/T genotype for the missense variant rs2675703 (P10L) may 
predispose some individuals to SAD. In fact, the T/T genotype was found only in the 
group of SAD patients and not in controls (Roecklein et al., 2009). The possible link 
between genetic polymorphisms of the OPN4 gene and SAD is further reinforced by 
the finding that patients with SAD have an abnormal hypothalamic response to light, 
and in particular blue light, as documented by fMRI studies (Vandewalle et al., 
2011b). Moreover, the prevalence of SAD and subsyndromal SAD is higher in 
delayed sleep phase syndrome individuals compared to controls, and, based on the 
role of mRGCs in the regulation of circadian rhythms, it is possible to hypothisize a 
possible role of genetic variants in the OPN4 gene in the determination of the 
circadian phenotype (Lee et al., 2011).  
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Table 7. Summary of genetic studies on chronotype (modified from Stenmeyer et al., 2009) 
Gene Species Region SNP AA change Phenotype Association Publication "#$"% &'()* +,-*!./ 0.1234 567 89:9!)*;!<=3> <- ?@)76!6A!)BC!D3EE3F!
 
  +,-*!./ 4.1GG0 567 89:9!)*;!<=3> <- ?@)76!6A!)BC!D3EE3F!
 
  
HI!JKL! !KH..."!!
<-! M-N*O*P*677Q6R6*O*P*677! 567! MO7SO()!6A!)BC!D3EEGF!!
  <-! M-N*O*P*677Q6R6*O*P*677! 567! %)AT6*U6NP!6A!)BC!D.112F!
  <-! M-N*O*P*677Q6R6*O*P*677V!89:9! <-! L-UOBBO)N;!6A!)BCV!D3EE3F!! ! <-! 89:9!)*;!<=3>! <-! ?@)76!6A!)BC!D3EE3F!! ! <-! M-N*O*P*677Q6R6*O*P*677V!89:9! <-! :6;N)TT-BO!6A!)BC!D3EE/F!
  5’ UTR K3G/4 <- M-N*O*P*677Q6R6*O*P*677V!89:9 <- :6;N)TT-BO!6A!)BC!D3EE/F!:+L?$8. &'()* +,-*!.2 K3>H>" <- M-N*O*P*677Q6R6*O*P*677 567 ")NW6*!6A!)BC!D3EEXF!
  +,-*!.2 03G>24 <- M-N*O*P*677Q6R6*O*P*677 <- %)AT6*U6NP!6A!)BC!D.111F!:+L?$83 &'()* +,-*!./ 03.EX4 567 09:9 567 K-S!6A!)BC!D3EE.F!
 
  :N-(-A-N "=.332K <- M-N*O*P*677Q6R6*O*P*677 <- ")NW6*!6A!)BC!D3EEGF! 
  GI!JKL! "...4! <-! M-N*O*P*677Q6R6*O*P*677! 567! ")NW6*!6A!)BC!D3EEGF!!
  +,-*!3H! 4H2GH0! 567! M-N*O*P*677Q6R6*O*P*677! <-! ")NW6*!6A!)BC!D3EEGF!!:+L?$8H &'()* +,-*!.GV./V!.2V!3E! K.1>E4V!"3G1E4V!KH..E"V0H>/H0V!;6BDHEH.=HE2>*AF!! 567! 89:9! 567! +UO7)@)!6A!)BC!D3EE.F!!
  
+,-*!.2!
>=YG=N6W6)A! ! M-N*O*P*677Q6R6*O*P*677! 567! Z-*67!6A!)BC!D3EE/F!
  ;6BDHEH.QHE2>*AF  
M-N*O*P*677Q6R6*O*P*677V!89:9!
 
567 0N[S6N!6A!)BC!D3EEHF!
 
  +,-*!.G K.1>E4 567 M-N*O*P*677Q6R6*O*P*677 567 Z-S)*77-*!6A!)BC!D3EEHF!00<0K[ &'()* :N-(-A-N K=G>34 <- 9B66W!W)AA6N* <- \)*P!6A!)BC!D3EE>F!
 
  :N-(-A-N 4=3XH" <- 9B66W!W)AA6N* 567 \)*P!6A!)BC!D3EE>F!
 
  +,-*!> "/E3K <- 89:9 <- &-S]-S!6A!)BC!D3EEHF!
 
  +,-*!> "/GXK <- 89:9 <- &-S]-S!6A!)BC!D3EEHF!
 
  +,-*!> 4X.10 567 89:9 ^67 &-S]-S!6A!)BC!D3EEHF!
 "%?; &'()* +,-*!3! K>>0U! 567! _09:9! 567! `'!6A!)BC!D3EEGF !"%?6! &'()*! +,-*!1! 4.33H0! 567! 89:9!)*;!<=3>! 567! K)a)*-!6A!)BC!D3EE>F!!MK<L.) &'()* +,-*!.! ".XEK! 567! 89:9!)*;!<=3>! <-! +UO7)@)!6A!)BC!D.111F!!
  +,-*!3! ">/EK! 567! 89:9!)*;!<=3>! <-! +UO7)@)!6A!)BC!D.111F!!MK<L.U &'()* +,-*!.! 4/.0! 567! 89:9!)*;!<=3>! <-! +UO7)@)!6A!)BC!D3EEEF!!
  +,-*!.! ".1XK! 567! 89:9!)*;!<=3>! <-! +UO7)@)!6A!)BC!D3EEEF!!K?M+#+99 &'()* +,-*!3E! 03XH>4! 567! M-N*O*P*677Q6R6*O*P*677! <-! :6;N)TT-BO!6A!)BC!D3EEEF! !&#0!8L. &'()* ! ! ! 89:9! <-! &-S]-S!6A!)BC!D.111F!!
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AIMS 
Our previous studies on the mRGCs system in Leber’s hereditary optic neuropathy, a 
neurodegenerative disease selectively affecting RGCs, have shown relative sparing 
of mRGCs and maintenance of the melanopsin-mediated melatonin suppression 
response to light. This observation explained the maintenance of pupillary light 
reflex (PLR) in these patients and pointed to the question of how mRGCs may be 
resistant to neurodegeneration. Thus, we wanted to verify if this is the case in other 
neurodegenerative diseases affecting RGCs, such as dominant optic atrophy. Further, 
we developed the hypothesis that mRGCs system could be affected and responsible, 
at least in part, for the occurrence of circadian rhythms disturbances in common 
neurodegenerative disorders such as Alzheimer disease, Parkinson disease and 
ultimately in normal human aging, based on the common feature of optic neuropathy 
and RGCs loss in all these conditions. Lastly, we hypothesized that functional 
genetic variation in the OPN4 gene, encoding for the melanopsin photopigment, may 
influence human chronotypes.  
Based on these premises this PhD thesis is articulated in three sections with the 
following aims: 
! extend the characterization of the mRGCs system in blind patients with 
hereditary optic neuropathies (Project 1) 
! explore the role of mRGCs system in age-related circadian abnormalities and 
the possible involvement of these cells in neurodegenerative disorders with 
evidence of retinal and/or circadian abnormalities (Parkinson, MCI and 
Alzheimer) (Project 2) 
! investigate if genetic variation in the melanopsin gene may be associated to 
morningness/eveningness phenotypes (Project 3) 
 
Concerning the 1st aim of this project we investigated: 
1. the mRGCs system in dominant optic atropy 
2. the mRGCs contribution to PLR in LHON patients by pupillographic 
recordings 
3. the role of the photopigment melanopsin in mRGCs resistance to 
neurodegeneration 
Concerning the 2nd aim of this project we investigated: 
1. the occurrence of optic neuropathy in AD, MCI and PD patients 
2. the occurrence of rest-activity circadian rhythm dysfunction in AD, MCI 
and PD patients  
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3. the pathology of mRGCs in post-mortem retinal and optic nerve 
specimens from AD patients and age-matched controls 
4. the possible correlation between the occurrence of circadian dysfunction 
and optic nerve involvement in AD and PD 
Concerning the 3rd aim of this project we investigated: 
1. the association of the P10L OPN4 missense polymorphic variant with 
human chronotypes 
2. the association of the P10L OPN4 missense polymorphic variant with 
seasonal affective disorder 
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METHODS 
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1. PATIENTS 
Project 1 
1.1. Immunohistochemical analysis of mRGCs and axonal count in optic nerve cross-
sections of a dominant optic atrophy case and age-matched control 
We performed immunohistochemical analysis of mRGCs and axonal counts in a 87-
year-old dominant optic atrophy patient and a 85-year-old control case. 
1.2. Pupillometric evaluations in LHON 
Pupillometric evaluation was performed in: 
• 13 LHON patients (mean age 44.8 ± 17.5; disease duration 18.2 ± 10.3 years) 
(10 males and 3 females)  
• 16 age-matched controls (mean age 43.4 ± 14.9; 7 males and 9 females) 
For pupillometric evaluation only one eye was tested for each subject. The eye with 
the worst visual acuity was tested in LHON patients.  
 
Project 2 
2.1. In-vivo evaluation of AD, MCI and PD patients by OCT, actigraphic recordings 
and sleep questionnaires 
All participants gave their informed consent to this prospective study, which was 
approved by the Internal Review Board (Comitato Etico Indipendente, Azienda Unità 
Sanitaria Locale di Bologna, Protocol #656/CE).  
Inclusion criteria for patients were: 
1. Diagnosis of Alzheimer disease according to NINCDS-ADRDA criteria, 
(McKhann et al., 1984). Patients with mild-moderate disease severity were included 
(Mini Mental State examination-MMSE score between 11 and 26) 
2. Diagnosis of mild cognitive impairment (Petersen et al., 2001) 
3. Diagnosis of probable Parkinson disease according to Gelb Criteria (Gelb et al., 
1999) 
Exclusion criteria for patients were: 
1. Spherical or cylindrical refractive errors higher than 3 or 2 diopters respectively 
2. Posterior pole pathology such as macular degeneration and optic neuropathies 
including glaucoma 
3. Unsustained fixation due to rest tremor  
4. Severe AD (MMSE <11) 
Inclusion criteria for controls were the absence of cognitive dysfunction as confirmed 
by MMSE and Brief Battery for Mental Deterioration, and absence of ocular 
pathologies as confirmed by ophthalmologic evaluation. 
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Optical coherence tomography (OCT) evaluation was performed in: 
• 20 AD patients (age 72.2 ± 10.6; range: 51-84 years; 11 males and 9 females) 
• 11 MCI patients (age 73.1 ± 6.2; range: 64-87 years; 6 males and 5 females) 
• 43 PD patients (age 65.6 ± 8.4; range: 46-83 years; 23 males and 20 females) 
• 88 controls (age 65.7 ± 10.7; range: 46-85 years; 36 males and 52 females) 
 
One-week actigraphic monitoring (Actigraph Mini Motion Logger, Ambulatory 
Monitoring Inc) was performed in: 
• 15 AD patients (age 70.9 ± 13.3; range: 52-84 years; 8 males and 7 females) 
• 7 MCI patients (age 72.4 ± 5.1; range: 64-78 years; 5 males and 2 females) 
• 9 PD patients (age 64.3 ± 8.2; range: 50-76 years; 4 males and 5 females) 
• 10 controls (age 65.8 ± 7.5; range: 54-80 years; 5 males and 5 females) 
 
2.2. Immunohistochemical analysis of mRGCs and axonal count in optic nerve cross-
sections in post-mortem specimens from AD patients and controls  
We have been able to collect and analyze: 
• 14 neuropathologically confirmed AD cases (age 82.6 ± 12.3; range: 62-98 
years; 8 males; 6 females) 
• 11 controls (age 78.5 ± 15.1; range 58-105) 
The inclusion criterium for AD cases was a neuropathological diagnosis of definite 
AD (Braak stage V or VI), according to modified CERAD criteria (Mirra et al., 
1991) and NIA/Reagan criteria (Hyman & Trojanowski, 1997)  
 
Project 3 
The genetic analysis of the single nucleotide polymorphism (rs2675703-P10L-
exon1) in the OPN4 gene was performed in 314 subjects (age 31.8 ± 9.9; range: 20-
73; 103 males and 211 females), classified for chronotypes according to the 
Morningness-Eveningness questionnaire (MEQ) (Horne and Östberg, 1976). In a 
subgroup of subjects (n=182) we also retrieved SPAQ questionnaires   assessing the 
presence of Seasonal Affective Disorder syndrome and sub-syndrome (Rosenthal et 
al., 1984; Muscettola et al., 1995; Magnusson et al., 1996).  
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2. IN-VIVO STUDIES 
2.1. Pupillometry 
For pupillometric evaluation of the pupillary light reflex (PLR) in LHON patients 
belonging to a large Brazilian pedigree (Sadun et al., 2003) and controls we used the 
same protocol published by Park and coauthors (Park et al., 2011). The setting and 
the general scheme of the pupillometric protocol are depicted in Figure 11. 
 
       
Figure 11. LED-driven Ganzfeld system and binocular eye-tracking camera (left) (Park et al., 2011); 
General scheme of the pupillometric evaluation (right) 
 
Briefly, we used alternating 1 sec blue and red light flashes at increasing intensities 
(from 1cd/m2 to 250 cd/m2) with different interstimulus durations, after 10 minutes 
of dark adaptation, as detailed below: 
 
1. RED0 (10’’-30’’)= 1cd/m2 
2. BLUE0 (10’’-30’’)=1cd/m2 
3. RED1 (10’’-30’’)=10cd/m2 
4. BLUE1 (10’’-50’’)=10cd/m2 
5. RED2 (10’’-1’10’’)=100cd/m2 
6. BLUE2 (10’’-1’10’’)=100cd/m2 
7. RED 2.4 (10’’-1’10’’)=250cd/m2 
8. BLUE 2.4 (10’’-1’10’’)=250cd/m2 
 
This protocol allows at isolating the contribution of rods, cones and mRGCs to PLR 
response. Light stimulation in all experiments was controlled by a LED-driven 
Ganzfeld system (Super Color Ganzfeld Q450 SC, Roland Consult, Germany). This 
system generates a wide range of stimuli from -4 to 2.6 log cd/m2 for blue (467 ± 17 
nm) lights and from -4 to -2.6 log cd/m2 for red (640 ± 10 nm) lights. 
A binocular eye-tracking camera system with infrared illuminating diodes (Arrington 
Research, Scottsdale, AZ) was used for real-time pupil recording with a sample rate 
of 60 Hz. The miniature video camera system is attached to a plastic eye frame so 
that there is no physical contact between the camera and the eye and so that a wide 
visual field view is afforded. 
!"#$%" !"#$%"
!&"
!"#$%&$
10’ DARK ADAPTATION 
!&"
'!#$%&$
Flash intensity = 250 cd/m2 
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The Rod-driven PLR is best studied at 1-sec low intensity (lower than -1 log cd/m2) 
blue-light stimuli in the dark. The Melanopsin-driven PLR is best studied at 1-sec 
high intensity (2.6 log cd/m2) blue-light stimuli in the dark. The cone-driven PLR is 
best studied at 1-sec red flash on blue background, which suppresses rod and 
melanopsin response. 
The PLR to red stimuli shows a monotonic increase, a saturation of peak amplitudes 
at high intensities and a fast recovery. The PLR to blue stimuli is characterized by 
the emergence of a sustained response after the 1-sec stimuli for intensities of 1 log 
cd/m2 or greater (Figure 12) 
 
 
Figure 12. Representation of the experimental condition for the isolation of the contribution of the 
single photoreceptors to the pupillary light reflex (upper panels: rod condition; left lower panel: 
melanopsin condition; right lower panel: cones condition) 
 
In order to compare inter-individual responses, raw pupil size curves have been 
transformed using the normalized measures relative to the individual baseline value. 
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For each condition (blue and red light) and each individual, two variables were 
computed: peak amplitude (PA) and sustained response (SR) (Figure 13). 
 
Figure 13. PA is the absolute value of the normalized pupil size variation, expressed as a percentage 
of variation from baseline. SR is the median value between 4 and 6 seconds after light onset, 
computed similarly to PA, and expressed as percentage of PA 
 
A severity score of pupillary light response was computed assessing the number of 
pathological parameters (below 2SD from the mean of controls). 
Parametric t-test comparisons were used to assess the differences between patients 
and controls (p < 0.05). Pearson test was used to assess the correlation between the 
pupillometric parameters, age, disease duration and visual acuity (p<0.05).  
2.2. Optical coherence tomography 
All subjects underwent RNFL thickness measurement by OCT (StratusOCT, 
software version 4.0.1; Carl Zeiss Meditec, Inc, Dublin, CA) (Figure 14). We used 
the RNFL thickness 3.4 acquisition protocol (Barboni et al., 2005, 2010). For each 
eye, we studied the average RNFL thickness (360-degree measure), as well as 
temporal (316–45-degree unit circle), superior (46–135 degrees), nasal (136–225 
degrees), and inferior quadrant thickness (226–315 degrees.) At the beginning of the 
examination, the OCT lenses were adjusted for the patient’s refractive error. 
Polarization was optimized to maximize the reflective signal, and the best centration 
of the scan with respect to the optic disc was used.  
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Figure 14. Stratus OCT (left); Example of RNFL thickness 3.4 acquisition protocol for a control 
subject. RNFL thickness for each quadrant is provided for OD and OS (right) 
 
For the statistical analysis one eye for each control, AD and MCI patient, was 
randomly chosen, having verified that there was no statistical difference between 
right and left eye, as previously reported (Barboni et al., 2005). Based on the 
characteristic asymmetry of PD we analyzed both the eyes homolateral and 
contralateral to the most affected body side in PD patients.  
Normal distribution of RNFL thickness measurements was evaluated by 
Kolmogorov-Smirnov test. Differences between patients and controls were assessed 
by ANCOVA using age and gender as covariates, followed by post-hoc pairwise 
comparisons. Significance was assumed for p<0.05. For PD patients the significance 
was corrected for multiple comparisons according to the Bonferroni method. 
Correlation bivariate analysis was performed using Pearson coefficient (p<0.05).  
For PD patients multivariate analysis was performed to investigate the effect of 
genetic, demographic (age and gender) and clinical parameters  (age at onset, disease 
duration, UPDRS-III score and stage of disease) on RNFL measurements using a 
multiple regression with a backward stepwise method to obtain a significant model in 
which all included variables had a p<0.05. The same analysis was performed for AD 
and MCI patients including demographic (age and gender) and clinical parameters  
(age at onset, disease duration and MMSE score). AD patients were further analyzed 
by subgrouping them, according to the MMSE score, in mild (%20) and moderate (& 
19) cases (Folstein et al., 1975).  
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2.3. Actigraphic recordings 
Spontaneous motor activity was measured by a wrist actigraph (Actigraph Mini 
Motionlogger, Ambulatory Monitoring Inc. Ardsley, NY, USA) worn on the non-
dominant wrist for 7 days. In PD patients actigraph was placed on the least affected 
side for unilateral cases and on non-dominant wrist for bilateral cases. Data were 
collected in 60-second epochs in 24-hour periods. An example of actigraphic 
monitoring for 7 days is provided in Figure 15. 
  
Figure 15. Example of actigraph (left); example of actigraphic monitoring for 7 days in a control 
subject (right).  
The collected data were analyzed by a commercial software (AW2, Ambulatory 
Monitoring Inc.), which allowed retrieving the following parameters: 
1. sleep minutes (minutes of rest activity during the night period) 
2. sleep efficiency (sleep time divided by the time in bed multiplied by 100). 
Each participant also completed a sleep diary over the seven days of monitoring 
indicating bed/rise time, time to sleep onset and eventual daytime naps.  
Raw actigraphic data were firstly inspected in order to detect the correspondence 
with the subject sleep diary and eventual artifacts (low activity due to the actigraph 
removal). Each single artifactual epoch was marked as “bad” epoch. Furthermore, to 
allow the comparison between subjects, all the recordings were aligned with the 
starting time at 12:00 am. Given that five subjects wore the actigraph for less than 7 
days (three for six days and two for five days), in order to adequately compared 
subjects, consecutive 120 hrs (5 days) of recordings were considered for subsequent 
analysis. Data were then exported to Matlab and the mean of each hour was 
computed as the mean of the “good” epochs. If consecutive “bad” epochs occupied 
an entire hour, these periods were treated as missing data and the hourly mean was 
calculated as the weighted mean of the pre and post-activity counts (Figure 16).  
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Figure 16. Five-days profile of hourly mean activity values in a subject. In the original data (grey 
dashed line) values of two consecutive hours are lacking (red arrows) due to the absence of artifact-
free epochs in the entire 120' interval. The Red line represent the activity profile after the replacement 
of the missing data. The new values (yellow squares) were computed as the weighted mean of 
adjacents valid data. 
 
For the analysis of circadian parameters derived from actigraphic recordings we 
chose to apply non-parametric methods (Witting et al., 1990; Van Someren et al., 
1997a,b; Van Someren et al., 1999) because the rest-activity rhythm is highly non-
sinusoidal and thus not well described using a cosinor analysis (Van Someren et al., 
1999).  
 
For all subjects the following non-parametric measurements were computed:  
- Interdaily stability: IS (0-1): quantitative measure of the invariability of the 
rhythm between the days (index of the strength of the rhythm to supposedly 
stable enviromental zeitgebers). Higher values indicate a more stable rhythm. 
IS is calculated as the ratio between variance of the average 24-hour pattern 
around the mean and the overall variance. !" ! ! !!! ! !!!!!!!!! !!! ! !!!!!!!!  
- Intradaily variabily: IV (0-2): indication of the fragmentation of the rhythm 
(i.e. frequency and extent of transitions between rest and activity). IV is 
calculated as the ratio of the mean squares of the difference between 
successive hours (first derivative) and the mean squares around the grand 
mean (overall variance) !" ! ! !!! ! !!!!!!!!!!!!! ! !! !! ! !!!!!!!!  
N=total number of data;p=number of data per day; !=mean of all data;!!! != hourly means; !!= individual data points 
- Relative amplitude: normalized difference between the most active 10h 
period (M10) and the least active 5h period (L5) in the average 24h pattern. 
Higher values indicate a stronger rhythm. !" ! !!"! !!!!"! !! 
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L5: sequence of the least-active hours in the 24-hour average activity profile. 
Average activity during L5 provides an indication of trough or nadir of the rhythm 
(i.e. regularity and restfulness of sleep period). Lower value indicate more restful 
sleep. 
M10: sequence of the 10 most-active hours in the 24-hour average activity profile. 
Average activity during M10 provides an indication of the peak of the rhythm (how 
active and regular the wake periods are).  
 
For PD patients levodopa-equivalent daily dose (LEDD) was calculated (100 mg L-
dopa equivalent to 1 mg cabergoline/lisuride/pergolide/pramipexole, 5 mg ropinirole, 
10 mg apomorphine, 76,92 mg L-dopa plus COMT inhibitor or 133,3 slow release L-
dopa formulation) (Wenzelburger et al., 2002). 
 
Differences in actigraphic parameters between patients and controls were assessed by 
parametric unpaired t-test (p<0.05). Correlation bivariate analysis between 
actigraphic data, demographic (age, gender) and clinical parameters (UPDRS-III, 
H&Y stage of disease, and LEDD for PD; MMSE score for AD and MCI; disease 
duration and OCT measurements for PD, AD and MCI) was performed using 
Pearson coefficient (p<0.05). We also stratified AD patients by MMSE score in two 
groups, mild (MMSE%20) and moderate (MMSE&19) and differences between the 
groups were assessed by unpaired t-test (p<0.05). For the analysis at single subject 
level we computed z-scores for all the actigraphic parameters investigated based on 
mean and SD of controls. Patients with more than 2 SD difference from the mean of 
controls were considered “circadian impaired”. Differences in clinical variables 
between “circadian impaired” and “circadian unimpaired” subgroups were evaluated 
by means of unpaired t-test (p<0.05). Correlations between clinical and circadian 
variables were computed separately for the two subgroups. 
2.4. Sleep questionnaires 
To investigate the occurrence of sleep disturbances we also included self-
administered questionnaires. 
Sleep questionnaires included: 
1. Epworth Sleepiness Scale (Vignatelli et al., 2003). The score range is 0-24 with a 
score of 10 or more indicating excessive daytime sleepiness 
2. Pittsburgh Sleep Quality Index (Buysse et al., 1989) with a score more than 5 
indicating pathological subjective sleep quality 
3. Berlin Questionnaire (Netzer et al., 1999) assessing the risk of sleep apnea 
4. Parkinson disease sleep scale (Chauduri et al., 2002) 
 47 
The Parkinson disease sleep scale consists of 15 items addressing at the following 
items: overall quality of night’s sleep (item 1), sleep onset and maintenance insomnia 
(items 2 and 3), nocturnal restlessness (items 4 and 5), nocturnal psychosis (items 6 
and 7), nocturia (items 8 and 9), nocturnal motor symptoms (items 10–13), sleep 
refreshment (item 14) and daytime dozing (item 15). Scores for each item range from 
0 (symptom severe and always experienced) to 10 (symptom-free). The maximum 
cumulative score for the PDSS is 150 (patient is free of all symptoms). 
Differences between patients and controls were assessed by unpaired t-test (p<0.05).    
 
Neurological examination was performed in all patients included in the study. 
Disease severity (UPDRS-III score-off, Hohen &Yahr stage of disease-off), disease 
duration, concomitant disease and therapy were retrieved for all patients 
Cognitive functions were assessed in AD, MCI patients and controls by Mini Mental 
State Examination (MMSE) score corrected for scholarity (Folstein et al., 1975), and 
if possible with Brief Battery for Mental Deterioration (BBDM) (Gallassi et al., 
1986, 2002)  
 48 
3. IN-VITRO STUDIES 
3.1. Melanopsin expression in Hek cells at different stressful paradigms and light 
conditions 
To test if the melanopsin expression influences cell viability in different stressful 
paradigms, under different light conditions (darkness, blue and white light), we used 
a tumor-derived immortal cell line (HEK-hMel-1) with stable expression of 
melanopsin under the control of a tetracycline-sensitive promoter. Melanopsin-
expressing cells have been tested in darkness and in different light conditions in 
comparison with the same cells not expressing melanopsin, after pro-oxidant 
challenge with tert-butyl-hydroperoxide (TBH) or rotenone. Rotenone is a 
respiratory complex I inhibitor which induced ROS production whithin mitochondria 
simulating the pathological condition determined by the LHON mtDNA mutations. 
TBH induces a cytoplasmic increase of ROS, representing a different paradigm of 
ROS exposure. Cells were grown in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, 
100 mg/ml streptomycin, 100µg/ml Hygromicin B, 15µg/ml Blasticidin, in an 
incubator with a humidified atmosphere of 5% CO2 at 37 °C.  
Tetracycline (1µg/ml) was added to promote melanopsin expression, which was 
verified by Western Blot. We seeded 100.000 cells in each well (24 well plates) and 
cell viability was detected by the sulforhodamine B (SRB) absorbance at 570 nm 
with a VICTOR3 Multilabel Plate Counter as previously described (Porcelli et al., 
2008). Stress paradigms were applied exposing cells to increasing concentrations of 
rotenone (0.5 µM; 2.5 µM; 5 µM) and TBH (50 µM; 200 µM). The experiments were 
performed in different light conditions, which included darkness, daylight and 30 
minutes of exposure to blue and white light. Experiments were performed with and 
without retinal (5 µM), a co-activating factor for melanopsin photoreception.  
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4. POST-MORTEM STUDIES 
4.1. Immunohistochemical analysis of melanopsin-containing retinal ganglion 
cells in human post-mortem retinas 
All tissues were initially immersion-fixed in neutral buffered formalin. Eyes and 
nerves were oriented for superior and temporal zones with tissue ink. The eyes were 
dissected horizontally at the meridian producing two collotes containing the entire 
retina (nasal and temporal), at that level bisecting the papillomacular bundle (Figure 
17).  
 
Figure 17. Upper left. Schematic representation of the horizontal section passing through the macula 
and the optic nerve head. An example of retinal reconstruction is provided (red rectangles). Upper 
right. Higher magnification pictures of the I and II captures (5X); optic nerve head (I) and retinal 
layers are visible (II). Lower panel left. An other example of embricated captures at 5X is provided 
(III and IV). Lower panel right. Higher magnification detail of mRGC in the RGL from the IV caption 
is provided. 
 
Tissue from the superior half was embedded in paraffin and serially sectioned at 5 
mm. Sections were immunostained for melanopsin [rabbit anti-melanopsin, code no. 
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5J68, characterized in detail by Hannibal et al., 2004a]. We used an indirect 
immunoperoxidase technique with diaminobenzidine as the substrate/chromogen 
(Hannibal et al., 2004a). For each subject we analyzed one eye both for the mRGCs 
and axonal count. Immunostaining was performed on seven to ten serial sections to 
define the extent of each single mRGC and establish the counting criteria for 
subsequent quantitative analysis. To this end, mRGCs were then identified and 
manually counted by two independent observers on five to six sequential slides 
originating from every fifth section (Figure 18).  
 
Figure 18. (A) On the left one example of mRGCs with nucleus and cytoplasm visible; on the right a 
fragment of cytoplasm is shown. (B) Tridimensional and schematic reconstruction of the mRGC cut 
through the nucleus and peripherally (C) Schematic representation of the single sections (width: 5 
microns) and the distance between two sections (d=20 microns).  
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Melanopsin stained RGCs were further confirmed and photographed at high 
magnification by the two observers. We counted each mRGC that demonstrated a 
significant amount of stain indicating a complete soma and having the nucleus and 
sometimes the nucleolus visible. In these latter cases, the cells were considered to be 
cut approximately through their middle. Furthermore, the length of each retina 
section was measured on serial photographs overlapping on the borders, covering the 
entire retina available (Figure 17). Counting of mRGCs allowed for calculation of 
their area density across the posterior retina in the nasal/temporal axis. This retinal 
cross-section, 5 mm in thickness, included cells cut approximately through their 
middle, with the nucleus visible. Hence, the sampling area around each section 
would be large, 2-fold (one for each side) the mean radius of the mRGC (5 mm) plus 
the thickness of the retinal section (5 mm), so that the density has been calculated 
dividing the number of mRGCs for the total sampling area (length of the retinal 
cross-sections multiplied by 15 mm). The total retinal area density of mRGCs in each 
eye was calculated assuming an average total surface in human retina of 1040mm2 
and an even superior/inferior distribution of mRGCs (Curcio and Allen, 1990). Total 
RGC number was calculated by assessing the number of axons in the optic nerve 
under the assumption that one RGC produces one axon. Thus, the total number of 
RGCs was derived by counting the axons in the optic nerve cross-sections using 
paraphenylenediamine (PPD)-based manual count (see next section). Finally, we 
calculated the ratio between the mRGCs density and total RGCs.  
4.2. Morphometric assessment of axonal population in optic nerve cross-sections 
Optic nerves were cut into cross-sections 2mm thick and 3mm posterior to the globe. 
Orientation was established by razor nicks and the specimens were processed for 
paraffin and plastic blocks. Semi-thin sections were cut on an ultramicrotome at 1 
mm from plastic-embedded tissues and stained with paraphenylenediamine for light 
microscopic examination of myelin profiles (Tenhula et al., 1992). Only for the DOA 
case the paraffin tissue blocks were cut with a microtome at 5 mm, stained with 
haematoxylin and eosin and immunostained using an indirect method with 
horseradish peroxidase and diaminobenzidine as substrate/chromogen for 
neurofilaments. All light microscopic photos of eyes and nerves were acquired with a 
Spot II digital camera (Diagnostic Instruments Inc.) and digitally saved on a 
computer. The axonal count in the optic nerves was manually performed on images 
acquired at 1000X with a 100X oil immersion lens. For total axon counts, each nerve 
cross section was partitioned into 8 regions (temporal, nasal, superior, inferior, and a 
set of inner/outer for each). Four pictures for each region were taken under 1000X 
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magnification to generate 32 zones. Counts were done by hand and confirmed by two 
independent observers.  Cross sectional areas were measured for each region using 
the “Spot II Advanced” software package.  Total axons counts and axon densities 
were then calculated for each region and extrapolated for the entire optic nerve. 
4.3. Neuropathological scoring of AD brain pathology 
A recently proposed “ABC” score was applied to grade the severity of brain 
pathology of AD patients included in this study (Montine et al., 2012). We were able 
to compute only the “B” and the “C” scores using the silver stain for the detection of 
neurofibrillary tangles (“B”) and the thioflavin stain for the detection of neuritic 
plaques (“C”), respectively. The brain regions analyzed were: hippocampus CA-1 
(uncus and lateral geniculate body), entorhinal cortex, middle frontal, 
superior/middle temporal, inferior parietal, primary visual and visual associative 
cortex. 
4.4. Counts and statistical analysis 
For each retina we retrieved: 
1) total number of mRGCs 
2) density of mRGCs  
3) axonal count 
4) mRGCs/RGCs ratio 
Unpaired t-test was used for comparison between groups. We also stratified both 
controls and AD patients by age, using the median age (80 years) as cut-off. We used 
ANOVA analysis for comparison between groups with Bonferroni post-hoc 
correction for multiple comparison (p<0.05). Correlations between mRGCs density, 
total axonal counts, mRGCs/RGCs ratio, age, Braak stage and neuropathological 
scores were assessed by Spearman test (p<0.05).  
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5. GENETIC STUDIES 
Association study of a polymorphic variant in the OPN4 gene with human 
chronotypes and seasonal affective disorder 
We assessed the missense variant rs2675703 (P10L) in the melanopsin gene (OPN4), 
previously reported by Roecklein and coauthors as associated with the Seasonal 
Affective Disorder (Roecklein et al., 2009). This SNP was previously identified and 
reported through the NCBI dbSNP public database (Sherry et al., 2001) (Figure 19).  
Reported frequencies in caucasian of the three genotypes of the P10L variant in 
caucasian are 73% (CC), 25% (TC) and 2% (TT). 
Figure 19. Details of the P10L SNP are reported (Roecklein et al., 2009) 
 
Chronotypes were assessed by the Horne–Ostberg morningness-eveningness (ME) 
Italian questionnaire (MEQ) to assess the ME preferences (Horne & Ostberg, 1976).  
Chronotypes were classified according to the MEQ into: extreme morning (70-86), 
moderated morning (59-69), intermediate (42-58), moderate evening (31-41), 
extreme evening (16-30).  The analysis was also performed grouping the extreme and 
moderate morning and the extreme and moderate evening in two single categories.  
To assess the occurrence of the seasonal affective syndrome or subsyndrome we used 
the validated Italian Version of the SPAQ questionnaire (Muscettola et al., 1995). 
This questionnaire is composed by three different sections. One of these, the 
Seasonality Score Index (SSI) or Global Seasonality Score (GSS), has six items that 
measure seasonal variations in mood, appetite, weight, sleep, energy and socialising. 
The sum of these items is the Seasonality Score (SS), which can range from 0 to 24. 
Other sections evaluate the degree to which the seasonal changes are experienced as 
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a problem and in which month of the year the subjects feel best or worst. These three 
scales allow classifying whether the subjects have: 
1. Seasonal Affective Disorder Syndrome (SAD): GSS more than 10 and seasonal 
changes experienced as a moderate problem. 
2. Seasonal affective disorder subsyndrome (S-SAD): GSS between 9 and 10 and 
seasonal changes experienced as a moderate problem or GSS more than 11 and 
seasonal changes experience as a mild problem. 
3. No Seasonal affective disorder 
 
The differences in allele and genotype frequencies between groups were assessed 
using '2 analysis or Fisher’s exact test (p<0.05). ANCOVA was used to test for 
associations between MEQ and SPAQ scores and genotypes, with age and gender as 
covariates. Bivariate correlation was performed between MEQ scores and age 
(Pearson test). A p value <0.05 was considered as significant. 
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RESULTS 
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1. PROJECT 1 
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1.1. Melanopsin RGCs in DOA and age-matched control 
To expand our previous observations of mRGCs sparing in LHON patients we 
studied a further 87-year-old patient with DOA, who belonged to a family of 152 
members reported by Kjer in the seminal description of DOA (Kjer, 1959). The 
frame-shift inducing 2826delT (p.V942fsX967) mutation in exon 28 of the OPA1 
gene was subsequently described (Thiselton et al., 2002). This patient complained of 
decreased vision and visual difficulties in poor light and in colour perception. His 
visual acuity was 0.1 in oculus destrum (right eye) and counting fingers in oculus 
sinistrum (left eye). Fundus examination revealed diffuse optic atrophy (Figure 20). 
 
 
Figure 20. Left panel: OD and OS fundus oculi of DOA patient; OS optic nerve cross-section at low 
an higher mag. Right panel: number of RGCs, mRGCs, mRGCs/RGCs ratio and retinal distribution of 
mRGCs in DOA patient 
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The histopathology of this subject’s eyes has been previously reported (Kjer et al., 
1983). We had available the left eye and optic nerve for this study (thanks to 
courtesy of Dr. Paul Kjer). The axonal count in the optic nerve cross-section, 
performed in the same fashion as for the study of LHON cases, showed a dramatic 
decrease to 15000 axons as compared with the 977851 axons counted in the 85-year-
old age-matched control eye (94% loss). Manual counting of mRGCs in the retinal 
specimens immunostained for melanopsin showed a density of 7 cells/mm2 for the 
DOA subject and 8.4 cells/mm2 for the control subject. Thus, the percentage of 
mRGCs, compared with the total number of RGCs, was 48.6% for the DOA subject 
and 0.9% for the age-matched control. Melanopsin RGCs were non-uniformly 
distributed in the 85-year-old control, with a significant enrichment in the parafoveal 
region, whereas the retina from the DOA case showed a flat distribution (Figure 20). 
These confirmatory results, by studying a single patient with a different 
mitochondrial hereditary optic neuropathy such as DOA, were added to those 
previously obtained with LHON patients and have been published in the journal 
Brain in 2010 (La Morgia et al., 2010) (see  Annex 1).  
1.2. Pupillometric evaluation of LHON patients and controls 
We evaluated by pupillometry (see methods) 13 LHON patients and 16 age-matched 
controls. All LHON patients showed a pupil response both with blue and red light 
showing variable degrees of preservation compared to controls. As a group, LHON 
patients had significantly lower peak amplitude of the pupil response both with the 
blue (p=0.004) and red light (p=0.007) and a significantly less sustained response to 
both blue (p=0.001) and red light (p<0.001) compared to controls.  However, at 
single subject level, considering as pathological the values below 2SD from the mean 
of controls, only one patient had all four parameters pathologic, four patients had 
three, one patient had two, and two patients had one (Figure 21).  
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Figure 21. Pupillometry results for controls and LHON  
Examples of patients with pupil response comparable to controls and patients with a 
weaker pupil response both at blue and red light are provided in Figure 22. 
  
Figure 22. (A-C): examples of sustained response at blue light for controls, LHON patient with a clear 
melanopsin response and LHON patient with a weaker pupil response. (D-F): examples of sustained 
response at red light for controls, LHON patient with a clear melanopsin response and LHON patient 
with a weaker pupil response 
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The amplitude of the peak response significantly correlated with the sustained 
response with blue light (p=0.001) in LHON patients (Figure 23).  
 
 
Figure 23. Correlation between peak amplitude and sustained response at blue light in LHON and 
controls 
 
The pupil light response did not correlate with clinical parameters such as visual 
acuity and disease duration and the number of abnormal pupil parameters did not 
correlate with visual acuity (Figure 24).  
 
Figure 24. Correlation between the visual acuity of the worst eye and number of abnormal pupillary 
parameters 
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1.3. Cell studies. 
The conclusions of our study on mRGCs relative sparing in mitochondrial hereditary 
optic neuropathies pointed to the question of why and how the mRGCs are 
metabolically resistant to mitochondrial dysfunction. To further investigate this issue 
we hypothesized that expression of the photopigment melanopsin, specific of 
mRGCs, may be responsible for their metabolic robustness.  
We used the HEK cells, engineerized to express melanopsin under a promoter 
controlled by tetracycline (provided by Dr Hannibal and Birgitte Georg, Dept. 
Clinical Biochemistry, Bispebjerg Hospital, Copenaghen, Denmark), to study cell 
viability under different paradigms of metabolic stress and light exposure, as detailed 
in the methods section.  
The effects of rotenone and TBH exposure at increasing concentrations of HEK cells 
without or with melanopsin expression and withour or with the addiction or retinal 
are shown in Figure 25 A-B (darkness) and Figure 25 C-D  (30 minutes of blue light 
exposure). No significant differences in cell viability were observed in any of the 
conditions used. Furthermore, other experiments with the same paradigm, using 
white light and 24-hour light exposure, similarly failed to show any differences in 
cell viability (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Results of cells studies in darkness (A-B) and after 30 min of blue light (C-D) 
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2. PROJECT 2 
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2.1. OCT evaluation 
2.1.1. Alzheimer disease 
We recruited 20 AD patients (40 eyes), of which two patients were excluded due to 
co-morbidity of glaucoma. Of the remaining 36 eyes enrolled, seven were excluded 
based on the previously established criteria (see methods) or because the OCT exam 
was technically not reliable. Three of the AD patients enrolled had non- specific 
visual complaints (difficulty in focusing objects). Overall, we included 18 AD 
patients (71.78±11.2; range 51-84; 10 males) and 74 age-matched controls (mean age 
69.1±8.1; range 52-85; 31 males), for which one randomly chosen eye was used for 
statistical analysis. The average RNFL thickness was reduced in AD patients 
compared to controls (p=0.034) (Table 8, Figure 26).  Considering separately the 
four quadrants, the RNFL thickness of superior (p=0.009) and nasal (p=0.016) 
quadrants was significantly thinner in AD patients compared to controls (Table 8). 
Demographic and the main clinical findings are summarized in Table 8.  
 
 AD (N=18) CONTROLS (N=74) ANCOVA 
GENDER 10M; 8F 31M; 43F  
AGE 71.78 ± 11.2 (51-84) 69.1 ± 8.1 (52-85)  
DIS DURATION 5.3 ± 2.6 (1-9)   
MMSEc 18.6 ± 3.4 (13.5-26.1)   
RNFLavg (microns) 87.8 ± 8.7 (71-104) 95.8 ± 12.3 (68-130) *p=0.034 
RNFL-T (microns) 67.9 ± 10.5 (49-84) 69.3 ± 10.5 (41-101) p=0.942 
RNFL-S (microns) 103.8 ± 13.6 (83-124) 117.1 ± 17.6 (81-152) *p=0.009 
RNFL-N (microns) 63.5 ± 11.7 (37-86) 74.3 ± 15.3 (48-133) *p=0.016 
RNFL-I (microns) 115.6 ± 16.5 (91-158) 122.4 ± 18.1 (85-154) p=0.284 
Table 8. OCT results in AD patients and controls 
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Figure 26. OCT results in AD patients. Average RNFL thickness (upper panel) and RNFL thickness 
of single quadrants (lower panel) in controls and AD patients 
 
The Pearson test and regression analysis did not disclose any significant correlation 
between demographic or clinical parameters and RNFL measurements, except for 
age. Average RNFL thickness correlated with age in both controls (p=0.01; r=-0.289) 
and AD patients (p=0.005; r=-0.635) (Figure 27). Considering separately the four 
quadrants, the RNFL thickness of superior (p=0.05; r=-0.465) and nasal (p=0.04; r=-
0.486) quadrants for AD patients, and of temporal (p=0.03; r=-0.247) and nasal 
(p=0.04; r=-0.235) quadrants for controls significantly correlated with age (data not 
shown).  
Stratification of AD patients according to MMSEc score in mild and moderate AD 
showed that only for the moderate AD patients the average (p=0.05), superior 
(p=0.018) and nasal (p=0.006) RNFL thickness were significantly reduced compared 
to controls (data not shown).  
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Figure 27. Correlation between RNFL average thickness and age for controls and AD patients 
2.1.2. Mild Cognitive Impairment 
We also evaluated by OCT 11 MCI individuals (73.09 ± 6.2; range 64-87; 6 males) 
and 54 age-matched controls (mean age 72.85 ± 5.6; range 64-85; 25 males). Clinical 
and demographic data are summarized in Table 9. None of the MCI patients had 
visual complaints. Three MCI eyes were excluded because the OCT exam was 
technically not reliable. Average RNFL thickness did not differ between MCI and 
controls (Table 9, Figure 28).  Similarly, considering separately the four quadrants, 
there were no significant differences between MCI and controls (Table 9). As for 
AD patients, the Pearson test and regression analysis did not disclose any correlation 
between demographic or clinical parameters and RNFL measurements, except for 
age and only for the superior quadrant (p=0.004; r=-0.790) (data not shown).  
 
Table 9. 
 MCI (N=11) CONTROLS (N=54) ANCOVA 
GENDER 6M; 5F 25M; 29F  
AGE 73.1 ± 6.2 (64-87) 72.8 ± 5.6 (64-85)  
DIS DURATION 3.9 ± 1.9 (2-8)   
MMSEc 24.9 ± 2.2 (20.3-27.4)   
RNFLavg (microns) 96.8 ± 10.4 (78-111) 94 ± 12.6 (68.3-129) p=0.44 
RNFL-T (microns) 68.1 ± 12.9 (46-97) 68.6 ± 12.7 (41-101) p=0.972 
RNFL-S (microns) 115.4 ± 19 (68-134) 115.4 ± 18.2 (81-152) p=0.681 
RNFL-N (microns) 81.3 ± 21.4 (57-134) 71.9 ± 13.3 (48-112) p=0.054 
RNFL-I (microns) 124.7 ± 14 (105-144) 120.3 ± 17.8 (85-176) p=0.419 
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Figure 28. OCT results in MCI patients. Average RNFL thickness (upper panel) and RNFL thickness 
of single quadrants in controls and AD patients  
2.1.3 Parkinson disease 
We included 43 PD patients (mean age 65.6±8.4 years; range 46-83; 23 males) and 
86 age-matched controls (mean age 65.5±10.7 years; range 46-85 years; 36 males). 
Among PD patients, three had a molecular diagnosis (two carried the G2019S 
LRRK2 mutation and one a PARK2 exon 2 deletion) and five had first-degree 
relatives affected with no molecular definition. We considered all these PD patients 
as genetic cases. For all patients we retrieved disease duration, UPDRS-III (off) 
score and stage of disease (Hoehn and Yahr). All PD patients included were on 
dopaminergic therapy. Disease duration was 9.1±6.5 years, Hoehn and Yahr stage of 
disease was 2.2±0.9 and UPDRS score was 25.9±12.4. Demographic, and the main 
clinical findings are summarized in Table 10. None of the PD patients had visual 
complaints. Five PD eyes (2 ipsilateral and 3 contralateral to the most affected body 
side) were excluded based on established criteria.  
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The average RNFL thickness was reduced in PD patients compared to controls, being 
close to significance (p=0.057) (Table 10, Figure 29). Considering separately the 
four quadrants, only the temporal RNFL thickness was significantly reduced in PD 
compared to controls (p=0.004) (Table 10). Post-hoc pairwise comparisons showed 
that the temporal RNFL thickness was significantly reduced for both the contralateral 
(p=0.008) and the ipsilateral (p=0.04) eye in PD compared to controls (Figure 29). 
The significance of RNFL thickness reduction in the temporal quadrant was 
maintained for the sporadic cases (p=0.006) and genetic cases (p=0.039) considered 
separately. Pearson test and multiple regression analysis did not disclose any 
correlation between genetic, demographic or clinical parameters and RNFL 
measurements, except for age. Average RNFL thickness correlated with age in both 
controls (p=0.001; r=-0.341) and PD patients (p=0.007; r=-0.412 and p=0.019; r=-
0.371 for the eye ipsilateral and contralateral to the most affected body side 
respectively) (data not shown).  
The results of OCT evaluation in PD are currently in press in the European Journal of 
Neurology (La Morgia et al., 2012b) (see Annex 3).  
 
PD IPSI EYE 
(N=41) 
PD CONTRA 
EYE 
(N=40) 
CONTROLS 
(N=86) 
ANCOVA 
GENDER 24 M; 19F 34M; 52F  
AGE 65.6 ± 8.4 (46-83) 65.5 ± 10.74  
DISEASE 
DURATION 
9.1 ± 6.5 (3-28)   
UPDRS (OFF) 25.9 ± 12.4 (10-61)   
HY stage (OFF) 2.21 ± 0.9 (1-5)   
RNFLavg (microns) 92.2 ± 12.8  
(68-121) 
91.9 ± 12.1 
(71-121) 
97 ± 12.4 
(68-130) 
p=0.057 
RNFL-T (microns) 62.3 ± 10.4 
(45-86) 
60.9 ± 12.8 
(33-87) 
68.5 ± 12.3 
(41-101) 
p=0.004* 
RNFL-S (microns) 115.2 ± 17.4 
(83-150) 
112.4 ± 15.6 
(76-144) 
118.9 ± 17.4 
(81-152) 
p=0.179 
RNFL-N (microns) 72.2 ± 18.3 
(39-111) 
72.9 ± 17.7 
(52-114) 
76.5 ± 15.7 
(48-133) 
p=0.362 
RNFL-I (microns) 119.3 ± 19.9 
(75-167) 
121.5 ± 18.6 
(79-161) 
124.1 ± 18.6 
(85-184) 
p=0.426 
Table 10. OCT results in PD and controls. Post-hoc pairwise comparisons: controls vs PD ipsilateral 
eye (p=0.04); controls vs PD contralateral eye (p=0.008)  
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Figure 29. RNFL thickness results. Asterisks indicate statistical significance after post-hoc pairwise 
comparisons. A. The average RNFL thickness is shown. B. The temporal RNFL thickness is shown 
C. The RNFL thickness of temporal, superior, nasal and inferior quadrants is shown for control eyes 
(black line) and for ipsilateral PD eyes (gray line). D. RNFL thickness of temporal, superior, nasal and 
inferior quadrants is shown for control eyes (black line) and for contralateral PD eyes (gray line) 
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2.2. Actigraphic evaluation in AD, MCI and PD 
Actigraphic monitoring of rest-activity rhythm for 7 days was performed in 15 AD 
patients, 7 MCI, 9 PD patients, all of them being subgroups of the cohorts 
investigated by OCT (see section 2.1), and 10 controls. “Bad” hours represent 0.5% 
of the total recording time (in particular 12 hours for AD, 1 hour for MCI, 7 hours for 
PD and 4 hours for controls). 
Clinical and demographic data of patients and controls are summarized in Table 11. 
All but 4 AD patients were on therapy for dementia (4 on donepezil, 2 on 
rivastigmine, 3 on memantine, 2 on galantamine and one on both galantamine and 
rivastigmine). MCI patients had multiple-domain (n=2), single-domain attentional 
(n=2) and single-domain amnesic cognitive dysfunction (n=3). All PD patients were 
on dopaminergic therapy (Table 11).  
 
  MIN MAX MEAN SD 
AD (n=15) DISDUR 1.00 9.00 4.9 2.5 
 MMSEc 13.4 26.1 18.9 3.9 
 AGE 52 84 70.9 10.3 
MCI (n=7) DISDUR 2.00 8 4 2.2 
 MMSEc 20.3 27.5 24.8 2.6 
 AGE 64 78 72.4 5.1 
PD (n=9) DISDUR 3 18 9.4 4.4 
 UPDRS_OFF 13.3 43.9 24.1 11.5 
 HY 1 3 1.8 0.8 
 LEDD 200 580 400.6  135.8 
 AGE 50 76 64.3 8.2 
CTRLS (n=10) AGE 54 80 65.8 7.5 
Table 11. Clinical and demographic data of patients and controls included in the actigraphic study 
 
Analysis of actigraphic data using non-parametric methods (see methods) 
demonstrated a tendency towards an increased intradaily variability (IV) (p=0.098) 
and reduced relative amplitude (RA) (p=0.057) for AD patients compared to 
controls. AD patients also tended to be less active during the wake period (p=0.058). 
PD patients demonstrated a tendency towards a reduced interdaily stability (p=0.095) 
and showed an increased IV (p=0.05) and reduced RA (p=0.028) compared to 
controls. Moreover, PD patients were more active during the night period than 
controls (p=0.04). The same analysis applied to MCI individuals failed to reveal any 
differences from controls. Interdaily stability (IS) of rest-activity rhythm did not 
significantly differ between patients of all groups and controls (Table 12; Figures 
30-32).  
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 AD (n=15) MCI (n=7) PD (n=9) Ctrls (n=10) 
IS 0.77 ± 0.15 0.83 ± 0.06 0.7 ± 0.21 0.84 ± 0.06 
IV 0.57 ± 0.35 0.44 ± 0.13 0.67 ± 0.34 0.41 ± 0.05 
RA 0.6 ± 0.13 0.67 ± 0.16 0.53 ± 0.2 0.7 ± 0.09 
M10 261.9 ± 35.23 272.08 ± 15.4 273.7 ± 22.59 282.59 ± 15.2 
L5 67.2 ± 28.49 57.5 ± 35.5 90.26 ± 47.96 50.5 ± 17.17 
Table 12. Summary of actigraphic findings in AD, MCI, PD patients and controls 
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Figures 30-32. Circadian actigraphic parameters (IS, IV and RA) in AD, MCI and PD patients 
compared to controls 
Individual data for IS, IV and RA results are shown in Figure 33. 
Overall, the graphic representation of single individuals for these three parameters 
shows that both AD and PD patients present the highest variability, with scattered 
values, compared to controls. The MCI individuals had some degree of variability for 
the IV and RA parameters.   
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Figure 33. Individual circadian actigraphic results (IS, IV and RA) for controls, MCI, AD and PD 
patients 
 
Zeta-transformed values [z=(v-µ)/(] of actigraphic parameters, considering the mean 
and SD of the control group, are shown in Figure 34. 
 
Figure 34. Z-scores for actigraphic parameters for controls and patients 
None of the actigraphic data assessing rest-activity circadian rhythm significantly 
correlated with clinical parameters such as age, disease duration, MMSE score (for 
AD and MCI) and UPDRS-III score, H&Y stage of disease and LEDD (for PD). 
Furthermore, none of the actigraphic parameters assessing rest-activity circadian 
rhythm significantly correlated with OCT data. However, we found a tendency 
toward a correlation between RNFL average, RNFL superior and RNFL nasal with 
the actigraphic parameter IV in AD patients (Figure 35). 
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  Figure 35. Correlation between intradaily variability and OCT measurements in AD patients            
 
Stratifying AD patients by MMSEc in mild and moderate AD we did not find any 
significant differences between the two groups in terms of actigraphic parameters.  
However, considering the patients with at least one circadian parameter (IS, IV and 
RA) outside the 2SD from the mean of controls (n=6), for which OCT data were 
available, we found a significant correlation between IV, average (p=0.035), superior 
(p=0.045) and  inferior (p=0.017) RNFL thickness (Figure 36). 
 
Figure 36. Correlation between IV and OCT parameters in “circadian-impaired” AD patients 
 
An example of actigraphic recording for control, AD and PD patients is provided in 
Figure 37. 
 
 
 
Figure 37. Examples of 7-days actigraphic recordings in control (left), AD (middle) and PD patients 
(right) 
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Examples of five-days profiles of hourly mean activity values are shown in Fig. 38.  
 
Figure 38. The upper panel shows the regular profile of a control subject; the middle panel shows the 
profiles of a circadian impaired AD patient (light blue) and of an AD patient with stable rhythm (dark 
blue); the lower panel shows the profiles of a circadian impaired PD patient (light green) and of a PD 
patient with stable rhythm  (dark green).  
 
Finally, the analysis of sleep parameters derived from actigraphic monitoring 
demonstrated a significant reduction of sleep efficiency in AD (p<0.001) and of both 
sleep minutes (p=0.005) and sleep efficiency (p=0.001) in PD patients compared to 
controls (Figures 39-40). 
 
 
Figure 39. Sleep minutes (mean and SD) in controls, AD, MCI and PD patients 
*p=0.005 
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Figure 40. Sleep efficiency (mean and SD) in controls, AD, MCI and PD 
Neither sleep minutes nor sleep efficiency significantly correlated with clinical 
parameters such as age, disease duration, MMSE score (for AD and MCI) and 
UPDRS-III score and H&Y stage of disease (for PD). 
2.3. Sleep questionnaires. 
We were able to collect sleep questionnaires for all AD patients, 5/7 MCI 
individuals, all PD patients and all controls. No significant differences emerged 
between patients and controls for subjective sleepiness evaluated by Epworth 
Sleepiness Scale (ESS), sleep quality evaluated by Pittsburgh Sleep Quality Index 
(PSQI) and risk of sleep apnea evaluated by Berlin test. In particular the risk of sleep 
apnea was high in 6/15 AD patients, 1/5 MCI patients, 3/9 PD patients and 2/10 
controls. The results of the single items of the PDSS scale for PD patients are 
summarized in Table 13. 
 Mean SD 
PDSS_1 6.5 2.1 
PDSS_2 9 1.7 
PDSS_3 8 2.4 
PDSS_4 9.2 1.4 
PDSS_5 7.8 2.2 
PDSS_6 8.6 2.4 
PDSS_7 9.7 0.6 
PDSS_8 5.4 4.7 
PDSS_9 9.9 0.1 
PDSS_10 6.5 2.1 
PDSS_11 9 1.7 
PDSS_12 8 2.4 
PDSS_13 9 1.4 
PDSS_14 7.8 2.2 
PDSS_15 8.6 2.4 
*p<0.001 *p=0.001 
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2.4. Immunohistochemical analysis of AD post-mortem retinas and optic nerve 
cross-sections  
We investigated sagittal retinal sections stained with melanopsin antibodies 
(Hannibal et al., 2004a) to recognize and count mRGCs (Figure 41) from 14 AD 
patients and 11 controls, adopting the same protocol used for the previous studies on 
mitochondrial optic neuropathies (La Morgia et al., 2010).  
Examples of mRGCs located in the retinal ganglion layer (RGL) and inner nuclear 
layer (INL) and regular RGC are provided in Figure 41. 
 
Figure 41. Examples of mRGC located in the RGL (left) and INL (middle), and regular RGC (right) 
(control3, 60 years) 
 
We clearly distinguished by intensity of the melanopsin stain two types of mRGCs, 
intense (Figure 41) and light-stained (Figure 42), corresponding to the M1 and M2 
types respectively (Schimdt et al., 2011b). 
  
Figure 42. Examples of light-stained mRGCs (control 3, 60 ys) 
 
Table 14 shows the main clinical and pathological features of the AD patients, as 
established by neuropathologic analysis of the brain, according to modified CERAD 
(Mirra et al., 1991) and NIA/Reagan criteria (Hyman et al., 1997).  
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ID AGE 
Pre-mortem 
dx 
MMSE CDR 
DIS DUR 
(ys) 
BRAAK 
STAGE 
#778 62 Dementia 26 (59 ys) n.a. 4 V (LBV) 
#777 86 
Vascular 
dementia 
n.a. n.a. 3 V 
#783 64 AD possible 3 (64 ys) 3 (64 ys) 6 VI 
#795 80 FTD 
Unable to 
complete 
4 n.a. V 
#801 75 AD 21 (72 ys) n.a. 7 V 
#800 96 
AD possible 
plus LBD 
0 (95 ys) 4 (95ys) 10 V 
#781 80 AD 7 (80 ys) 3 (80 ys) 7 V-VI 
#837 70 AD probable 25 (69 ys) 1 (69 ys) 4 V 
#806 98 Dementia 9 (97 ys) 3 (97 ys) 8 V 
#768 83 AD probable 14 (78 ys) n.a. 7 VI 
#769 71 FTD n.a. n.a. 14 VI 
#776 98 AD possible n.a. 2 (96 ys) n.a. V 
#799 95 AD 17 (93 ys) 3 (93 ys) 18 V 
#805 95 AD n.a. 3 (92 ys) 11 V 
Table 14. Demographic, clinical (MMSE and clinical dementia rating scale-CDR) and 
neuropathological data of AD cases; n.a.= not available; LBV: Lewy Body variant  
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The qualitative evaluation at light microscopy of the melanopsin-stained AD retinal 
sections compared to controls showed a grossly preserved structure of the retinal 
layers, including the RGL. We observed mRGCs located in both RGL and INL, as 
previously reported (Hannibal et al., 2004a). The morphology of mRGCs on the 
gross histological examination resembled that of controls. Some examples of mRGCs 
in AD patients are provided in Figure 43. 
 
Figure 43. Examples of mRGCs in AD post-mortem retinas (#783) 
 
However, in AD patients a frequent feature of fragmented dendrites was noted at 
high magnification (Figure 44), which was not evident at the same frequency in the 
age-matched controls.  
 
Figure 44. Examples for normal dendrites in controls (upper panels) (control 4, 74 ys and control 2, 85 
ys) and fragmented dendrites in AD patients (lower panels) (#805, 95 ys) 
 
Based on the gross histological examination, we recognized the presence of macular 
degeneration in one 98-year-old AD patient (#806) and of proliferative diabetic 
retinopathy in another 70-year-old AD case (#837).  The retrospective evaluation of 
the clinical charts of these two patients confirmed the diagnosis of macular 
degeneration and diabetic retinopathy, respectively. Based on these comorbidities 
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involving retinal pathology we decided to exclude these two cases from the statistical 
analysis.  
We also examined at light microscopy the optic nerve cross-sections from the same 
AD patients and controls for which we studied the sagittal retinal specimens for 
mRGCs counts. Optic nerves were embedded in epon plastic and stained with PPD to 
identify the myelin profiles, indicative of the single axons. At gross examination we 
identified one AD case (#777, 86 yrs male) with an extreme loss of axonal profiles 
compatible with non-arteritic ischemic optic neuropathy (NAION), which for this 
reason was excluded from the statistical analysis. All the remaining cases (n=11) 
showed an essentially preserved anatomy with some of the AD patients having a 
noticeable optic neuropathy with different degrees of axonal depletion (Figure 45), 
as previously reported (Hinton et al., 1986).  
 
Figure 45. Comparison of human postmortem optic nerves in a control (A1), and AD patient (B1), and a 
patient with LHON (C1). Note higher density of axons in the control at higher magnification (A2) as 
compared to the AD (B2) and the LHON (C2) nerve tissues. Arrows in B2 and C2 point to degenerative 
profiles (magnification in A1, B1 and C1 is 25x; A2, B2 and C2 is 1000x).  
Some examples of optic nerve cross-sections profiles from AD cases with different 
degrees of axonal loss are provided in Figure 46 (#800, #799, #795). 
 
Figure 46. ON cross-sections of AD patients showing different degrees of axonal depletion 
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Interestingly, as shown by the above figures, the axonal loss affects the large fibers at 
the superior quadrant for the #799 and #795 AD, as well as nasal and inferior 
quadrants, whereas the temporal sector is mostly spared by neurodegeneration 
(Figure 46). Overall, after the excluded cases, the quantitative analysis and the 
following statistics have been performed on a set of 11 AD patients (81.7±13.1 years; 
5 male and 6 females) and 11 age-matched controls (78.5±15.1 years; 7 males and 4 
females).  
Melanopsin RGCs were equally distributed in the RGL and INL in both AD and 
controls without differences between groups (Figure 47). 
 
Figure 47. Melanopsin RGCs distribution in the RGL and INL for controls and AD 
 
Melanopsin RGCs density was significantly reduced in AD patients compared to 
controls (p=0.008) (Figure 48). 
 
Figure 48. mRGCs density in controls and AD patients 
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Axonal count also showed a reduction in AD patients compared to controls, close to 
statistical significance (p=0.067) (Figure 49). 
 
Figure 49. Axonal counts in controls and AD patients 
 
As a result, the mRGCs/RGCs ratio, assuming that the axonal count equals the RGCs 
number, was comparable between AD patients and controls (p=0.683) (Figure 50). 
 
  
Figure 50. mRGCs/RGCs ratio in controls and AD patients 
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Both mRGCs density (p=0.033; r=-0.643) and axonal count (p=0.006; r=-0.763) 
significantly correlated with age only in controls (Figure 51).  
 
 
Figure 51. Correlation between axons, mRGCs density and age in controls 
 
Stratifying all the previous data by decades we observed a decline of axonal count 
with age in both controls and AD. At difference, mRGCs density declined with age 
in controls, whereas in AD patients it was reduced across all ages. Remarkably, in 
the 60s and the 70s decades, this reduction of mRGCs density occurred in AD 
patients in the presence of an essentially normal number of axons in the optic nerve 
(Figure 52). 
 
 
 
Figure 52. Axonal counts and mRGCs density by decades in controls and AD 
 
Furthermore, we subgrouped controls and AD patients in four categories, using 80 
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80 ys, controls % 80 ys, AD < 80 ys and AD % 80 ys). Both mRGCs density 
(p=0.004) and axonal count (p=0.003) were significantly different between groups 
(Figure 53, Table 15).  
 
    CI 95% 
   
Standard error Sig. lower limit upper limit 
mRGCs 
density 
youngCtrls vs 
youngAD 
1.4 0.012 0.9089 9.1 
youngCtrls vs 
oldAD 
1.2 0.005 1.2711 8.3 
axons youngCtrls vs 
oldAD 
95894.4 0.004 108294.1 676513.7 
youngAD vs 
oldAD 
102648.9 0.022 38078.7 646321.5 
Table 15. Significant post-hoc comparisons (Bonferroni) are shown between groups  
 
 
Figure 53. mRGCs density, axonal counts and mRGCs/RGCs ratio for subgroups 
Considering separately males and females we did not observe any difference for the 
mRGCs density and axonal count in the control group, whereas a tendency towards a 
higher mRGCs density was evident for AD females compared to AD males 
(p=0.078) (Figure 54). 
 
Figure 54. mRGCs density results by gender in controls and AD patients 
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Finally, we failed to observe any correlation between mRGCs density, axonal count 
and mRGCs/RGCs ratio neither with disease duration nor with Braak score in AD 
cases. However, a significant correlation was evident between mRGCs density and 
the B-score assessing the severity of neurofibrillary tangles (NFTs) deposition at the 
level of the superior/middle temporal cortex (p=0.014; r=-0.775), and the C-score 
assessing the severity of neuritic plaques (NPs) deposition at the lateral geniculate 
body of hippocampus (p=0.014; r=-0.710) (Figure 55). 
 
 
Figure 55. Correlation between the mRGCs density and NFTs-score in superior-middle temporal 
cortex and between the mRGCs density and NPs-score at lateral geniculate body of hippocampus 
 83 
3. PROJECT 3 
&'%6*-"%"4*./+&%&,1'"(*$%0*("$(&%$#*$77".,)3"*0)(&+0"+*
3.1. Genetic variant of the OPN4 gene and chronotypes 
We assessed the genotypes (CC, TC and TT) related to the single nucleotide 
polymorphism (rs2675703-P10L-exon1) in the OPN4 gene, previously associated 
with the seasonal affective disorder (Roecklein et al., 2009), in 314 subjects (mean 
age 31.8 ± 9.9 years; 103 male-32.8% and 211 females-67.2%) characterized for 
their chronotype by the Morningness Eveningness Questionnaire (MEQ). 
The frequency of chronotypes is shown in Table 16 and Figure 56. 
 
Chronotype FREQUENCY 
EXTREME 
EVENING 
20 (6.4%) 
MODERATE 
EVENING 
44 (14%) 
INTERMEDIATE 190 (60.5%) 
MODERATE 
MORNING 
54 (17.2%) 
EXTREME 
MORNING 
6 (1.9%) 
Table 16. Frequency of chronotypes              Figure 56. Chronotype distribution  
 
The distribution of chronotypes was not different by gender (Figure 57). 
 
  Figure 57. Distribution of chronotypes by gender 
0= EXTR EVENING 
1= MOD EVENING 
2= INTERMEDIATE 
3= MOD MORNING 
4=EXTR MORNING 
 84 
We found a significant correlation between MEQ score and age (p=0.007; r=-0.152) 
(Figure 58). 
 
 
Figure 58. Correlation between MEQ score and age 
 
Neither the genotypes (CC, TC and TT) nor the allelic distribution were significantly 
different between chronotypes, either considering the five categories separately 
(p=0.616) or grouped (p=0.428) (Table 17, 18). These results were not different if 
we included only subjects below 40 years of age (data not shown).  
 
Table 17. Distribution of the five categories of chronotype by P10L genotype 
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Table 18. Distribution of the three categories of chronotype by P10L genotype 
 
The distribution of the genotypes by chronotype and by MEQ score is shown in 
Figure 59.  
  
Figure 59. Distribution of P10L genotypes for the three chronotypes (left). MEQ score of the three 
P10L genotypes (right) 
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3.2. Genetic variant of the OPN4 gene and SAD 
Global seasonality score (GSS) was assessed in 182 subjects of the previous cohort 
and failed to show any significant association with genotypes. However, individuals 
with the T/T genotype tended to have higher GSS (p=0.08) (Figure 60).  
 
Figure 60. GSS in the three P10L genotypes  
 
None of the genotypes revealed a significant association with the seasonal affective 
disorder (SAD) syndrome or the sub-syndrome (subSAD). Again, the TT genotype 
tended to be more represented in the (SAD) syndrome or the sub-syndrome 
(subSAD) groups (Figure 61).  
 
Figure 61. Distribution of the three P10L genotypes in the three categories (No Sad, Subsyndrome and 
SAD syndrome) 
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DISCUSSION 
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For the sake of clarity, the discussion is organized in three sections, which reflect the 
three projects of this PhD thesis. 
5.1. Project 1- Melanopsin RGCs in hereditary optic neuropathies 
The expansion of our initial investigation on mRGCs in hereditary optic 
neuropathies, after the two retinal specimens from Leber Hereditary Optic 
Neuropathy patients, involved an 87-year old dominant optic atrophy case. This 
patient had a terminal stage, very severe optic atrophy and demonstrated the highest 
rate of mRGCs sparing, reaching mRGCs/RGCs ratio of 48.6% (?1% in controls; 
3.1% in mild LHON and 38.5% in severe LHON cases) compared to 0.9% in the 
age-matched control (Figure 20). The distribution of mRGCs in the DOA case was 
flattened, whereas in the 85-year old control the peak in the macular region was 
maintained as previously shown for LHON patients and age-matched controls.  
Two conclusions can be drawn by the overall results of this study. The main 
conclusion is that in two inherited optic neuropathies affecting selectively RGCs, the 
mRGCs system is relatively preserved, thus explaining the maintenance of the 
pupillary light reflex and the absence of sleep complaints in these blind patients. Our 
histological results are well supported by the normal melatonin suppression response 
after light exposure demonstrated in patients. A second conclusion concerns the first 
documentation that mRGCs may undergo reduction with age in humans, as shown by 
our morphometric evaluation in the control retinas. Furthermore, the distribution of 
mRGCs in the human retina peaks in the macular region. The DOA case represented 
an exception, possibly because of the combination of age and severe 
neurodegeneration. This study, including the LHON and DOA cases, has been 
published in the journal Brain (La Morgia et al., 2010) (see annex 1).  
As an in-vivo follow-up study, we applied a recently described pupillometric method 
(Park et al., 2011) able to discriminate the contribution of mRGCs to the pupillary 
light reflex, to study a cohort of LHON affected patients, belonging to a single very 
large pedigree from Brazil (Sadun et al., 2003). We demonstrated that LHON 
patients maintained the pupillary light response to both red and blue light (Moura et 
al., 2011). However, both the amplitude of the pupil response and the ability to 
maintain a sustained response (mainly driven by mRGCs) were significantly reduced 
in LHON patients compared to controls. This reduced efficiency in initiating and 
maintaining the pupil constriction, suggests some loss of mRGCs compared to 
controls. In fact, the sustained response with blue light showed the most evident 
discrepancy between LHON and controls, pointing to a fast escape of the pupil due 
to the loss of mRGCs (Bremner, 2004). Interestingly, stratifying the patients 
according to the number of abnormal pupil parameters, we did not find any 
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correlation with visual function impairment, suggesting that the pupil function is 
dissociated at least in part from visual function in these patients. These findings are 
in line with previous observations demonstrating that both visual and pupil function 
are abnormal in LHON, but a relative sparing of the pupil afferent fibers is evident, 
comparing visual and pupil function (Bremner et al., 1999). Overall, these data are 
compatible with our previous histological results. In fact, mRGCs were relatively 
spared compared to the rate of loss of RGCs in optic neuropathy patients, but 
reduced as absolute number compared to age-matched controls (La Morgia et al., 
2010). Thus, the pupillary reflex in LHON is present but less efficient when 
compared to controls. The only other study using a similar protocol in one monocular 
LHON case showed similar findings (Kawasaki et al., 2010). These studies leave 
open the question of how and why the mRGCs are resistant to the metabolic 
mitochondrial dysfunction compared to the regular RGCs. 
To address this question we set an in-vitro investigation based on the hypothesis that 
the expression of the melanopsin photopigment might exert a protective role on 
mitochondrial dysfunction in mRGCs. We used a cell model enginerized to express 
melanopsin under the control of tetracycline. All experiments compared the same 
cells expressing or not this photopigment, under different conditions of light 
exposure and metabolic stress mimicking the mitochondrial dysfunction in LHON 
and DOA. To this end, cells were grown in the presence of increasing concentrations 
of rotenone, a classic mitochondrial complex I inhibitor, and in the presence of TBH, 
a pro-oxidant agent acting at the cytoplasmic level, and cell viability was measured 
by the SRB assay (Ghelli et al., 2008). These experiments were carried out in 
darkness, after white light and blue light exposure. Cell survival was not influenced 
by the expression of the melanopsin photopigment in none of the experimental 
conditions used. Within the limits of this set of experiments, our results indicate that 
melanopsin itself may not be responsible for the survival of mRGCs in mitochondrial 
optic neuropathies. A further candidate, which has not been explored in this project, 
is the neuropeptide pituitary adenilate cyclase-activating polypeptide (PACAP). This 
neuropeptide is selectively expressed by mRGCs and not by regular RGCs (Hannibal 
et al., 2002a, 2006a). Furthermore, there is evidence for its neuroprotective role in 
literature pointing to a possible role in mRGCs metabolic robustness.  
A different point of view is related to the photoreceptive function of mRGCs, which 
makes them able to cope with the potentially harmful effect of light on cell viability. 
Light is a well known damaging agent on retinal cells, and RGCs, in particular, are 
the first retinal cell type exposed to incoming light. In LHON and DOA, under the 
condition of dysfunctional mitochondrial metabolism characterized by increased 
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ROS production, light might become a triggering factor for cell death adding to the 
mitochondrial impairment (Osborne et al., 2008). In this respect, mRGCs, despite 
carrying the same metabolic imbalance, are intrinsically protected by their 
photoreceptive properties, which are able to quenche the damaging effects of light. 
This scenario has been debated in literature, but needs a solid experimental 
demonstration. 
Finally, mRGCs robustness might be a more general phenomenon, beyond the 
mitochondrial metabolic dysfunction, as shown by a set of data from literature. For 
example, there is evidence that mRGCs survive to optic nerve transection, suggesting 
a general robustness of this cellular system (von Bussman et al., 1993; Robinson et 
al., 2004; Li et al., 2008). Remarkably, mRGCs are a photoreceptive system that 
predates the development of the eye as organ for vision and shares many similarities 
with the invertebrate photoreception (Davies et al., 2010). This very long 
evolutionary selection may underlie the present observations, leaving open the 
mechanisms implicated in their robustness in mitochondrial optic neuropathies.  
5.2. Project 2- Optic nerve pathology, mRGCs and rest-activity circadian rhythm in 
AD, MCI and PD patients 
5.2.1. OCT and rest-activity circadian rhythm in AD, MCI and PD patients 
The first question we have addressed with this study concerned the occurrence of a 
significant optic neuropathy in common neurodegenerative disorders, such as AD 
and PD, and which pattern characterized this optic neuropathy. Our OCT results 
documented the occurrence of subclinical optic neuropathy in both disorders, with a 
clearly distinguishable pattern. In AD patients there was a significant reduction of 
RNFL thickness in the average measurements as well as in the superior and nasal 
quadrants (Figure 26). This reduction, however, was not evident when we 
considered only mild AD patients, being significant in the moderate subgroup. 
Opposite to this pattern, we documented in PD patients a reduction of RNFL 
thickness selectively limited to the temporal quadrant, and a close-to-significance 
reduction of the average measurements (Figure 29). The MCI individuals were 
unremarkable for all parameters measured by OCT compared to controls. 
The existence of an optic neuropathy in AD patients has been histologically 
recognized since 1986 (Hinton et al., 1986) even if has been long debated in 
literature (Guo et al., 2010). In recent times, the use of OCT for in-vivo objective 
anatomical measurements of RNFL thickness prompted a number of studies in many 
neurodegenerative disorders including AD. Most studies reported a reduction in the 
average measurements (Parisi et al., 2011; Iseri et al., 2006; Paquet et al., 2007; Lu et 
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al., 2010; Kesler et al., 2011), as well as in the superior quadrant (Parisi et al., 2001; 
Iseri et al., 2006; Berisha et al., 2007; Lu et al., 2010; Kesler et al., 2011). 
Remarkably, none of these studies, including our current investigation, revealed an 
involvement of the temporal quadrant. Our results also point to RNFL thinning of the 
nasal quadrant, which has also been documented by a few of the above quoted 
reports (Parisi et al., 2001; Iseri et al., 2006). Overall, the subclinical optic 
neuropathy in AD seems to affect the magnocellular component of RGCs, as 
documented both histologically (Hinton et al., 1986; Sadun and Bassi, 1990) and 
more recently electrophysiologically (Sartucci et al., 2010). In this regard, it is of 
note that this pattern resembles that of glaucomatous optic neuropathy and, 
remarkably, there is a widely documented evidence of increased prevalence of 
glaucoma in AD patients (Bayer et al., 2002a,b; Tamura et al., 2006). The limit 
distinguishing glaucoma from AD-related optic neuropathy is blurry and there is a 
consistent possibility that optic nerve involvement in AD is characterized by a 
continuous spectrum of severity ranging from a subclinical to a glaucoma-like optic 
neuropathy. The pattern followed by this neurodegenerative process affecting RGCs 
is the same. In this context our results are coherent with the current knowledge on 
AD optic neuropathy and set for the hypothesis we are pursuing in this project of a 
possible co-involvement of mRGCs in AD.  
Our inconclusive results with MCI individuals are in contrast with some reports 
documenting a reduction of RNFL thickness also in MCI (Paquet et al., 2007, Kesler 
et al., 2011). There are multiple possible reasons for our failure to observe such a 
reduction: first, the small sample size of our cohort, and secondly, we did not include 
only the amnesic variant of MCI, the most predictive for conversion to AD (Fischer 
et al., 2007). 
In PD patients our OCT study also revealed a subclinical optic neuropathy, affecting 
significantly only the nerve fibers entering the temporal quadrant of the optic disc. 
The contralateral eye was more affected than the ipsilateral to the most affected body 
side, supporting an asymmetry of the neurodegenerative process that involves both 
the substantia nigra and the eye on the same side. Similarly, an asymmetric 
impairment has been reported for the olfactory function, further supporting a general 
asymmetry in the neuropathological process in PD (Zucco et al., 2001). These results 
identified in PD patients a pattern of axonal loss typically seen in LHON and DOA, 
where the temporal fibers belonging to the papillo-macular bundle are 
characteristically susceptible (Carelli et al., 2004). Both diseases are associated with 
a complex I defect (Carelli et al., 2007, 2009), which is also recognized as a key 
feature in the pathogenesis of PD, either in the sporadic cases as well as in the 
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genetic forms (Schapira et al, 2008; Whithworth et al., 2009), linking the current 
results with the pattern observed in LHON and DOA. Previously, other authors 
documented optic nerve pathology in PD, some reporting a preferential loss of fibers 
in the infero-temporal quadrants, consistent with the involvement of the papillo-
macular bundle (Inzelber et al., 2004; Yavas et al., 2007; Moschos et al., 2011). 
Macular and foveal abnormalities have also been documented (Hajee et al., 2009). 
However, Altintas and coauthors reported a significant RNFL thinning of the 
superior and nasal quadrants (Altintas et al., 2008), whereas Archibald and coauthors 
failed to find any differences between PD and controls (Archibald et al., 2011b). The 
role of a specific PD neuropathology in the retina is controversial and clear evidence 
of alfa-synuclein deposition is still missing. The most consistent link we hypothesize 
between the subclinical optic nerve involvement in PD and the major mitochondrial 
optic neuropathies LHON and DOA is based on complex I dysfunction and altered 
mitochondrial dynamics (Carelli et al., 2004). This latter link is highlighted by 
mitochondrial network fragmentation in patient-derived cells from both DOA and 
PD affected individuals carrying respectively OPA1 and PINK1/Parkin mutations 
(Carelli et al., 2004; Schapira et al., 2008; Withworth et al., 2009). The balance 
between mitochondrial fission and fusion seems crucial for the correct execution of 
mitochondrial quality control and excessive mitophagy has been documented in 
RGCs of OPA1 mutant mouse leading to their degeneration, as well as it is now a 
central theme in PD pathogenesis (Withworth et al., 2009; White et al., 2009; Vives-
Bauza et al., 2011).  
Overall, all our results on RNFL thickness in AD, MCI, PD and controls were 
correlated to the aging process, confirming previous studies at both histological and 
OCT level (Johnson et al., 1987; Balazsi et al., 1984, Feuer et al., 2011; Budenz et 
al., 2007). Thus, a neurodegenerative process affects, with the documented 
differences in pattern, both AD and PD patients in an age-related fashion supporting 
the possibility that mRGCs could be involved.  
The second question we addressed with this study concerned the occurrence of rest-
activity circadian rhythm abnormalities in AD, MCI and PD patients compared to 
age-matched controls. We used a prolonged actigraphic monitoring to assess the 
interdaily stability, intradaily variability and relative amplitude of the rest-activity 
circadian rhythms applying non-parametric methods (Witting et al., 1990; Van 
Someren et al., 1999). We also derived, by these recordings, sleep minutes and sleep 
efficiency. As a general observation, both categories of AD and PD patients 
displayed a wide variability for all the parameters measured, possibly reflecting a 
heterogeneity of the circadian disturbances in these diseases (Figures 33 and 34). In 
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particular, AD patients showed a tendency towards an increased intradaily variability 
and reduced relative amplitude of the rest-activity circadian rhythm. Furthermore, 
AD patients tended to be less active during the day. PD patients revealed a 
significantly increased intradaily variability, reduced relative amplitude of rest-
activity circadian rhythm and increased activity during the resting period compared 
to controls. MCI individuals were not significantly different from controls for any of 
the parameters measured.  
Most of the studies reporting the occurrence of circadian dysfunction in AD included 
moderate or severe AD patients, documenting a generalized and more relevant 
circadian dysfunction than in our mild-moderate case series (Satlin et al., 1995; 
Witting et al., 1990; Hatfield et al., 2004; Van Someren et al., 1996; Harper et al., 
2008; Volicer et al., 2001). Previous studies investigating mild AD patients failed to 
reveal significant abnormalities (Van Someren et al., 1996; Hatfield et al., 2004). 
However, studies using laboratory-based polysomnography showed reduced sleep 
efficiency and amount of slow wave sleep, even in the mild cases (Prinz et al., 1982; 
Moe et al., 1995). Similarly, in our series of mild-moderate cases we found reduced 
sleep efficiency compared to controls. Moreover, in many of the case series reported, 
a broad range of activity pattern was also evident in subjects suffering moderate 
dementia, with some patients showing a pattern resembling that of controls and 
others with severely compromised behavior (Hatfield et al., 2004). Interestingly, 
Hatfield and coauthors conducted a 1-year follow-up study in mild-moderate AD 
patients, showing that the actigraphic pattern did not deteriorate at follow-up, even if 
there was a significant decrease in cognitive functions (Hatfield et al., 2004). This 
suggests that cognitive and circadian abnormalities behave with a different rate of 
progression and may be sustained by different pathophysiological mechanism. 
Further, in this case series the patients with a poor outcome in terms of 
instituzionalization or severe deterioration of cognitive functions had a significantly 
lower stability of circadian parameters at baseline evaluation (Hatfield et al., 2004). 
Compatibly with these observations, we also documented that AD patients with the 
most severely affected circadian parameters presented the worst outcome with one 
patient being instituzionalized and one rapidly deteriorating (data not shown). In 
other words, the presence of significant circadian dysfunction in the early stage of 
disease may be a predictive factor of poor outcome in patients with AD. Thus, our 
failure to show significant differences between AD patients and controls may depend 
on the inclusion of only mild-moderate cases and on the heterogeneity of circadian-
impaired patients at a group level. We were constrained in selecting the mild-
moderate AD patients because of the need for compliance to carry out both OCT and 
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ophthalmological examinations.  Other limitations intrinsic to this study may be 
represented by the overall small sample size of this cohort and the non-controlled 
conditions in terms of season of actigraphic recordings, light exposure and meal-time 
due to the difficulties of studying these patients in a more controlled laboratory 
setting. Moreover, the duration of our actigraphic monitoring may be not fully 
sufficient to detect abnormalities of circadian parameters (Van Someren, 2007). 
Actigraphic parameters did not correlate with clinical data (disease duration and 
severity of cognitive impairment) or OCT data in the overall group of AD patients. 
However, selecting only patients with at least one abnormal circadian parameter, we 
demonstrated that IV significantly correlated with average, superior and nasal RNFL 
thickness at OCT evaluation (Figure 36). This correlation is particularly significant 
for our hypothesis, supporting the possible involvement of retinal pathology, i.e. loss 
of mRGCs, in the pathogenesis of circadian dysfunction.  
Concerning the PD patients, our actigraphic investigation documented a significant 
increase of the intradaily variability, reduction of relative amplitude and increased 
activity during the resting period. These findings are concordant with those reported 
by Whitehead and coauthors in a cohort of 50 patients (Whitehead et al., 2008). Only 
another study assessed the rest-activity circadian rhythm in PD patients, showing a 
significant reduction of the circadian rhythm pattern evaluated with a different 
methodology (Niwa et al., 2011). Further, the finding of increased activity during the 
resting period is concordant with other actigraphic studies in PD (Van Hilten et al., 
1984; Stavitsky et al., 2010). The interpretation of actigraphic results in PD patients 
must take into account the possible role of confounding factors such as the motor 
disability, the circadian fluctuations of motor functions and the influence of 
dopaminergic drugs (Whitehead et al., 2008; Bruguerolle et al., 2002). However, 
Vezoli and coauthors demonstrated in a MPTP-monkey model of PD that circadian 
dysfunction occurs early, before the appearance of motor symptoms, suggesting that 
this may be a pathological feature independent from the evolution of motor disability 
(Vezoli et al., 2011). Furthermore, a recent Drosophila model of PD expressing $-
synuclein mutants recapitulated non-motor symptoms including abnormal sleep-like 
behavior, altered locomotor activity and abnormal circadian periodicity, all preceding 
the onset of motor symptoms (Gajula Balija et al., 2011). Compatibly with these 
evidences from animal models of PD we failed to correlate our actigraphic results 
with both duration and severity of motor symptoms. Moreover, there is evidence that 
dopamine depletion per se may be relevant for the occurrence of circadian 
impairment (Boulamery et al., 2010; Gravotta et al., 2011). This might be particulary 
important if we consider that dopamine depletion has been demonstrated in PD 
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retinas (Harnois and Di Paolo, 1990) and that a direct interaction of retinal 
dopaminergic amacrine cells with mRGCs has also been shown (Zhang et al., 2008; 
Vugler et al., 2007).  
We also documented a significant reduction of sleep minutes and sleep efficiency in 
PD patients and of sleep efficiency in AD patients, as previously reported (Stavitsky 
et al., 2012; Yesavage et al., 2004). These findings are in accordance with many 
reports documenting the occurrence of sleep disturbances in PD and AD (Menza et 
al., 2010; Iranzo et al., 2011; Wu and Swaab, 2007; Tractenberg et al., 2006) 
At variance with others, we did not find any difference in terms of sleep 
questionnaires assessing excessive daytime sleepiness and subjective quality of sleep 
between AD, PD patients and controls. This result may be explained by the small 
sample size of our cohort and the wide heterogeneity in the questionnaires scores.  
5.2.3. Melanopsin RGCs and optic nerve studies in post-mortem specimens 
from AD cases and controls  
We analyzed the post-mortem retinal specimens and corresponding optic nerve 
cross-sections of 11 neuropathologically definite AD patients and 11 age-matched 
controls. Looking at the overall results, we documented a significant loss of mRGCs 
in AD retinas compared to controls and a close-to-significance loss of axons in optic 
nerve cross-sections, and thus of RGCs. Consequently, the mRGCs/RGCs ratio was 
similar for AD cases and controls (Figures 48-50). These results may apparently 
suggest that, to some extent, the neurodegenerative process in AD affects in parallel 
and at similar rate both mRGCs and RGCs. The observation of axonal loss in AD 
cases just confirms the previous notion in literature that optic neuropathy can be 
found in AD patients (Guo et al., 2010; Hinton et al., 1986; Sadun and Bassi, 1990), 
further evidenced in this project by the OCT results. Qualitatively, the axonal loss in 
the optic nerve specimens of the most severe cases affected the large axons of the 
supero-nasal and inferior sectors, with sparing of the papillomacular bundle temporal 
fibers (Figure 46), substantiating at histopathological level the pattern observed at 
OCT (Figure 26). This pattern is coherent with that seen in glaucoma, supporting the 
argument that in AD patients it might be a spectrum of optic neuropathy continuum 
ranging from mild axonal loss to glaucoma-like cases. This may explain the high 
prevalence of glaucoma in AD patients (Bayer et al., 2002).  
Axonal loss in controls is an age-dependent phenomenon (Figure 51). This is 
beautifully shown by the progressive loss of axons over the decades (Figure 52), 
which again confirms observations done more than 20 years ago (Dolman et al., 
1980; Balazsi et al., 1984; Johnson et al., 1987). Our results on AD patients also 
indicate a similar age-related dependence of axonal loss but with a sharper decline 
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after 80s. We interpret this as the additional effect of aging and neurodegeneration 
affecting RGCs in AD patients. Similar results correlating the axonal loss to age 
were obtained by our OCT studies in both controls and AD patients (Figure 27). 
Concerning the mRGCs population, this is also lost in an age-related fashion in 
controls, as we previously reported (La Morgia et al., 2010) (Figure 51). 
Intriguingly, in AD cases we found that mRGCs were remarkably reduced in density 
at a similar degree across decades (Figure 52).  This finding suggests that mRGCs 
undergo a neurodegenerative process, which most probably is independent from the 
axonal loss, or in other words from the optic neuropathy. In fact, mRGCs density 
reduction occurs also in patients with no axonal loss and normal optic nerve (60s and 
70s). This leads to an mRGCs/RGCs ratio inferior to 1% in AD patients younger than 
80 years, whereas this ratio rises to 1.5% in patients older than 80 years, and over 2% 
in the 2 cases with the most severe axonal loss (see Figure 53).  
Thus, compared to controls, the patterns of axonal and mRGCs loss, as calculated by 
z-scores, is profoundly different (Figure 62), suggesting that for mRGCs there is a 
distinctive neurodegenerative phenomenon, part of the Alzheimer neuropathology, 
whereas for RGCs there is the overlapping of AD neuropathology and aging. 
 
 
Figure 62. Pattern of axonal and mRGCs loss in controls and AD patients 
 
In support to the above conclusions, the morphology of mRGCs qualitatively showed 
an increased amount of fragmented dendrites, which may be a hallmark of a 
neurodegenerative process that specifically affects this population of cells. The 
evidence that mRGCs may be affected by the neurodegenerative process of AD, 
independently from age, possibly explains the occurrence of circadian rhythm 
dysfunction documented by some authors also in the early stage of the disease (Hu et 
al., 2009; Sterniczuk et al., 2010).  
Interestingly, mRGCs density correlated with the severity of AD pathology at the 
level of superior-middle temporal cortex and lateral geniculate body of the 
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hippocampus, suggesting that the degree of mRGCs loss might be an index of the 
severity of the disease. 
Considering the entire project 2 we can conclude that OCT, actigraphic recordings 
and histopathological studies indicate that the visual system is consistently affected 
in a subgroup of AD patients. These are possibly the patients suffering more 
extensively circadian disturbances. In fact, when we isolated the “circadian-
impaired” patients based on the actigraphic parameters, we have been able to 
highlight a correlation with the OCT retinal measurements in the same patients.  
 
5.3. Project 3-OPN4 polymorphism, chronotype and seasonal affective disorder 
The third project of this PhD thesis was focused on the previous report that genetic 
variation in the OPN4 gene, encoding for the melanopsin photopigment, was 
associated with SAD (Roecklein et al., 2009). Based on the role of mRGCs in 
circadian photoentrainement and the recent data on their involvement in regulation of 
sleep homeostasis, and knowing that different chronotypes have a different 
homeostatic regulation of sleep, we evaluated a possible association of the same 
missense P10L variant with chronotype.  
We failed to show any significant association between this polymorphic variant and 
chronotypes. Genetic determination of chronotypes has already been investigated, by 
studying clock genes, with heterogeneous and frequently non-reproduceable results 
(Wulff et al., 2009). A possible confounding factor is represented by age. We also 
considered the subgroup of patients younger than 40 years, again without finding any 
significant association between genotypes of the P10L variant and chronotype.  
This investigation is the first to address the possibility that genetic variants in the 
OPN4 gene may be influential on sleep and we focused in particular on the 
chronotype. Association studies need very large cohorts to reach statistical power 
and the current study might just not be sufficient to highlight a positive association. 
In fact, the TT genotype of the P10L variant is present at a very low frequency in the 
general population and this implies that a very large cohort of individuals should be 
analyzed to reach a solid statistical significance. Furthermore, our cohort was also 
umbalanced in terms of gender, with a prevalent representation of females. Last, we 
screened only one polymorphic variant of the OPN4 gene based on its previous 
association with SAD (Roeckelein et al., 2009), but other possible candidate SNPs 
may be further investigated.   
In a subgroup of this cohort we also had available SPAQ questionnaires evaluating 
the possible occurrence of symptoms suggestive of the SAD syndrome. Interestingly, 
even if not significant, we found a tendency for an association between the TT 
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genotype with SAD and subSAD. Individuals with TT genotype tended to have also 
a higher GSS score, in particular females. Within the limits of a non-significant 
tendency, this finding is supporting the initial results by Roecklein and coauthors in a 
second independently collected cohort (Roecklein et al., 2009). A major difference 
between our study and that of Roecklein and coauthors resides in the definition of 
SAD, which was based on a psychiatric diagnosis in their study, whereas our cohort 
was investigated only by means of questionnaires.  
However, the concordance of our results with the previous study is particularly 
intriguing if we consider the strong circadian basis of SAD, the abnormal 
hypothalamic response to light (Vandewalle et al., 2011b) and the beneficial effect of 
light therapy, and in particular of blue light, demonstrated in these patients 
(Glickman et al., 2006). 
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CONCLUSIONS AND FUTURE DIRECTIONS 
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The three projects of this PhD thesis have as a common theme the role played by the 
newly recognized photoreceptors in the retina, the retinal ganglion cells expressing 
the photopigment melanopsin (mRGCs), in driving photoentrainment of circadian 
rhythms. The three projects undertook investigations exploring different issues in 
human pathologies associated by the link of optic nerve pathology and circadian 
dysfunction of rest-activity rhythm, hypothesizing the causal involvement of mRGCs 
(for a review see La Morgia et al., 2012a).  
 
With the first project, we made the remarkable observation that in retinal and optic 
nerve specimens from patients affected by inherited mitochondrial optic neuropathies 
(LHON and DOA), which selectively affect retinal ganglion cells (RGCs), the 
subpopulation of mRGCs was relatively spared. These results explained some 
clinical features of these blind patients such as the maintenance of the melatonin 
suppression response induced by light, the absence of subjective sleep complaints 
and, to some degrees, the maintenance of the pupillary light reflex. To better define 
in vivo this latter issue, we applied the innovative protocol of pupillometric 
evaluation distinguishing the mRGCs-driven sustained response to blue light from 
the transient response evoked by red light. By this mean we studied LHON affected 
patients documenting how they may range from perfectly normal pupillary responses 
to partially reduced responses, characterized by the phenomenon of pupillary escape. 
We then asked the question if the mechanisms underlying mRGCs resistance to 
mitochondrial dysfunction resided in the main biological, unique, feature of these 
cells, i.e. the expression of the photopigment melanopsin. In a series of experiments 
that took advantage of a cellular model where melanopsin expression could be driven 
by tetracycline, we studied different stress models, under different light conditions, 
failing to find that melanospin expression could represent a protective factor to these 
metabolic insults. Thus, the question of what makes so robust these ancient 
photoreceptors, which evolved before the development of the eye as an organ for 
vision, remains open. These findings underline the long selection for a fundamental 
function in life, the photoentrainment of circadian rhythms. In the next future, more 
studies will be needed to fully characterize the metabolic properties of mRGCs. In 
particular, fields of investigation will involve handling of calcium fluxes in these 
cells, as well as the overall mitochondrial network characteristics and maintenance, 
the role played by other factor exclusively expressed by mRGCs such as PACAP, 
and lastly the role played by light in damaging retinal cell components. 
? 
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The second project investigated the two most frequent age-related neurodegenerative 
disease, Alzheimer and Parkinson disease. The hypothesis, in this case, was that in 
both disorders there is evidence of optic neuropathy and circadian dysfunction. We 
thought to link these two features hypothesizing that the mRGC neuronal system 
could be affected. We first characterized the optic neuropathy in both AD and PD 
patients by optical coherence tomography, which allows quantitative assessment of 
retinal and optic nerve head anatomy. We confirmed that both AD and PD patient 
present different degrees of optic neuropathy, evidencing a sharply distinguishable 
pattern. AD optic neuropathy is characterized by a glaucoma-like pattern with loss of 
large axons as reflected by the reduction of RNFL thickness in the supero-nasal 
quadrants at OCT. Opposite to AD, the PD optic neuropathy is characterized by the 
exclusive loss of the small axons in the papillomacular bundle, as reflected by the 
temporal loss of RNFL thickness. We second characterized, by means of prolonged 
actigraphic recordings, the rest-activity circadian rhythm in AD and PD patients, in 
order to assess the circadian dysfunction in these patients. In both diseases we 
identified a wide variability, which hampered the possibility to obtain clearly 
significant results in the overall group of AD patients. However, it seems clear that a 
subgroup of AD, as well as PD patients can be selected for having at least one of the 
circadian parameters measured significantly abnormal. Interestingly, the subgroup of 
“circadian-impaired” AD patients revealed a correlation between the parameters of 
circadian dysfunction and those of optic neuropathy, as assessed by OCT. The third 
approach, limited to AD, was to thoroughly investigate directly the mRGC system in 
post-mortem retinal and optic nerve specimens, following our protocol established in 
studying mitochondrial optic neuropathies. This approach has been revealing by 
showing that mRGCs are lost in a fashion independent from that of the optic 
neuropathy, which seems mostly a mixture of an age-related process overlapped by 
the neurodegeneration. The reduction in density of mRGCs did not obey the age-
dependance, being present across all decades, from 60s to 90s, with similar 
magnitude. Considering that we also qualitatively observed frequent abnormalities of 
the mRGCs morphology, in particular fragmentation of their dendritic arborization, 
we may conclude that the overall mRGC system is affected and possibly contributes 
to the genesis of the circadian dysfunction in AD.  
These results generate many questions and future projects to elucidate the 
involvement of mRGCs in AD. For example, what is the role of amyloid deposition 
in the retina? It would be interesting to explore if a specific subclass of mRGCs is 
specifically involved in AD. To this end the use of flat-mounted retinal preparations 
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may be of great help, by studying the dendritic morphology, considering the 
abnormalities observed in this study. Furthermore, is there a corresponding 
recognizable pathology affecting the SCN in hypothalamus? Similar to our approach 
in mitochondrial optic neuropathies, the mRGCs could be also explored in vivo by 
light-controlled pupillometry applied to different neurodegenerative disorders for 
which there is evidence of circadian dysfunction. Another possibility is to investigate 
the mRGCs system using functional MRI paradigms, as previously reported 
(Vandewalle et al., 2009a). Further, given the role of mRGCs in regulating the 
homeostatic process in sleep, another possible research field is the detailed 
characterization of sleep homeostasis in AD. The accurate assessment of circadian 
dysfunction in neurodegeneration and aging is of particular importance if we 
consider that the presence of abnormal circadian rhythm activity has been recognized 
as a strong predictor for the development of dementia (Tranah et al., 2011). To this 
end, the follow-up study of MCI subjects, in particular the amnesic subgroup, will be 
of special interest, possibly validating visual/circadian parameters as predictors of 
conversion to dementia. Further, the possibility to counteract the impairment of the 
system deputed to circadian photoentrainment by light-therapy and other 
chronobiological approaches is of extreme importance in this context (Zhou et al., 
2012). 
The entire set of histopathological studies that we carried out in AD, is also planned 
for PD patients, following the same experimental design. For PD patients we will 
also verify the possible presence of $-synuclein deposition in the retina, as a specific 
marker of neurodegeneration, in the context of mRGCs/RGCs system. 
Another possible intriguing scenario will be the characterization of the mRGCs 
system in normal aging, and in particular in centenarians. 
The last project of this PhD thesis addressed the possible association between 
melanopsin gene variants, human chronotypes and seasonal affective disorder. We 
did not find a significant association between the previously reported missense 
variant of the OPN4 gene with chronotype, whereas a partial confirmation for the 
association with SAD was found. However, the investigation of other variants of the 
OPN4 gene in conjunction with the evaluation of other clock genes might be planned 
for the next future in a more homogeneous and large cohort, together with other 
functional measurements, such as slow wave activity during sleep, pupillometric and 
functional magnetic resonance studies with different paradigms of light stimulation 
in different chronotypes and in circadian rhythm sleep disorders, such as delayed and 
advanced sleep phase syndrome.  
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Melanopsin retinal ganglion cells are resistant
to neurodegeneration in mitochondrial optic
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Mitochondrial optic neuropathies, that is, Leber hereditary optic neuropathy and dominant optic atrophy, selectively affect
retinal ganglion cells, causing visual loss with relatively preserved pupillary light reflex. The mammalian eye contains a light
detection system based on a subset of retinal ganglion cells containing the photopigment melanopsin. These cells give origin to
the retinohypothalamic tract and support the non-image-forming visual functions of the eye, which include the photoentrain-
ment of circadian rhythms, light-induced suppression of melatonin secretion and pupillary light reflex. We studied the integrity
of the retinohypothalamic tract in five patients with Leber hereditary optic neuropathy, in four with dominant optic atrophy and
in nine controls by testing the light-induced suppression of nocturnal melatonin secretion. This response was maintained in
optic neuropathy subjects as in controls, indicating that the retinohypothalamic tract is sufficiently preserved to drive light
information detected by melanopsin retinal ganglion cells. We then investigated the histology of post-mortem eyes from two
patients with Leber hereditary optic neuropathy and one case with dominant optic atrophy, compared with three age-matched
controls. On these retinas, melanopsin retinal ganglion cells were characterized by immunohistochemistry and their number and
distribution evaluated by a new protocol. In control retinas, we show that melanopsin retinal ganglion cells are lost with age
and are more represented in the parafoveal region. In patients, we demonstrate a relative sparing of these cells compared with
the massive loss of total retinal ganglion cells, even in the most affected areas of the retina. Our results demonstrate that
doi:10.1093/brain/awq155 Brain 2010: 133; 2426–2438 | 2426
Received March 17, 2010. Revised April 15, 2010. Accepted May 12, 2010
! The Author (2010). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.
For Permissions, please email: journals.permissions@oxfordjournals.org
 at Universit? di Bologna - Sistem
a Bibliotecario d'Ateneo on April 3, 2011
brain.oxfordjournals.org
Downloaded from
 
melanopsin retinal ganglion cells resist neurodegeneration due to mitochondrial dysfunction and maintain non-image-forming
functions of the eye in these visually impaired patients. We also show that in normal human retinas, these cells are more
concentrated around the fovea and are lost with ageing. The current results provide a plausible explanation for the preservation
of pupillary light reaction despite profound visual loss in patients with mitochondrial optic neuropathy, revealing the robustness of
melanopsin retinal ganglion cells to a metabolic insult and opening the question of mechanisms that might protect these cells.
Keywords: circadian rhythms; neuro-ophthalmology; mitochondrial diseases; LHON; neuropathology
Abbreviations: DOA=dominant optic atrophy; LHON=Leber hereditary optic neuropathy; mRGCs=melanopsin-containing retinal
ganglion cells; RGCs= retinal ganglion cells
Introduction
Optic neuropathies are characterized by loss of retinal ganglion
cells (RGCs) leading to optic atrophy and blindness. Inherited
optic neuropathies due to mitochondrial dysfunction, i.e. Leber
hereditary optic neuropathy (LHON) and Kjer type dominant
optic atrophy (DOA), are known for initially affecting the parvo-
cellular RGCs (papillomacular bundle), which causes dyschroma-
topsia, loss of visual acuity, cecocentral scotomas and temporal
optic atrophy (Carelli et al., 2004). Despite loss of vision, patients
with LHON and DOA are described with visual-pupillary dissoci-
ation and relatively preserved pupillary light reaction (Wakakura
and Yokoe 1995; Bremner et al., 2001).
It is now known that, besides the image-forming function, the
eye conveys non-image-forming light information to the brain
driving the photoentrainment of circadian rhythms, masking be-
haviour, light-induced melatonin suppression and the pupillary
light reflex (Fu et al., 2005). This system operates in parallel to
the well-known image-forming pathway served by the classical
outer retinal photoreceptors, the rods and cones. The non-image-
forming system uses the newly identified photopigment melanopsin
(Opn4) expressed in a subset of intrinsically photosensitive RGCs
(Berson et al., 2002; Hattar et al., 2002). These cells project mainly
to the hypothalamic suprachiasmatic nucleus, the master circadian
clock, forming the so-called retinohypothalamic tract (Sadun et al.,
1984; Hannibal et al., 2002, 2004; Hattar et al., 2006). They also
target other areas of the brain, such as the olivary pretectal nucleus,
constituting the afferent limb of the pupillary light reflex (Hannibal
and Fahrenkrug, 2006; Hattar et al., 2006).
In humans, melanopsin-containing RGCs (mRGCs) comprise
!1% of the total number of RGCs, and they are located in
both the RGC layer and the inner nuclear layer (Hannibal et al.,
2004; Dacey et al., 2005). These mRGCs have large dendritic
fields, which run predominantly in the outer sublayer of the
inner plexiform layer. The dendrites contain melanopsin and re-
spond to light by depolarization. The mRGCs also receive input
from rods and cones through the bipolar and amacrine cells, which
modulate their activity (Viney et al., 2007). There is substantial
evidence that melanopsin is a photopigment exhibiting bistability
(Mure et al., 2007), which uses an invertebrate (rhabdomeric)
signal transduction pathway (Peirson and Foster, 2006).
Melanopsin-containing RGCs are now considered the ‘circadian
photoreceptors’ and their function explains the maintenance of
photoentrainment of circadian rhythms in mouse models and
human ocular diseases characterized by loss of rods and cones
(Foster et al., 1991; Freedman et al., 1999; Hannibal et al.,
2004). Furthermore, the preservation of light-induced melatonin
suppression has been demonstrated in blind subjects, including
patients with various optic neuropathies (Czeisler et al., 1995;
Hatonen et al., 1998; Perez-Rico et al., 2009).
The present study was designed to investigate whether, in mito-
chondrial optic neuropathies such as LHON or DOA, mRGCs are
affected to an extent that would produce circadian rhythm dis-
turbances. Furthermore, we describe the characteristics and distri-
bution of mRGCs in normal human retina and in hereditary optic
neuropathies.
Materials and methods
Melatonin suppression test by light
We studied nine control subjects (mean age 34.33" 8.96) and nine
subjects with molecularly confirmed mitochondrial optic neuropathy,
five LHON and four DOA (mean age 35.33" 9.89). The study proto-
col was approved by the Internal Review Board ethical committee and
written informed consent was obtained from both controls and pa-
tients. All the subjects enrolled in the study reported no history of
working night shifts nor did they travel more than two time zones
within 1 month prior to the test. The subjects had not taken drugs
interfering with nocturnal melatonin synthesis (i.e. beta-blockers,
alpha-blockers, non-steroidal anti-inflammatory drugs, serotonin reup-
take inhibitors, neuroleptics, antiepileptics and monoaminoxidase in-
hibitors). All control subjects had normal vision. The hereditary optic
neuropathy subjects had an extensive ophthalmologic evaluation
including, as an objective indicator of their clinical severity, optical
coherence tomography (StratusOCT, software version 3.0; Carl Zeiss
Meditec Inc., Dublin, CA) measurements of retinal nerve fibre
layer thickness (RNFL 3.4 protocol). To characterize the chronotype,
psychiatric disturbances, sleep disturbances and quality of life, all sub-
jects filled out self-administered questionnaires (Horne-O¨stberg
Morningness–Eveningness Scale; Pittsburgh Sleep quality index, Zung
depression and anxiety scales, SF-36 quality of life scale, Epworth
Sleepiness Scale and Berlin Questionnaire). This study was carried
out between December 2007 and May 2008.
The study protocol consisted of one baseline night and one light
exposure night (Supplementary Fig. 1). A sleep diary was used the
week prior to the test to monitor the sleep–wake cycle. Subjects
were asked to refrain from alcohol 48 h prior to each test and not
drink coffee or eat bananas, cheese or chocolate 12 h before the
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test. For the baseline night, all subjects were lying down in the bed in
a dim light (55 lux) room and were blindfolded from 10pm to 8 am.
The same setting was used for the melatonin suppression night except
for the exposure to monochromatic (470 nm) blue light from 1:30 to
3:30 am (Supplementary Fig. 1). The light was generated by two
vertical lamps (38 LEDs) that projected light onto the ceiling (Sivra,
Guzzini!, Italy). The ceiling surface that reflected this light was
100 cm!150 cm and positioned "2m from the subject eyes
(Supplementary Fig. 1). Irradiance at the level of the subjects’ corneas
was 58 mW/cm2, as detected by spectroradiometric assessment. Blood
samples were collected each hour from 00:30 to 3:30 am and mela-
tonin plasma concentrations evaluated by radioimmunoassay
(Melatonin Direct RIA-KIPL3300; Pantec-Biosource Europe S.A.). The
minimum detection limit of the assay was 2 pg/ml. The magnitude of
melatonin suppression was assessed by two previously reported
control-adjusted scores: melatonin suppression score and suppression
rate (Brainard et al., 2001; Hebert et al., 2002). We also computed
the percentage difference between melatonin plasma levels before and
after light exposure in the melatonin suppression night (absolute per-
centage difference) (for details see Supplementary material).
Immunohistochemical analysis of
melanopsin-containing retinal
ganglion cells in human retinas
Eyes with optic nerves were obtained post-mortem from two male
subjects with LHON (59- and 52-year-old) and from one male subject
with DOA (87-year-old). Eyes were also acquired from an eye tissue
bank (Lions Eye Bank of Oregon, USA) for age- and sex-matched
controls (males; 58, 54 and 85 years old, respectively). We excluded
tissues from subjects with a history of diabetes and neurological dis-
orders. All tissues were initially immersion-fixed in neutral buffered
formalin. Eyes and nerves were oriented for superior and temporal
zones with tissue ink. The eyes were dissected horizontally at the
meridian producing two collotes containing the entire retina (nasal
and temporal), at that level bisecting the papillomacular bundle.
Tissue from the superior half was embedded in paraffin and serially
sectioned at 5 mm. Sections were immunostained for melanopsin
[rabbit anti-melanopsin, code no. 5J68, characterized in detail by
Hannibal et al. (2004)] using an indirect immunoperoxidase technique
with diaminobenzidine as the substrate/chromogen or immunofluores-
cence (Hannibal et al., 2004). Immunostaining was performed on
seven to ten serial sections to define the extent of each single
mRGC and establish the counting criteria for subsequent quantitative
analysis. To this end, mRGCs were then identified and manually
counted by two independent observers on five to six sequential
slides originating from every fifth section. Melanopsin stained RGCs
were further confirmed and photographed at high magnification by
the two observers.
We counted each mRGC that demonstrated a significant amount of
stain indicating a complete soma and having the nucleus and some-
times the nucleolus visible. In these latter cases, the cells were con-
sidered to be cut approximately through their middle. Furthermore,
the length of each retina section was measured on serial photographs
overlapping on the borders, covering the entire retina available.
Counting of mRGCs allowed for calculation of their area density
across the posterior retina in the nasal/temporal axis. This retinal
cross-section, 5 mm in thickness, included cells cut approximately
through their middle, with the nucleus visible. Hence, the sampling
area around each section would be large, 2-fold (one for each side)
the mean radius of the mRGC (5 mm) plus the thickness of the retinal
section (5 mm), so that the density has been calculated dividing the
number of mRGCs for the total sampling area (length of the retinal
cross-sections multiplied by 15mm). The total retinal area density of
mRGCs in each eye was calculated assuming an average total surface
in human retina of 1040mm2 and an even superior/inferior distribu-
tion of mRGCs (Curcio and Allen, 1990).
Total RGC numbers were calculated through measurements in the
optic nerve and based on the assumption that one RGC produces one
axon that passes through the optic nerve. Optic nerve cross-sections
were previously analysed by axonal morphometry for normal subjects
at different ages with paraphenylenediamine-based image analysis
(Tenhula et al., 1992). Thus, to obtain the ratio of mRGCs on the
total number of RGCs for the control eyes, we considered an average
of 1 200 000 RGCs per retina, as previously reported by our laboratory
(Johnson et al., 1987). For the two LHON subjects, the total number
of RGCs was measured by counting the axons in the optic nerve
cross-sections, using similar paraphenylenediamine-based manual
count (see next section). For the DOA subject, the counting of
axons in the only optic nerve cross-section available was performed
by identifying axons using an immunostaining for neurofilaments in
sections cut from paraffin-embedded blocks, not having plastic-
embedded tissue available.
Each retinal section was divided into two hemiretinas (nasal and
temporal) assuming the macula as the zero point centred 15# temporal
to the optic disc. Position of each mRGC, either in the inner nuclear
layer or in the RGC layer, was reported in grades considering its dis-
tance from zero on a proportional scale in which the maximum length
was 60# and 90# for temporal and nasal hemiretina, respectively.
For statistical analysis (see below), we also calculated the number
of mRGCs in each 20# sector, starting from the parafoveal sector
(10# nasally and 10# temporally to the macula).
Morphometric assessment in
optic nerves
Optic nerves were cut into cross-sections 2mm thick and "3mm pos-
terior to the globe. Orientation was established by razor nicks and the
specimens were processed for paraffin and plastic blocks. The paraffin
tissue blocks (DOA subject) were cut with a microtome at 5 mm,
stained with haematoxylin and eosin and immunostained using an in-
direct method with horseradish peroxidase and diaminobenzidine as
substrate/chromogen for neurofilaments. Semi-thin sections were cut
on an ultramicrotome at 1 mm from plastic-embedded tissues (LHON
subjects) and stained with paraphenylenediamine for light microscopic
examination of myelin profiles. All light microscopic photos of eyes and
nerves were acquired with a Spot II digital camera (Diagnostic
Instruments Inc.) and digitally saved on a computer.
The axonal count in the optic nerves from the two LHON and DOA
subjects was manually performed on images acquired at 1000! with a
100! oil immersion lens. The optic nerve cross-section profiles were
divided into five regions, each with a different axonal density, to
account for the non-homogeneous distribution of axonal loss (for
details on the sampling method applied, see Methods section in
Supplementary material). Each image was reviewed by two independ-
ent observers. The counts for the five regions were summed to obtain
the total axon count for each optic nerve.
Statistical analysis
Statistical analysis was performed using Statistical Package for Social
Sciences (SPSS ver.12.0, Chicago, IL). Light-induced suppression of
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melatonin secretion was evaluated by means of a paired-sample t-test
comparing plasma melatonin levels at the corresponding time point in
the baseline and light suppression nights. Differences between the
groups in melatonin plasma levels and optical coherence tomography
measurements were assessed by one-way ANOVA considering signifi-
cant a P-value lower than 0.05. For self-administered questionnaires, a
non-parametric analysis (Kruskal–Wallis) was performed. Correlation
between melatonin suppression scores and clinical variables was
assessed by using Pearson coefficient for questionnaires and
Spearman analysis for ophthalmologic data.
To evaluate the homogeneity of mRGC distribution throughout the
retina, we performed a one-way ANOVA, comparing their mean
number between different 20! retina sectors for each group
(see Figs 2 and 4 as well as Supplementary material). Moreover, by
means of parametric statistic, we compared the number of mRGCs in
controls and optic neuropathy subjects, both in the entire retina and
for each equivalent sector.
Results
Melatonin suppression test by light
Exposure to light during night suppresses melatonin secretion
(Klein and Weller, 1972) and this response is conveyed by the
mRGC–retinohypothalamic tract pathway (Brainard et al.,
2001). A few studies investigated this response in blind human
subjects showing that it may be preserved (Czeisler et al., 1995;
Hatonen et al., 1998; Perez-Rico et al., 2009). However, the blind
subjects investigated were not homogeneous for pathology and
only a few were affected by optic neuropathy of variable aeti-
ology. We aimed to explore the light-induced suppression of
melatonin secretion in a homogeneous group of nine patients af-
fected by mitochondrial optic neuropathy (five LHON and four
DOA), which selectively affects the RGCs, compared with nine
sex- and age-matched controls. Demographic, genetic and
ophthalmologic data of patients with optic neuropathy are pro-
vided in Table 1. The results of the melatonin suppression tests for
controls and optic neuropathy subjects are shown in Fig. 1.
All optic neuropathy subjects had poor vision but a relatively
preserved pupillary light reflex. Mean visual acuity and standard
deviation of the better eye was 0.09" 0.1 for LHON subjects and
0.2" 0.1 for DOA subjects, with no significant differences. Thus,
the two mitochondrial optic neuropathies were grouped together
for further analysis. All optic neuropathy subjects showed severe
optic atrophy on fundus examination. Optical coherence tomog-
raphy evaluation revealed a substantial reduction of retinal nerve
fibre layer thickness in both optic neuropathies (Fig. 1A and
Supplementary Table 1). Self-administered questionnaires assess-
ing quality of life, sleep and mood disturbances did not reveal
significant differences between controls and optic neuropathy sub-
jects except for items A (physical functioning) and C (bodily pain)
of Short Form 36-Item quality of life scale (raw data for controls
and optic neuropathy subjects are provided in Supplementary
Tables 2 and 3).
The study design, described in the Methods section, included a
basal night and a test night (Supplementary Fig. 1). All subjects
showed a physiological increase of melatonin plasma levels during
the baseline night, but the melatonin plasma levels were higher
(P50.05) in optic neuropathy subjects than controls (Fig. 1B).
A significant suppression of melatonin plasma levels induced by
blue light was observed in both control (P50.0001) and optic
neuropathy subjects (P50.005) (Fig. 1B). Individual profiles
of baseline and light suppression nights are provided in
Supplementary Figs 2 and 3. Furthermore, we compared the re-
sults of the melatonin suppression test in LHON and DOA subjects
and found no significant differences (data not shown). Specifically,
the magnitude of suppression was not statistically different be-
tween groups, for each of the three indices considered: control
adjusted melatonin suppression score (P=0.9), suppression rate
(P=0.5) and absolute percentage difference (P=0.64) (Fig. 1C).
We failed to identify any correlation between melatonin suppres-
sion scores and the ophthalmologic outcome measurements
(i.e. retinal nerve fibre layer thickness by optical coherence tom-
ography and visual acuity). A positive correlation was detected
only between the absolute percentage difference score and the
Pittsburgh sleep quality index (P=0.019) in both controls and
optic neuropathy subjects.
These results suggest that light suppression of melatonin secre-
tion is maintained in visually impaired subjects with mitochondrial
optic neuropathy, indicating that the mRGC-retinohypothalamic
tract pathway is essentially spared. This observation is in agree-
ment with the relative preservation of the pupillary light reflex, as
assessed at clinical exam in the patients with LHON and DOA.
Table 1 Demographic, genetic and ophthalmologic data
ID Sex Age Mutation Onset Visual acuity
Oculus
destrum
Oculus
sinistrum
L1 M 32 11778/ND4 mtDNA (homoplasmic) 26 0.01 0.02
L2 M 31 11778/ND4 mtDNA (homoplasmic) 15 0.01 0.0125
L3 F 52 3460/ND1 mtDNA (homoplasmic) 12 0.05 0.02
L4 M 28 14484/ND6 mtDNA (heteroplasmic) 17 0.32 0.16
L5 M 26 3460/ND1 mtDNA (homoplasmic) 17 0.04 0.02
D1 F 22 Mut OPA1 (frame-shift/stop-codon) Exon 27; 2708-2711del (TTAG) (heterozygous) 6 0.16 0.16
D2 M 41 Mut OPA1 (splicing error) Exon 9; 984 + 3A4T (heterozygous) 1 0.05 0.05
D3 F 41 Mut OPA1 (missense) Exon 27; 2729T4A (Val910Asp) (heterozygous) 1 0.2 0.2
D4 M 45 Mut OPA1 (frame-shift/stop-codon) Exon 27; 2708-2711del (TTAG) (heterozygous) 510 0.32 0.4
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Characterization of
melanopsin-containing retinal
ganglion cells in human retinas
Despite the plethora of histological studies investigating mRGCs in
different animal species, only a few have characterized this cellular
system in human retinas (Hannibal et al., 2004; Dacey et al.,
2005; Vugler et al., 2007). To fill this gap, we investigated
three pairs of eyes from normal donor subjects: a 58-year-old
(Control 1), a 54-year-old (Control 2) and an 85-year-old
(Control 3) male subject. The oldest subject was investigated to
take into account the ageing process; in fact, previous studies
from our group showed that after the age of 60 there is a pro-
gressive loss of axons that corresponds to a decrease of RGCs
(Johnson et al., 1987).
Immunohistochemistry, using human melanopsin antibodies on
sagittal sections of the retina, revealed the presence of mRGCs
and their dendrites with the cell bodies either in the RGC layer
Figure 1 (A) Retinal nerve fibre layer thickness evaluated by optical coherence tomography in optic neuropathy and control subjects.
Average retinal nerve fibre layer (RNFL) thicknesses of temporal, superior, nasal and inferior quadrants are shown for control, LHON and
DOA subjects. Retinal nerve fibre layer thickness was significantly lower in optic neuropathy subjects compared with controls in each
quadrant. There were no statistical differences between LHON and DOA subjects except for superior retinal nerve fibre layer thickness,
which was significantly lower in LHON subjects (P=0.037). The average retinal nerve fibre layer thickness was 97.3 mm ! 8.4 in controls,
52 mm ! 9 in LHON and 59.3mm ! 5.8 in DOA subjects. (B) Melatonin suppression test results in control and optic neuropathy subjects.
Box plots of melatonin plasma levels at the four sampling times (00:30, 01:30, 02:30, 03:30 am) are shown for the baseline (dark grey)
and light suppression (light grey) nights in control (CTRLs; left panel) and optic neuropathy (right panel) subjects. In the control group, a
significant difference in melatonin plasma levels between the baseline and the test night was evident for the third (P=0.000008) and
fourth samples (P=0.00015); this difference was also evident in optic neuropathy subjects for the third (P=0.0018) and fourth
(P=0.0046) samples. Asterisks indicate these significant differences. (C) Melatonin suppression scores for controls and optic neuropathy
subjects. Box plots of control-adjusted melatonin suppression score (caMSS), suppression rate and absolute difference (%) scores are
shown for control (dark grey) and optic neuropathy (ON; light grey) subjects in the left, middle and right panels, respectively. No statistical
differences were evident between groups, demonstrating similar magnitude of light-induced melatonin suppression.
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or in the inner nuclear layer, as previously reported (Fig. 2A)
(Hannibal et al., 2004). The mRGCs were characterized by
having a large cell body (15–20 mm) with a centrally located nu-
cleus. The pigment was located primarily in the membrane of the
soma and in the dendrites. The dendrites were located in two
different layers. The majority of dendrites were found at the
border of the inner nuclear layer known as the OFF layer of the
inner plexiform layer. The dendrites were also located close to
RGC layer, known as the ON layer of the inner plexiform layer.
Occasionally, delicate thin axons were also identifiable by their
melanopsin brown staining as they ran from the RGC soma into
and along the retinal nerve fibre layer (Fig. 2A).
To evaluate the ratio of mRGCs relative to the total number of
RGCs in human retinas, we assumed that the number of RGCs is
equivalent to the number of axons counted in optic nerve
cross-sections. Thus, we used 1 200 000 as the average number
of RGCs in controls younger than 60 years of age, as reflected by
optic nerve axonal counts previously carried out in our laboratory
(Tenhula et al., 1992). To evaluate the loss of axons with ageing,
we manually counted them in an optic nerve cross-section from
the 85-year-old subject, obtaining an estimate of 978 000 axons.
To obtain the mRGC density relative to retinal surface, we
assumed that mRGCs are homogeneous in distribution over the
1040mm2 established total retinal surface (Curcio and Allen,
1990). Thus, quantitative evaluation by manual counting of
mRGCs resulted in a mean density of !18 cells/mm2 for Control
1 and 13 cells/mm2 for Control 2, whereas the mean density was
8 cells/mm2 for Control 3 (Supplementary Table 4). Finally, the
percentage of mRGCs, over the total number of RGCs, was
1.5% for Control 1, 1.1% for Control 2 and 0.9% for the
oldest, Control 3 (Fig. 2B). We next evaluated how many of the
mRGCs were located in the RGC layer and in the inner nuclear
layer, obtaining comparable numbers in the two layers
(Supplementary Fig. 4 and Table 4). Overall, these data indicate
that in humans, the number of mRGCs in the RGC layer is about
equal to those located in the inner nuclear layer, at odds with the
previous estimations in rodents (Baver et al., 2008).
A further objective of our study was to describe the distribution
of mRGCs on the two hemiretinas, nasal and temporal, relative
to the fovea (central retina) by using intervals of 20" (for recon-
struction of the retina, see the ‘Methods’ section and
Supplementary Fig. 5). The 20" range was chosen in order to
have a larger sample size per angle and for isolated comparison
of the parafoveal and peripapillary zones. The overall estimation
for the two younger controls showed a higher number of mRGCs
in the parafoveal region centred 15" temporal to the optic disc
(Fig. 2C, left panel), which was close to significance when com-
pared with the far temporal end (P=0.052). A second enrichment
in mRGCs was observed at the far end of the nasal hemiretina.
Comparing these results with those obtained in the oldest subject,
we observed a general loss of mRGCs in the latter except for
those in the parafoveal region (Fig. 2C, right panel), which was
significantly different from the remaining retinal sectors (P=0.05)
except for the far nasal end. Thus, these results indicate a general
loss of mRGCs that is age related, which spares the parafoveal
region. This overall decrease of mRGCs in the oldest subject par-
allels the previously described reduction of axons (and RGCs) after
the age of 60 in humans (Johnson et al., 1987) and is similar to
previous descriptions of mRGC loss with ageing in animals (Semo
et al., 2003).
Our characterization of mRGCs in normal and ageing humans
showed that these cells constitute !1% of total RGCs, are roughly
equally distributed in the RGC layer and the inner nuclear layer
and are more represented in the central retina. The mRGCs, like
other RGCs, become less numerous with age. These results cor-
roborate previous reports using flat-mounted retinas (Hannibal
et al., 2004; Dacey et al., 2005), validating our methodology of
using serial retinal sections sagittal to the optic nerve head and
with temporal-nasal orientation.
Analysis of melanopsin-containing
retinal ganglion cells in mitochondrial
optic neuropathy patients
To explore directly the histopathology of mRGCs in mitochondrial
optic neuropathies, we studied retinal specimens collected at aut-
opsy from patients with LHON and DOA, comparing them with
control subjects. We had available four eyes from two LHON sub-
jects, one eye from a DOA individual, and the above described six
eyes from three age- and sex-matched controls for comparison.
The two LHON subjects were brothers, included in a prospective
clinical study, thus systematically evaluated prior to death (Sadun
et al., 2003). They both belonged to a large Brazilian pedigree of
Italian maternal ancestry carrying the 11778/ND4 mutation in
mitochondrial DNA (Carelli et al., 2006). However, the severity
of optic neuropathy differed markedly in these two subjects. The
59-year-old man had a late-onset and mild form of LHON, where-
as his 52-year-old brother had a classical LHON with young–adult
onset and severe optic atrophy. The neuro-ophthalmologic
evaluation of these two LHON subjects is summarized in Table 2
and Figs 3A and B.
The patient with mild LHON suffered visual loss at 51 years of
age precipitated by abuse of tobacco and alcohol; he remained
mildly affected until his death. His fundus examination revealed
mild optic neuropathy with temporal optic atrophy (Fig. 3A, upper
panels). Post-mortem evaluation of the optic nerves revealed a
similar sectorial loss of axons (Fig. 3A, middle panels).
Examination at higher magnification documented the remaining
axonal density as high nasally, intermediate in the transition
zone and low temporally (Fig. 3A, lower panels).
The patient with severe LHON suffered visual loss at 27 years of
age and remained stable for 25 years before he died. Fundus
examination showed complete optic atrophy bilaterally (Fig. 3B,
upper panels). Post-mortem evaluation of the optic nerves
revealed reduced cross-sectional profiles with massive axonal loss
throughout except for some sparing nasally (Fig. 3B, middle
panels). Examination at higher magnification documented the
remaining axonal density as depleted nasally, low in the transition
zone and very low temporally (Fig. 3B, lower panels).
The patient with DOA was an 87-year-old man, belonging to a
family of 152 members reported by Kjer in the seminal description
of DOA (Kjer, 1959). The frame-shift inducing 2826delT
(p.V942fsX967) mutation in exon 28 of the OPA1 gene was
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Figure 2 (A) Melanopsin retinal ganglion cells in control retinas. Upper line: (left) one example of a brown-stained mRGC located in the
RGC layer is shown including the large cell body with the nucleus and a dendrite running at the border of the inner nuclear layer; (middle)
a brown-stained mRGC located in the inner nuclear layer is depicted; (right) the peripheral staining of melanopsin under the plasma
membrane is evident in this mRGC located in the RGC layer. Lower line: (left) one example of a long dendrite running close to the RGC
layer is shown; (right) one example of a thin axon filled with brown-stained melanopsin in the retinal nerve fibre layer is depicted (scale bar
represents 20 mm). (B) Ratio of mRGCs relative to the total number of RGCs in control retinas. The ratio of mRGCs relative to the total
number of RGCs is shown for Control 1 (left), Control 2 (middle) and Control 3 (right), respectively. (C) Retinal distribution of mRGCs in
control subjects. Distributions of mRGCs in four eyes from averaged Controls 1 and 2 (left) and in the two eyes from Control 3 (right) are
shown. The mean number of mRGCs (! SD) is reported for each 20" sector of the temporal and nasal hemiretinas, centred to the fovea.
Mean number of mRGCs in parafoveal sector (t10"#n10") is greater in the two younger controls, being close to statistical significance with
respect to the far temporal hemiretina (P=0.052). In the oldest, Control 3, the number of mRGCs in parafoveal sector (t10"#n10") is also
greater and significantly different (P=0.05) with respect to all sectors except for n50"#n70" and n70"#n90" (t10"#n10" versus:
t60"#t50" P=0.01; t50"#t30" P=0.024; t30"#t10" P=0.024; n10"#n30" P=0.024; n30"#n50" P=0.015). RNFL= retinal nerve fibre
layer; RGCL = retinal ganglion cell layer; IPL = inner plexiform layer; INL = inner nuclear layer.
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recently described (Thiselton et al., 2002). This patient complained
of decreased vision and visual difficulties in poor light and in
colour perception. His visual acuity was 0.1 in oculus destrum
(right eye) and counting fingers in oculus sinistrum (left eye).
Fundus examination revealed diffuse optic atrophy (Fig. 3C).
The histopathology of this subject’s eyes has been previously
reported (Kjer et al., 1983). We had available the left optic
nerve for this study, and a severe loss of axons affected most
of the cross-section, similar to the findings in the LHON subjects
(Fig. 3C).
Immunohistochemistry with melanopsin antibodies on the ret-
inas from these LHON and DOA subjects revealed the presence
of mRGCs and of their dendrites similar to the control subjects,
notwithstanding the severe loss of total RGCs (Fig. 4A). In terms
of gross morphology, dimension and dendritic branching pattern,
these mRGCs did not differ from those described in the control
retinas.
The residual axons were counted manually in the optic nerve
cross-sections from the optic neuropathy cases. This count re-
vealed an average between the two eyes of !300000 axons
for the mild LHON (74% loss as compared with 1 200 000
axons in normal eyes) and !22 500 for the severe LHON (98%
loss) and 15 000 for the DOA (94% loss as compared with
977 851 axons counted for the age-matched control eye)
(Fig. 4B, left panel). Quantitative evaluation by manual counting
of mRGCs resulted in a density of 9 cells/mm2 for mild LHON, 8
cells/mm2 for severe LHON and 7 cells/mm2 for the DOA subject
(Supplementary Table 4). These counts were approximately half of
those obtained for the two younger controls (Fig. 4B, middle
panel).
For LHON subjects, the total RGC number was based on direct
axonal counts in the corresponding optic nerve cross-sections, as
described above. Thus, the percentage of mRGCs was increased
as the total number of RGCs decreased. This percentage was
3.1% for mild LHON and 38.5% for severe LHON compared
with an average of 1.3% for the two age-matched controls
(Fig. 4B, right panel). To match the age of the DOA subject we
used the 85-year-old Control 3. Thus, the percentage of mRGCs,
compared with the total number of RGCs, was 48.6% for the
DOA subject and 0.9% for Control 3 (Fig. 4B, right panel). The
mRGCs were approximately equally distributed in the RGC layer
and inner nuclear layer in the optic neuropathy cases, similar to
control subjects, indicating that the relative distribution of mRGCs
in RGC layer and inner nuclear layer among both control and
optic neuropathy subjects was not different (see Supplementary
Fig. 4 and Table 4).
The analysis of mRGC distribution for nasal and temporal hemi-
retinas in the two LHON subjects shows that despite an overall
absolute loss of mRGCs, more remain in the parafoveal region
(Fig. 4C, left panel). This result was significantly different from
sectors t60"#t50", t50"#t30" and n50"#n70" (P=0.002, 0.04
and 0.008, respectively). The retina from the patient with DOA
had an essentially uniform distribution of mRGCs, not showing the
parafoveal enrichment (Fig. 4C, right panel). A sector-by-sector
comparison of the optic neuropathy subjects with the correspond-
ing age-matched controls failed to reveal significant differences.
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The overall comparison of all 11 eyes from controls and optic
neuropathy subjects investigated is depicted in Fig. 4D. This dem-
onstrates clearly the non-uniform distribution of mRGCs in human
retinas, with a significant enrichment in the parafoveal region that
is maintained despite neurodegeneration in LHON and ageing.
The single retina from the DOA case, exposed to the combination
of both neurodegeneration and ageing, showed a flat distribution
of mRGCs.
Discussion
We investigated a class of optic neuropathies characterized by
selective and massive loss of RGCs and preservation of the
pupillary light reflex (Wakakura and Yokoe 1995; Bremner
et al., 2001; Carelli et al., 2004). In these optic neuropathies,
RGC loss is due to a neurodegenerative process caused by mito-
chondrial dysfunction, and in the present study we document the
resistance of mRGCs to this pathogenic mechanism. Nine patients
with LHON or DOA maintained light-induced suppression of
melatonin nocturnal secretion comparable to nine control subjects,
despite their severe visual loss and optic atrophy. We examined 11
retinas from optic neuropathy subjects and age-/sex-matched con-
trols and we demonstrated the relative preservation of mRGCs
compared with total RGC loss in affected subjects. Furthermore,
we characterized the mRGC system in human retinas, showing
that these photoreceptors are more concentrated around the
macula and undergo a reduction in numbers with ageing, possibly
Figure 3 (A) Ocular findings in the mild LHON case (mLHON). Upper line, on the left the oculus destrum (OD) fundus with moderate
temporal pallor of the optic disc is shown; on the right the oculus sinistrum (OS) fundus is characterized by a more severe sectorial
temporal pallor of the optic disc. Middle line, on the left oculus destrum optic nerve cross-section shows severe depletion of axonal bundles
involving the temporal fibres; on the right oculus sinistrum optic nerve cross-section reveals more extended depletion of axonal bundles
involving the temporal fibres (scale bar represents 1mm). Lower line, on the left, high-magnification images of nasal axonal bundles
demonstrate high, virtually normal axonal density, whereas in the middle the transition zone is characterized by intermediate axonal
density, and on the right, the temporal sector shows low axonal density (scale bar represents 20 mm). Axons are identified as myelin
profiles stained by paraphenylenediamine on semithin sections cut from plastic-embedded tissue (see ‘Materials and methods’ section).
(B) Ocular findings in the severe optic atrophy case (sLHON). Upper line, funduscopic images show complete optic atrophy on both oculus
destrum (left) and oculus sinistrum (right). Middle line, oculus destrum (left) and oculus sinistrum (right) optic nerve cross-sections reveal
diffuse and severe depletion of axonal bundles involving the entire optic nerve with some preservation of the nasal bundles (scale bar
represents 1mm). Lower line, high-magnification images of nasal axonal bundles demonstrate depleted axonal density (left), whereas the
transition zone reveals low axonal density (middle) and the temporal sector shows very low axonal density (scale bar represents 20 mm).
Axons are identified as myelin profiles stained by paraphenylenediamine on semithin sections cut from plastic-embedded tissue (see
‘Materials and methods’ section). (C) Ocular findings in the DOA case. Upper line, funduscopic images show complete optic atrophy on
both oculus destrum (left) and oculus sinistrum (right). Middle line, OS optic nerve cross-section shows diffuse and very severe depletion
of axonal bundles involving the entire optic nerve (scale bar represents 1mm). Lower line, images at increasing magnification show the
axonal depletion of spared bundles in the central area of the optic nerve cross-section (scale bars represent, respectively, 100, 50 and
20 mm). Axons are identified as axoplasm immunostained for neurofilaments on sections cut from paraffin tissue blocks (see ‘Materials and
methods’ section).
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Figure 4 (A) Melanopsin cells in control and optic neuropathy retinas. In the upper line, examples of brown-stained mRGCs located both
in the RGC layer and in the inner nuclear layer for all three controls are provided (scale bar represents 60 mm). The Control 3 sections were
stained by immunofluorescence and all nuclei are red, whereas melanopsin is green (scale bar represents 50 mm). Single to multilayered
RGCs are shown in these pictures. In the lower line, examples of brown-stained mRGCs located in the RGC layer in all three optic
Continued
Melanopsin RGCs in LHON and DOA Brain 2010: 133; 2426–2438 | 2435
 at Universit? di Bologna - Sistem
a Bibliotecario d'Ateneo on April 3, 2011
brain.oxfordjournals.org
Downloaded from
 
explaining the higher incidence of circadian rhythm disorders, such
as sleep disturbances in elderly persons. The current results provide
a plausible explanation for the relatively preserved pupillary light
reaction despite profound visual loss in these patients, revealing
the robustness of mRGCs to a metabolic insult and opening the
question of mechanisms that might protect these cells.
Our study stems from a few reports in the literature showing
that patients with optic neuropathy may maintain the
light-induced melatonin suppression response at night, including
two DOA subjects (Czeisler et al., 1995; Hatonen et al., 1998;
Perez-Rico et al., 2009). In contradistinction, a study of patients
with various optic neuropathies reported the frequent occurrence
of sleep timing disorders, which may indicate a defective photo-
entrainment of circadian rhythms (Wee and Van Gelder, 2004). In
our study, the mitochondrial optic neuropathy subjects, who were
homogeneous for pathology, had no differences compared with
controls in terms of melatonin suppression even if with larger vari-
ability. Remarkably, the maintenance of light-induced melatonin
suppression was unrelated to the severity of the optic neuropathy
in these patients, strongly suggesting that despite the dramatic
loss of total RGCs, the mRGCs were still able to convey light
information to the pineal gland through the retinohypothalamic
tract. It is worth noting that optic neuropathy subjects showed
higher melatonin levels during the baseline night than controls;
this may indicate a certain rearrangement of melatonin secretion
induced by changes in the pattern of light input because of RGC
loss (Lubkin et al., 2002).
To corroborate these results, we studied post-mortem human
retinas from patients with optic neuropathy and controls. We first
characterized the mRGC system in normal human retinas using
sagittal sections from standard paraffin embedded eyes, having
validated a protocol for cell counting in serial sections stained
with melanopsin antibodies. Using this approach, we reached re-
sults strikingly similar to previous estimates of mRGCs in
flat-mounted human retinas, showing that in middle-aged
normal people mRGCs represent !1% of total RGCs, approxi-
mately equally distributed in RGC layer and inner nuclear layer
(Hannibal et al., 2004). Furthermore, we report here the first
evaluation of aging on mRGCs in humans, demonstrating that
after age of 80 there is a reduction of mRGCs, which is about
the same rate as the general reduction of RGCs. This observation
is concordant with previous reports on the age-related decrease of
mRGCs in animal models (Semo et al., 2003). A further finding of
our study was that mRGCs are more concentrated in the parafo-
veal region, as previously reported (Dacey et al., 2005; Jusuf
et al., 2007). A second peak of mRGC numbers was observed
at the far end of the nasal hemiretina, which was not previously
documented in human retinas. It is tempting to speculate that for
non-image-forming and time-integrated functions, the far nasal
retina is well positioned to see the temporal peripheral field,
where the background illumination can be observed rather than
the foreground. However, in animals, different patterns of mRGC
distribution have been found (Hattar et al., 2002; Semo et al.,
2005).
The analysis of pathological retinas from patients with mito-
chondrial optic neuropathy revealed a relative sparing of
mRGCs, as shown by the increase of their ratio over total RGCs
from !1% in controls up to 49% in the most severe case. These
cells were clearly present in the retinal regions most severely
depleted by neurodegeneration, such as the parafoveal area,
which generates the papillomacular bundle (Sadun et al., 2000).
In terms of absolute numbers, mRGCs are reduced to about half in
the LHON cases compared with controls. In the case of the DOA
subject the absolute number of mRGCs was about equal to the
control. This may be explained by the age-related reduction of
mRGCs seen in combination with the neurodegenerative cell loss
in the DOA case.
Our results show that mRGCs are lost in patients with LHON
and DOA but at a much slower rate compared with the regular
RGCs. In fact, this loss does not result in a defective light-induced
suppression of melatonin secretion, which indicates a sufficient
preservation of the retinohypothalamic tract. This observation in
living patients is consistent with a recently published study, which
reported that it requires !80% loss of mRGCs to manifest
Figure 4 Continued
neuropathy subjects are shown (scale bar represents 60mm). Their persistence is remarkable despite the complete absence of the other
RGCs. The DOA sections were stained by immunofluorescence and all nuclei are red, whereas melanopsin is green (scale bar represents
25 mm). (B) Axonal (RGCs) and mRGC count, and mRGC/RGC ratio for control, LHON and DOA subjects. On left, histograms of
axonal counts for averaged Controls 1 and 2, mild LHON (mLHON), severe LHON (sLHON), Control 3 and DOA subjects are shown
demonstrating a severe loss of axons in optic neuropathy subjects. In the middle, histograms of mRGC counts for averaged Controls 1 and
2, mild LHON, severe LHON, Control 3 and DOA subjects are shown revealing a relative preservation of mRGCs in the optic neuropathy
subjects as compared with the severe rate of axonal loss, which equals total RGCs. On the right, the ratio of mRGCs relative to the total
number of RGCs is shown for averaged Controls 1 and 2, and Control 3 (upper line), and for mild LHON, severe LHON and DOA subjects
(lower line). In the optic neuropathy subjects there is a striking increase in the rate of mRGCs, which is inversely correlated with the severity
of RGC loss, indicating their relative preservation. (C) Retinal distribution of mRGCs in subjects with optic neuropathy. Distributions of
mRGCs in four eyes from averaged mild LHON and severe LHON (left) and one eye from DOA (right) are shown. The mean number of
mRGCs ("SD) is reported for each 20#sector of temporal and nasal hemiretinas, centred on the fovea. Mean number of mRGCs in
parafoveal sector (t10#$n10#) is greater in the two LHON subjects, being significantly different compared with the sectors t60#$t50#,
t50#$t30# and n50#$n70# (P=0.002, 0.04 and 0.008, respectively). In the DOA case the number of mRGCs is uniformly distributed,
lacking a parafoveal peak. (D) Overall retinal distribution of mRGCs in control and optic neuropathy subjects. The distribution of mRGCs
for each eye of Controls 1–3 and for mild LHON, severe LHON and DOA cases are shown. The relative size of the black circles represent
the number of mRGCs for each 5# sector (the x-axis shows the fovea as point 0 and the other sectors as relative to the centre, being
negative for the temporal hemiretina and positive for the nasal hemiretina). In the last line the cumulative distribution of mRGCs is
reported for all controls, all optic neuropathy subjects and merged for everybody. OD = oculus destrum; OS=oculus sinistrum.
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abnormal non-image-forming visual responses in a mouse model
with targeted destruction of mRGCs (Goz et al., 2008). Similarly,
the observed sparing of mRGCs would explain the relative main-
tenance of pupillary light reflex despite profound visual impair-
ment in LHON and DOA (Bremner et al., 1999, 2001). We
have previously shown, in a post-mortem study of a single
LHON case with an extremely severe optic atrophy (Sadun
et al., 2000), spared axons leaving the optic chiasm and projecting
to the pretectum that constitute the afferent arm of the pupillary
light reflex (Bose et al., 2005). Furthermore, we also showed,
using selective wavelength pupillometry, that the pupil contraction
amplitude to blue light, which specifically stimulates mRGCs, was
minimally reduced in the only affected eye in a unilateral case of
LHON (Kawasaki et al., 2010).
Although the current study is the most extensive in human sub-
jects to date, the number of investigated cases is still limited, es-
pecially the post-mortem histopathology of DOA (Kjer et al.,
1983). Thus, for DOA our conclusions are not as firm as they
are for LHON. Indeed, an abnormal masking response on the cir-
cadian running wheel was reported in an OPA1 mouse model of
DOA (Davies et al., 2007). However, the testing paradigm and
the limited loss of RGCs found in this mouse make comparison
between our results and these observations difficult. Our results
on the single DOA case show partial sparing of mRGCs similar to
LHON subjects, yet further investigations are needed to resolve
these issues.
The present study reveals a robustness of mRGCs despite mito-
chondrial dysfunction and leads to the question of which mech-
anisms underlie this resistance to neurodegeneration. There is a
previous body of evidence that supports the current findings.
Remarkably, an old study of RGC loss after optic nerve transection
showed that a small subset (!1%) of cells with large bodies, in-
tensively stained with cytochrome c oxidase (complex IV), survived
retrograde cell death (von Bussmann et al., 1993). It is tempting
to speculate that these spared cells, with high mitochondrial
activity as shown by the intense cytochrome c oxidase staining,
were mRGCs. In fact, mRGCs were shown to be partially spared in
a more recent experimental model of axotomy (Robinson and
Madison, 2004). Studies of mRGCs in animal models of glaucoma
with high intraocular pressure have also shown mRGC survival
(Li et al., 2006). A further evidence of mRGC robustness comes
from studies on cell toxicity to monosodium glutamate, showing
that despite severe loss of RGCs, the mRGCs remain and are
functional (Chambille and Serviere, 1993; Hannibal et al., 2001).
We do not presently know if mRGCs present distinctive features
in mitochondrial metabolism compared with the regular RGCs. The
latter are obviously vulnerable to mitochondrial dysfunction, being
the selective target for cell death in mitochondrial optic neuropa-
thies such as LHON and DOA. RGCs have axons that run an
unmyelinated and long stretch in the intraocular retinal nerve
fibre layer. This absence of myelin, necessary for optical transpar-
ency, also imposes a very high energy requirement upon the RGCs
(Carelli et al., 2004). Another hypothesis is that light exposure to
the RGCs and their axons may be directly harmful, especially in
the setting of dysfunctional mitochondria, as in these optic neu-
ropathies (Osborne et al., 2008). It is intriguing to speculate that
mRGCs may be intrinsically protected from light damage by
expressing melanopsin photopigment. Specific investigations are
needed to explore the neuroprotective mechanisms that may pre-
serve mRGCs.
In conclusion, two important implications for medicine are
drawn from our study. Firstly, notwithstanding their low vision,
patients with LHON and DOA have retained the anatomical circuit
supporting the light entrainment of circadian rhythms, thus avoid-
ing consequences of circadian misalignment. Second, elucidating
the distinguishing features of mRGC mitochondrial metabolism will
improve our understanding of intimate pathogenic mechanisms
and provide novel approaches for therapeutic interventions in
these currently untreatable inherited optic neuropathies.
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a b s t r a c t
In the last decade, there was the seminal discovery of melanopsin-expressing retinal ganglion cells
(mRGCs) as a new class of photoreceptors that subserve the photoentrainment of circadian rhythms
and other non-image forming functions of the eye. Since then, there has been a growing research interest
on these cells, mainly focused on animal models. Only recently, a few studies have started to address the
relevance of the mRGC system in humans and related diseases.
We recently discovered that mRGCs resist neurodegeneration in two inherited mitochondrial disorders
that cause blindness, i.e. Leber hereditary optic neuropathy and dominant optic atrophy. The mechanism
leading to mRGCs sparing in these blinding disorders, characterized by extensive and selective loss of
RGCs, is currently unknown and under investigation. Other studies reported on mRGCs in glaucoma,
on genetic variation of the melanopsin gene (OPN4) in seasonal affective disorder and on the role of
mRGCs in migraineous photophobia. Our own data and studies from others have shown a significant
reduction of mRGCs with aging.
We anticipate that these studies will lead to many other investigations addressing the role of mRGCs
and circadian photoreception in the pathogenesis of circadian and sleep abnormalities in neurodegener-
ative disorders.
! 2010 Elsevier Ltd. All rights reserved.
1. Introduction
Many physiological functions in the human body are character-
ized by rhythmic changes within a 24 h period generated by the
circadian pacemaker, the hypothalamic suprachiasmatic nucleus
(SCN) (Reppert & Weaver, 2002). Studies on the mechanisms of
photoentrainment, i.e. how light adjusts the phase of the circadian
rhythms to the astronomical day length, led to the breakthrough
discovery in 2002 of a third, non-rod non-cone photoreceptor in
the mammalian retina, expressing a photopigment named
melanopsin (Berson, Dunn, & Takao, 2002; Hannibal, Hindersson,
Knudsen, Georg, & Fahrenkrug, 2002; Hattar, Liao, Takao, Berson,
& Yau, 2002; Provencio, Rollag, & Castrucci, 2002). Melanopsin
was identified in a subtype of retinal ganglion cells (RGCs), which
constitute about 1% of total RGCs (Berson et al., 2002; Dacey et al.,
2005; Hannibal, Hindersson, Nevo, & Fahrenkrug, 2002; Hannibal
et al., 2004; Hattar et al., 2002; Provencio et al., 2000) (Fig. 1).
The melanopsin-expressing RGCs (mRGCs) constitute the
monosynaptic neuronal pathway identified in mammals by Moore
and Lenn (1972) and Hendrickson, Wagoner, and Cowan (1972)
and later described in humans referred to as the retinohypotha-
lamic tract (RHT) (Berson et al., 2002; Dacey et al., 2005; Hannibal
et al., 2002; Hattar et al., 2002; Sadun, Schaechter, & Smith, 1984).
It is now well established that mRGCs, through the RHT, mediate
non-image forming functions of the eye, including the photoen-
trainment of circadian rhythms to the light–dark cycle (Guler
et al., 2008; Hatori et al., 2008).
The mRGCs are characterized by unique properties being intrin-
sically photosensitive due to the expression of melanopsin, even in
the absence of any other retinal input (Berson et al., 2002; Hattar
et al., 2002; Lucas et al., 2003). This property allows these cells
to absorb and process light whereas the other RGCs may suffer pos-
sible damage when exposed to direct light energy (Osborne, Li, Ji,
Mortiboys, & Jackson, 2008; Tu et al., 2005). The mRGCs are max-
imally sensitive to short-wavelength blue light (between 459 and
483 nm). Melanopsin is a bistable photopigment, allowing mRGCs
to regenerate their chromophore without involving other cells,
similar to the photoreceptors of invertebrates (Fu et al., 2005;
Mure, Rieux, Hattar, & Cooper, 2007). In fact, the phylogenetic ori-
gin of mRGCs is very ancient and relates to invertebrate rhabdo-
meric photoreception, which predates the development of the
eye as the organ for vision (Peirson, Halford, & Foster, 2009). Thus,
a long-lasting evolutionary pressure conserved this photoreceptive
system, possibly selecting its intrinsic robustness. Moreover,
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mRGCs provide the earliest light detection in mammals being func-
tionally active at day 0 postnatal, highlighting the importance of
their function in the developing retina (Hannibal & Fahrenkrug,
2004; Tarttelin et al., 2003). Finally, there is now growing evidence
that mRGCs project to many areas of the brain serving many non-
visual forming functions besides photoentrainment of circadian
rhythms, such as regulation of the pupillary light reflex, melatonin
secretion and its suppression by light, masking behavior, cognition,
wakefulness and sleep (Berson, 2003; Dijk & Archer 2009; Lupi,
Oster, Thompson, & Foster, 2008; Tsai et al., 2009). These many
functions served by mRGCs are mirrored by their projections,
which not only include the SCN, but also other hypothalamic nu-
clei, such as the ventro-lateral preoptic nucleus that contains sleep
active neurons, and the subparaventricular zone involved in tem-
perature and hormone regulation (Saper, Lu, Chou, & Gooley,
2005). The mRGCs also project to the olivary pretectal nuclei, consti-
tuting the afferent arm of the pupillary light response, the lateral
habenula, a relay site between limbic and striatal areas, the amygdala
involved in regulation of emotions and the intergeniculate leaflet of
the thalamus playing a crucial role in mediating the non-photic reg-
ulation of circadian rhythms (Berson, 2003; Hannibal et al., 2004;
Hattar et al., 2006; Vandewalle, Maquet, & Dijk, 2009). The wide-
spread impact of light on the brain also includes the wavelength-
dependent activation of alertness-related subcortical structures such
as the brainstem, and in particular the locus coeruleus, as
documented by functional-MRI studies (Vandewalle et al., 2007a;
Vandewalle et al., 2007b). These cells also provide innervation to
areas of the brain more typically characterized as crucial to vision,
such as the lateral geniculate nucleus and the superior colliculus
(Dacey et al., 2005; Hannibal & Fahrenkrug, 2006; Hattar et al., 2006).
Thus, the recent identification of mRGCs came as an important
discovery that contributes greatly to our knowledge of retinal func-
tion, and it has fueled numerous studies aimed at delineating de-
tails of this cellular system with particular reference to
chronobiology. The majority of studies have taken advantage of
animal models by manipulating their genetic expression to define
the physiology of mRGCs. Some of these studies took advantage of
animal models recapitulating human diseases to infer how patho-
genic mechanisms may involve mRGCs (Vugler, Semo, Joseph, &
Jeffery, 2008). However, to date, only a few studies investigated
the mRGCs-system directly in humans or in human pathology
(Dacey et al., 2005; Hannibal et al., 2004; Vugler et al., 2007).
2. Retinal pathology and light-suppression of melatonin led to
the discovery of mRGCs
The discovery of mRGCs came from the observation that mice
with extensive degeneration of rods and cones, such as homozy-
gous (rd/rd) mice lacking rods or mice lacking all functional rod
and cone photoreceptors (rd/rd cl) were still capable of normal cir-
cadian photoentrainment (Foster et al., 1991; Freedman et al.,
1999; Lucas, Freedman, Muñoz, Garcia-Fernández, & Foster,
1999). Moreover, a few studies of human blind subjects with
mixed pathology of rods and cones or optic neuropathy docu-
mented the preservation of the light-induced melatonin suppres-
sion response indicating the existence of a different light
perception system (Czeisler et al., 1995; Hätönen et al., 1998). An
extreme example on the same theme is the completely blind mole
rat Spalax ehrenberghi. This animal, despite the severe regression of
the conventional visual pathways is still able to photoentrain its
circadian rhythms. In fact, there are approximately 900 RGCs still
existent in the mole rat despite its rudimentary subcutaneous eyes
and most of these project to structures in the brain related to cir-
cadian photoreception (Cooper, Herbin, & Nevo, 1993). In this ani-
mal David-Gray and coauthors isolated a cone-like photopigment,
purported to contribute to non-image forming functions
(David-Gray, Janssen, DeGrip, Nevo, & Foster, 1998). Later mela-
nopsin has been recognized as a major pigment in this species
(Hannibal, Hindersson, Nevo, & Fahrenkrug, 2002).
Along the same lines, studies on the action spectrum of light-in-
duced melatonin suppression response in normal human subjects
led to the presumption that a short-wavelength pigment, clearly
different from the photopigments of the classical scotopic and
photopic visual systems, was crucial to mediate this response
(Brainard et al., 2001; Thapan, Arendt, & Skene, 2001). All these
observations were key in the discovery of mRGCs as a new class
of photoreceptors mediating non-image forming functions of the
eye (Berson et al., 2002; Hattar et al., 2002).
3. Mitochondrial optic neuropathies: the right model to study
abnormal circadian photoreception?
Human blind subjects have been always considered a useful
model for the study of circadian rhythm disorders (Sack & Lewy,
2001). However, in most studies, subjects enrolled were affected
by heterogeneous retinal pathology and the occurrence of circa-
dian rhythms misalignment was not considered with respect to
the type of retinal disease. Based on the scattered data available,
the occurrence of circadian photoentraiment disturbances seemed
to be determined by the absence of light perception. In fact, the
vast majority (77%) of blind subjects with light perception have
normally entrained circadian rhythms, suggesting a preservation
of the mRGCs–RHT–SCN circuit. In contradistinction, most of the
subjects without light perception, especially those with ocular
enucleation, have abnormal circadian photoentrainment (Skene &
Arendt, 2007). Thus, the presence of circadian rhythm disturbances
seemed to be related to the severity as well as the type of ocular
disease (Wee & Van Gelder, 2004).
Diseases of the outer retina, selectively affecting rods and cones,
and thus sparing themRGCs, were particularly useful to identify the
existence of mRGCs. Similarly, we thought that genetically
Fig. 1. Melanopsin expression in a subset of retinal ganglion cells in the human
retina. A flat–mount preparation from a normal part of human retina removed due
to cancer shows melanopsin immunoreactivity in the membrane of the soma and
processes of approximately 1% of retinal ganglion cells forming a photosentitive
network covering the entire retinal surface.
C. La Morgia et al. / Vision Research 51 (2011) 296–302 297
determined neurodegenerative optic neuropathies, selectively
affecting RGCs, would be a good model to study the possible occur-
renceof abnormalities in circadianphotoentrainment. Twosuchdis-
orders, i.e. Leber hereditary optic neuropathy (LHON) and dominant
optic atrophy (DOA) are in fact characterized by the selective loss of
RGCs due to mitochondrial dysfunction (Carelli, Ross-Cisneros, &
Sadun, 2004). Thus, we studied the mRGCs–RHT–SCN system in
LHON and DOA using both a functional, i.e. melatonin suppression
test by light, and a histological approach. We demonstrated that
the mRGCs–RHT–SCN system is substantially unaffected in these
visually impaired patients as they maintain the light-induced sup-
pression of melatonin secretion. Furthermore, our histological
investigation on post-mortem retinal and optic nerve specimens
from LHON and DOA cases demonstrated a relative sparing of
mRGCs (Fig. 2) leading to the unpredicted conclusion that these cells
are resistant to neurodegeneration in mitochondrial optic neuropa-
thies (LaMorgia et al., 2010). These studies suggest the preservation
of circadian photoentrainment in these patients.
Our findings are compatible with at least two observations.
First, despite LHON and DOA patients are severely visually im-
paired, they usually maintain light perception vision (Carelli
et al., 2004). Second, LHON and DOA patients have also preserved
pupillary light response (Bremner, Tomlin, Shallo-Hoffmann,
Votruba, & Smith, 2001; Wakakura & Yokoe, 1995), which can
now be explained by our findings of mRGCs sparing. We had pre-
viously shown, in a post-mortem study of a single LHON case with
extremely severe optic atrophy, spared axons leaving the optic chi-
asm and projecting to the pretectum (Bose, Dhillon, Ross-Cisneros,
& Carelli, 2005; Sadun, Win, Ross-Cisneros, Walker, & Carelli,
2000). Also mice with rotenone-induced optic neuropathy, a model
for LHON, preserve the pupillary light reflex, suggesting selective
sparing of mRGCs (Zhang, Jones, & Gonzalez-Lima, 2006). Further
indirect confirmation of our results is provided by a single case
study of Kawasaki and coauthors who demonstrated, using selec-
tive wavelength pupillometry in a case of LHON, that the pupil re-
sponse, driven by mRGCs, was spared (Kawasaki, Herbst, Sander, &
Milea, 2010). Furthermore, Pérez-Rico and coauthors (2009) dem-
onstrated, that 5 out of 10 blind subjects maintaining the light-in-
duced melatonin suppression response included 2 DOA subjects.
Our study raises the question of how mRGCs are resistant to
mitochondrial dysfunction. A review of the literature provides a
body of supporting evidence for the resistance of these cells to dif-
ferent kind of injuries. Three studies on the dying-back model of
RGCs after optic nerve transection are revealing. The first study
showed that a small subset (about 1%) of surviving RGCs with large
bodies intensively stained with cytochrome c oxidase (COX; mito-
chondrial respiratory complex IV) (von Bussmann, Garey, & Jen,
1993); their size and number would be most consistent with
mRGCs. Preliminary data from our laboratory confirm that mRGCs
are intensively stained with both mitochondrial and COX antibod-
ies, suggesting an abundant mitochondrial population within these
cells (Carla Giordano, unpublished results). A more recent study
demonstrated that mRGCs were indeed among the surviving RGCs
after axotomy (Robinson & Madison, 2004) and the last study sug-
gested that involvement of the PI3K/Akt pathway was key to their
survival (Li et al., 2008). Other evidences of mRGCs robustness are
provided by studies on cell toxicity to monosodium glutamate
(Chambille & Serviere 1993; Hannibal, Vrang, Card, & Fahrenkrug,
2001). The neuroprotective role of pituitary adenylate cyclase-acti-
vating polypeptide (PACAP), a neuropeptide specifically expressed
by mRGCs, has been emphasized by studies on experimental mod-
els of monosodium glutamate toxicity and ocular ischemia (Atlasz
et al., 2008; Seki et al., 2010). Furthermore, the neuroprotective ef-
fect of PACAP administration was also shown in RGCs after optic
nerve transection, providing a plausible candidate for mRGCs resis-
tance to death after axotomy (Seki, Itoh, Nakamachi, & Shioda,
2008).
Our results in mitochondrial optic neuropathies make it tempt-
ing to speculate that spared mRGCs have specific metabolic prop-
erties and probably have high mitochondrial activity. This is also
suggested by our preliminary results with immunostaining of
mRGCs by mitochondrial and COX antibodies (Carla Giordano,
unpublished results). Intense COX staining has also been demon-
strated by others in surviving RGCs after axotomy (von Bussmann
et al., 1993). The metabolic robustness of mRGCs to mitochondrial
dysfunction may be specific to complex I impairment, considering
that LHON is due to mitochondrial DNA point mutations affecting
complex I subunits, as well as a mouse model of LHON was ob-
tained by intravitreal injection of rotenone, a classic complex I
inhibitor (Carelli et al., 2004; Zhang et al., 2006). In the latter, the
authors noted the preservation of pupillary light response as in pa-
tients with LHON (Zhang et al., 2006). Moreover, a complex I defect
has also been documented in OPA1 mutant fibroblasts from DOA
patients (Zanna et al., 2008). Complex I dysfunction in mitochon-
drial optic neuropathies has been shown to lead at least to three
pathogenic mechanisms: (1) ATP synthesis driven by complex I-
dependent substrates (malate and glutamate) may be impaired
even if the complex II-dependent pathway can complement this
defect (Carelli et al., 2007). (2) ROS production is chronically in-
creased challenging the antioxidant intra-mitochondrial enzymatic
Fig. 2. Postmortem human retinas, immunoperoxidase staining for melanopsin, light microscopy; (A) Retina from a normal 58-year-old male demonstrates melanopsin-
positive retinal ganglion cells (mRGCs) in both the RGC layer (RGCL) and the inner nuclear layer (INL). (B) Retina from a 52-year-old LHON male patient carrying the 11778/
ND4mutation of mtDNA with severe optic neuropathy. Note the positive staining for a single mRGC in the RGCL, its dendritic arborization and the absence of non-melanopsin
RGCs (as compared to micrograph A). In LHON retinas mRGCs can also be found within the INL at a similar frequency with normal controls (La Morgia et al., 2010). (Both A and
B, magnification 400!.)
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activities (manganese superoxide dismutase and glutathione per-
oxidase) (Carelli et al., 2007). (3) Cells are sensitized to undergo
apoptosis by shifting the threshold voltage for permeability transi-
tion pore (PTP) opening (Porcelli et al., 2009). Thus, the protection
of mRGCs in comparison to the other RGCs may be mediated
through compensation of any of these mechanisms. Furthermore,
melanopsin-driven photoreception has been reported to trigger
the mobilization of intracellular calcium and, considering the
essential role played by the mitochondrial network in buffering
calcium, we can postulate an important and specific role played
by mitochondria in the metabolic homeostasis of mRGCs (Hartwick
et al., 2007; Kumbalasiri, Rollag, Isoldi, Castrucci, & Provencio,
2007). The ‘metabolic robustness’ assumed for mRGCs could be de-
rived by a specific resistance to ROS due to handling of light and
calcium mobilization capability of these cells. The mRGCs photore-
ceptive properties stand in support of this hypothesis. Light expo-
sure to normal RGCs may be directly harmful in the setting of
dysfunctional mitochondria, as in LHON and DOA, by increasing
the ROS-mediated damage (Osborne et al., 2008). We may specu-
late that mRGCs may be intrinsically protected from light damage
and ROS overproduction by expressing the melanopsin photopig-
ment, which absorbs short wavelength light. Thus, melanopsin it-
self may be the other candidate for a neuroprotective role
besides the above mentioned PACAP. At the present stage all these
are speculations and working hypothesis needing solid experimen-
tal proofs.
4. Glaucoma optic neuropathy: are mRGCs lost or spared?
Glaucoma is the most common optic neuropathy (Quigley &
Broman, 2006). The late stages of glaucoma are characterized by
an extensive loss of RGCs, which leads to optic atrophy and blind-
ness. Classically, the loss of RGCs in glaucoma follows a physical
pattern selecting for nerve fibers in the arcuate bundles first. Re-
cently, the involvement of mRGCs as well as regular RGCs in glau-
coma has been postulated (Jean-Louis, Zizi, Lazzaro & Wolintz,
2008). Indeed, there are two studies in animal models of glaucoma
that suggest a loss of mRGCs or melanopsin photopigment leading
to impairment of circadian rhythms regulation (Drouyer et al.,
2008; Wang et al., 2008). Furthermore, preliminary data in humans
suggested abnormal circadian rhythm of melatonin secretion and
of light-induced melatonin suppression in glaucoma patients
(Cooper et al., 2008; Perez Rico, de la Villa, & Blanco, 2010). Inter-
estingly, the pupillary light reflex is also compromised in glaucoma
patients, as documented by pupillographic studies (Kalaboukhova,
Fridhammar, & Lindblom, 2007). However, others have shown that
mRGCs may be spared in some animal models of chronic ocular
hypertension (Jakobs, Libby, Ben, John, & Masland, 2005; Li et al.,
2006).
Thus, further studies are warranted to clarify the involvement
of mRGCs in the natural history of glaucoma, and to investigate
the occurrence of sleep and circadian rhythms abnormalities in pa-
tients with late-stage glaucoma.
5. Melanopsin genetics and seasonal affective disorders
A circadian misalignment has been demonstrated in many
mood disorders (Lewy, 2009). The circadian basis for affective dis-
orders is well supported, especially for winter depression, i.e. sea-
sonal affective disorder (SAD), which is characterized by the annual
recurrence of the mood disturbance in fall/winter, with remission
in spring/summer. Abnormalities of hormonal circadian rhythms
have been reported in SAD and light therapy, particularly with blue
light, has been demonstrated as an effective treatment for this dis-
order (Glickman, Byrne, Pineda, Hauck, & Brainard, 2006; Lewy
et al., 2009). These data suggest the involvement of the circadian
system and, in particular, of the mechanisms underlying the pho-
toentrainment of circadian rhythms in the pathogenesis of the dis-
ease. These findings prompted the investigation of the genetic
variation of the OPN4 gene that encodes for melanopsin, and a mis-
sense variant (P10L) was found associated to SAD, suggesting the
possible role of the mRGCs-system in its pathogenesis (Roecklein
et al., 2009).
6. Melanopsin and photophobia in migraine
Another recently published study reported on the contribution
of mRGCs to photophobia in migraine (Noseda et al., 2010). This
contribution has been substantiated by the observation that blind
people with light perception, despite the severe defective visual
acuity, maintain photophobia during migraine attacks, at differ-
ence with blind people without light perception (mostly of them
with ocular enucleation). The authors proved, using anterograde
tracing and single-unit recordings, that the synaptic contact with
trigemino-vascular neurons in the posterior thalamus mainly de-
rives from mRGCs, suggesting a major role of the non-image form-
ing system of the retina in mediating migraine-related
photophobia (Noseda et al., 2010). The contribution of mRGCs to
photophobia has also been documented in rodless and coneless
mice (Matynia, Parikh, Chen, Nusinowitz, & Gorin, 2010; Semo
et al., 2010).
7. Melanopsin and aging
The aging process is associated with well-documented changes
in sleep. These changes may result from an abnormal homeostatic
regulation of sleep, expressed as an impaired consolidation of
NREM sleep highlighted by a reduction of slow wave activity and
increased awakenings during the night (Dijk, Duffy, & Czeisler,
2000), and/or from a dysfunction of circadian rhythms regulation
(Cajochen, Münch, Knoblauch, Blatter, & Wirz-Justice, 2006). De-
cline in the amplitude of circadian rhythms such as core body tem-
perature, melatonin and cortisol secretion have been reported in
the elderly (Cajochen et al., 2006). Moreover, a phase-advance of
circadian rhythms, in particular of the sleep–wake cycle, and a
shortening of the circadian period are also noted in the elderly
(Carrier, Paquet, Morettini, & Touchette, 2002). Many factors have
been implicated in the occurrence of circadian timing disturbances
with age. Among them we mention: (1) Neurodegenerative
changes in the SCN, i.e. reduction of vasopressin and vasoactive
intestinal peptide expressing neurons. (2) Alterations in the pineal
gland, melatonin levels and melatonin receptors with a decline in
the amplitude of melatonin rhythm and expression of melatonin
receptors (Wu & Swaab, 2007). (3) Reduction of light input to the
SCN due to a decreased capacity of the semicataractous lens to
transmit short wavelength light (Turner & Mainster, 2008). Fur-
thermore, many degenerative changes occur in the retina and optic
nerve with aging (Johnson, Miao, & Sadun, 1987; Chakravarthy,
Evans, & Rosenfeld, 2010).
The contribution of the mRGCs-system to the occurrence of the
circadian misalignment in aging may be more important than ex-
pected. We evaluated post-mortem retinal specimens from con-
trols, comparing two subjects in the mid fifties with one subject
over eighty (La Morgia et al., 2010). We found that mRGCs, as well
as regular RGCs, are lost with age, as previously reported in animal
models and humans (Johnson et al., 1987; Semo, Lupi, Peirson,
Butler, & Foster, 2003; Esquiva et al., 2010). We also showed that
mRGCs are more concentrated around the fovea and this distribu-
tion is maintained with aging despite the general loss of mRGCs
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(Dacey et al., 2005; Jusuf, Lee, Hannibal, & Grünert, 2007; La
Morgia et al., 2010).
The loss of mRGCs and related impairment of circadian rhythms
and sleep in the elderly is at odds with the metabolic robustness of
mRGCs documented in mitochondrial optic neuropathies particu-
larly since mitochondrial dysfunction is implicated in the aging
process (Trifunovic & Larsson, 2008). This paradox needs to be
investigated.
8. Future directions
The role of mRGCs-dependent functions in human pathology is
just beginning to be understood. It is already well established that
loss of these cells may be implicated in the pathogenesis of circa-
dian, sleep, cognitive and mood disorders.
Glaucoma is a key model that needs to be investigated in re-
gards to circadian photoreception in optic neuropathies. Moreover,
retinal dysfunction and RGCs loss has also been documented in
several neurodegenerative diseases including Alzheimer and
Parkinson disease (Archibald, Clarke, Mosimann, & Burn, 2009;
Berisha, Feke, Trempe, McMeel, & Schepens, 2007; Bodis-Wollner,
2009; Hinton, Sadun, Blanks, & Miller, 1986). In both diseases there
is evidence of circadian dysfunction (Willis, Kelly, & Kennedy,
2008; Wu & Swaab, 2007) and efficacy of light as therapy (Burns,
Allen, Tomenson, Duignan, & Byrne, 2009; Paus et al., 2007). A
reasonable link connecting the retinal pathology and circadian dys-
function in Alzheimer and Parkinson disease may be the involve-
ment of mRGCs in the neurodegenerative process.
Preliminary data associating genetic variations of the OPN4
gene with SAD suggests that polymorphic variants of this gene
may also contribute to the human chronotype, i.e. the preference
to be active early or late in the day (morningness/eveningness)
(Roenneberg et al., 2007). Interestingly, melanopsin is implicated
in sleep homeostasis, i.e. build-up of sleep pressure during the
wakefulness, as demonstrated in the Opn4!/! mouse model, in
which a significant attenuation of electroencephalographic slow
wave activity, a marker of sleep homeostasis, was documented
(Tsai et al., 2009). Similarly, a different sleep homeostatic regula-
tion has been found in morningness/eveningness types, again
potentially linking the role of melanopsin in contributing to the
chronotype (Mongrain, Carrier, & Dumont, 2006; Mongrain &
Dumont, 2007).
It is now well established that many human pathological condi-
tions are responsive to the light stimulation of the circadian pace-
maker (SCN) including circadian rhythm sleep disorders, (delayed
and advanced sleep phase syndrome, shift work disorder, jet lag
and irregular sleep–wake rhythm disorder), age-related sleep dis-
turbances, Alzheimer and Parkinson disease. In all these conditions
light therapy may be effective (Burns et al., 2009; Dowling et al.,
2008; Morgenthaler et al., 2007; Paus et al., 2007). Better definition
of the parameters of the light sources for light therapy trials is war-
ranted to optimize the efficacy of this approach in stimulating the
mRGCs-system.
The mounting evidence for a direct contribution of mRGCs to vi-
sion may indicate a possible avenue for intervention (Brown, Gigg,
Piggins, & Lucas, 2010; Chen, Ecker, & Hattar, 2010; Dacey et al.,
2005; Gias, Semo, Vugler, & Coffey 2010). The extent to which
mRGCs contribute to visual acuity is not fully defined yet, nor is
the contribution of other recently described opsin-expressing cells
in the inner retina (Semo, Vugler, & Jeffery, 2007). These more re-
cent observations may have important implications for a subset of
blind subjects where mRGCs are spared. This is the case for mito-
chondrial optic neuropathies, such as LHON and DOA, as we have
demonstrated that mRGCs are relatively spared in comparison to
regular RGCs. It would be extremely useful to distinguish the visual
acuity driven by the mRGC channel as distinct from that provided
by rods and cones. Currently the physiological separation of these
two pathways has been achieved by a pupillometric protocol in-
tended to elicit the pupillary light response (Park et al., 2010). It
has been shown that awareness of light, i.e. a form of blind sight,
may be evoked in blind patients, such as those lacking an outer ret-
ina, using short-wavelength stimulus, specific for mRGCs (Zaidi
et al., 2007). Another promising approach has been illustrated
when visual function was partially restored in a mouse model of
retinal degeneration by an ectopic expression of melanopsin into
regular RGCs (Lin, Koizumi, Tanaka, Panda, & Masland 2008).
The recent recognition that mRGCs project to many structures
of the central nervous system contributing to vision, opens the
question of their role in many light-mediated responses, such as
photophobia in migraine. Similarly, photosensitivity and electro-
encephalographic photoparoxysmal responses may be modulated
by the mRGCs projections.
Our studies on mitochondrial optic neuropathies, LHON and
DOA, as well as a few other recent studies on the role of the
mRGCs-system in human patho-physiology gives promise that
the next decade will deliver us many more surprises in the field
of melanopsin.
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SHORT COMMUNICATION
Loss of temporal retinal nerve fibers in Parkinson disease: a
mitochondrial pattern?
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Background: Optic nerve involvement is frequent in mitochondrial disease, and ret-
inal abnormalities are described in Parkinson!s disease (PD).
Methods: We evaluated retinal nerve fiber layer (RNFL) thickness by optical
coherence tomography in 43 patients with PD and in 86 age-matched controls. We
considered separately the eyes ipsilateral and contralateral to the most affected body
side in patients with PD. ANCOVA analysis, Pearson test, and multiple regression
analysis were used (P < 0.05).
Results: Patients with PD showed significantly thinner temporal RNFL thickness
compared to controls (P = 0.004), more evident in the eye contralateral to the most
affected body side. Average RNFL thickness significantly correlated with age in both
controls and patients with PD (p values ranging from 0.001 to 0.019), whereas in
patients with PD RNFL thickness did not correlate with clinical variables.
Conclusions: Our study reveals a loss of retinal nerve fibers in the temporal quadrant
in PD, which is typically susceptible in mitochondrial optic neuropathies.
Introduction
Parkinson disease (PD) is one of the most common age-
dependent neurodegenerative disorders and is charac-
terized by the loss of dopaminergic neurons in the
substantia nigra [1]. The typical clinical picture of PD
includes the presence of motor symptoms such as
bradykinesia, tremor, and rigidity. However, non-
motor symptoms are increasingly recognized in PD,
implying wider neurodegenerative involvement [2].
There is mounting evidence of mitochondrial
dysfunction in the pathogenesis of PD. Complex I
deficiency leads to Parkinsonian features in humans and
animal models [3]. Furthermore, monogenic forms of
PD are associated with mutations affecting proteins
that are either located in mitochondria or may trans-
locate to mitochondria under specific circumstances,
such as for the PINK1/Parkin pathway [4].
Mitochondrial optic neuropathies, such as Leber!s
hereditary optic neuropathy (LHON) and dominant
optic atrophy (DOA), are associated with complex I
defect and a preferential involvement of the papillo-
macular bundle, which enters the optic disk on the in-
fero-temporal side [5–7]. Ocular involvement in PD has
been recognized for a long time [8]. More recently, the
availability of optical coherence tomography (OCT),
which allows objective anatomical measurements in the
retina, including the retinal nerve fiber layer (RNFL)
thickness, prompted the investigation of retinal gan-
glion cells and optic nerve in PD [9–14]. In this study,
we measured by OCT the RNFL thickness in patients
with PD compared with age-matched controls to
investigate optic nerve in PD.
Patients and methods
Consecutive patients with PD followed at the IRCCS
Istituto delle Scienze Neurologiche di Bologna, were
recruited from September 2010 to June 2011. Diagnosis
of probable PD was established according to the Gelb
criteria [15].
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All study participants underwent a standard oph-
thalmologic evaluation to exclude spherical or cylin-
drical refractive errors higher than three or two
diopters, respectively, posterior pole pathology such as
macular degeneration, and optic neuropathies including
glaucoma. Furthermore, patients with unsustained fix-
ation owing to rest tremor were excluded. All partici-
pants gave their informed consent to the study, which
was approved by the Internal Review Board (Comitato
Etico Indipendente, Azienda Unita` Sanitaria Locale di
Bologna, Protocol #656/CE).
We included 43 patients with PD (65.6 ± 8.4 years;
range 46–83) and 86 age-matched controls (mean age
65.5 ± 10.7 years; range 46–85 years). Amongst
patients with PD, three had a molecular diagnosis (two
carried the G2019S LRRK2 mutation and one a
PARK2 exon 2 deletion) and five had first-degree rel-
atives affected without molecular definition. We con-
sidered all these eight patients with PD as genetic cases.
For all patients, we retrieved disease duration, UPDRS-
III (off) score, and stage of disease (Hoehn and Yahr).
All subjects underwent RNFL thickness measurement
by OCT (StratusOCT, software version 4.0.1; Carl
Zeiss Meditec Inc, Dublin, CA, USA). We used the
RNFL thickness 3.4 acquisition protocol, as previously
described [6,7]. An experienced operator (CLM) per-
formed the examination with pupil dilated. The OCT
lenses were adjusted for the patient!s refractive error.
Polarization was optimized to maximize the reflective
signal, and the best centration of the scan with respect
to the optic disk was used.
For the statistical analysis, one eye for each control
was randomly chosen, having verified that there was no
statistical difference between right and left eye [6]. Based
on the characteristic asymmetry of PD, we analyzed
both the eye ipsilateral and contralateral to the most
affected body side in patients with PD, as defined by
neurological examination and UPDRS-III score.
Statistical analysis was performed using the SPSS
18.0 package (PASW Statistics 18.0; SPSS Inc., Chi-
cago, IL, USA). Normal distribution of RNFL thick-
ness measurements was evaluated by Kolmogorov test.
Differences between patients with PD and controls
were assessed by ANCOVA using age and gender as co-
variates, followed by post hoc pairwise comparisons.
Significance was assumed for P < 0.05 corrected for
multiple comparisons according to the Bonferroni
method. Correlation bivariate analysis was performed
using Pearson coefficient (P < 0.05). Multivariate
analysis was performed to investigate the effect of ge-
netic, demographic (age and gender), and clinical
parameters (age at onset, disease duration, UPDRS-III
score, and stage of disease) on RNFL measurements
using a multiple regression with a backward stepwise
method to obtain a significant model in which all in-
cluded variables had a P < 0.05.
Results
All patients with PD included were on dopaminergic
therapy. Disease duration was 9.1 ± 6.5 years, Hoehn
and Yahr stage of disease was 2.2 ± 0.9, and UPDRS
score was 25.9 ± 12.4. Demographic and the main
clinical findings are summarized in Table 1. None of the
patients with PD had visual complaints. Five PD eyes
(two ipsilateral and three contralateral to the most af-
fected body side) were excluded based on established
criteria.
The average RNFL thickness was reduced in patients
with PD compared to controls, being close to signifi-
cance (P = 0.057) (Table 1, Fig. 1). Considering sepa-
rately the four quadrants, only the temporal RNFL
thickness was significantly reduced in PD compared to
controls (P = 0.004) (Table 1). post hoc pairwise
comparisons showed that the temporal RNFL thick-
ness was significantly reduced for both the contralateral
(P = 0.008) and the ipsilateral (P = 0.04) eye in PD
compared to controls (Fig. 1). The significance of
RNFL thickness reduction in the temporal quadrant
was maintained for the sporadic cases (P = 0.006) and
genetic cases (P = 0.039) considered separately.
Pearson test and multiple regression analysis did not
disclose any correlation between genetic, demographic
or clinical parameters and RNFL measurements, except
for age. Average RNFL thickness correlated with age in
both controls (P = 0.001; r = )0.341) and patients
with PD (P = 0.007; r = )0.412 and P = 0.019;
r = )0.371 for the eye ipsilateral and contralateral to
the most affected body side, respectively).
Discussion
Our study reveals a subclinical optic neuropathy, as
evidenced by the reduction in the average RNFL
thickness, with significant involvement of the nerve
fibers entering the temporal quadrant of the optic disk
in the overall group of patients with PD. The con-
tralateral eye was more affected than the ipsilateral to
the most affected body side, supporting an asymmetry
of the neurodegenerative process that involves both the
substantia nigra and the eye on the same side. Similarly,
an asymmetric impairment has been reported for the
olfactory function, further supporting a general asym-
metry in the neuropathological process in PD [16]. The
reduction in the RNFL thickness was correlated with
age in both controls and patients with PD. Overall,
these findings add to the mounting evidence of non-
motor involvement in PD [2].
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Our study identified a pattern of axonal loss typi-
cally seen in LHON and DOA, where the temporal
fibers belonging to the papillomacular bundle are
characteristically susceptible [5]. Both diseases are
associated with a complex I defect [5], which is also
recognized as a key feature in the pathogenesis of PD,
either in the sporadic cases or in the genetic forms [3,4],
linking the current results with the pattern observed in
LHON and DOA.
Optic nerve pathology in PD has been previously
documented by others, some reporting a preferential
loss of fibers in the infero-temporal quadrants, con-
sistent with the involvement of the papillomacular
bundle [9,10,13]. Macular and foveal abnormalities
have also been documented [12]. However, Altintas
Table 1 Summary of demographic and clinical data in Parkinson!s disease (PD) and controls
PD ipsilateral eye (N = 41) PD contralateral Eye (N = 40) Controls (N = 86) ANCOVA
Gender 24 M; 19F 34M; 52F
Age 65.6 ± 8.4 65.5 ± 10.74
Disease duration 9.1 ± 6.5
UPDRS (Off) 25.9 ± 12.4
HY stage 2.21 ± 0.9
RNFLavg (lm) 92.2 ± 12.8 91.9 ± 12.1 97 ± 12.4 P = 0.057
RNFL-T (lm) 62.3 ± 10.4 60.9 ± 12.8 68.5 ± 12.3 P = 0.004a
RNFL-S (lm) 115.2 ± 17.4 112.4 ± 15.6 118.9 ± 17.4 P = 0.179
RNFL-N (lm) 72.2 ± 18.3 72.9 ± 17.7 76.5 ± 15.7 P = 0.362
RNFL-I (lm) 119.3 ± 19.9 121.5 ± 18.6 124.1 ± 18.6 P = 0.426
aPost hoc pairwise comparisons: controls vs. PD ipsilateral eye (P = 0.04); controls vs. PD contralateral eye (P = 0.008). Demographic and
clinical data of PD and controls and ANCOVA (age and gender as covariates) results are reported.
(a) (b)
(d)(c)
Figure 1 RNFL thickness results. Asterisks indicate statistical significance after post hoc pairwise comparisons. (a) The average RNFL
thickness is shown. (b) The temporal RNFL thickness is shown. (c) The RNFL thickness of temporal, superior, nasal, and inferior
quadrants is shown for control eyes (black line) and for ipsilateral PD eyes (gray line). (d) RNFL thickness of temporal, superior, nasal,
and inferior quadrants is shown for control eyes (black line) and for contralateral PD eyes (gray line).
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et al. [11] reported a significant RNFL thinning of the
superior and nasal quadrants, whereas Archibald et al.
[14] failed to find any differences between PD and
controls.
The role of a specific PD neuropathology in the ret-
ina is controversial and clear evidence of alpha-synuc-
lein deposition is still missing. The most consistent link
we hypothesize between the subclinical optic nerve
involvement in PD and the major mitochondrial optic
neuropathies LHON and DOA is based on complex I
dysfunction and altered mitochondrial dynamics [5].
This latter link is highlighted by mitochondrial network
fragmentation in patient-derived cells from both DOA-
and PD-affected individuals carrying, respectively,
OPA1 and PINK1/Parkin mutations [3–5]. The balance
between mitochondrial fission and fusion seems crucial
for the correct execution of the quality control check,
and excessive mitophagy has been documented in
RGCs of OPA1 mutant mouse leading to their degen-
eration, as well as it is now a central theme in PD
pathogenesis [4,17,18].
In conclusion, the current study implicates optic
nerve in the neurodegenerative process of PD. The
significant reduction in the temporal fibers suggests a
mitochondrial pattern of retinal axonal loss in PD,
supporting and in agreement with mitochondrial dys-
function in the pathogenesis of PD.
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